US20040210239A1 - System and method of use for treating occluded vessels and diseased tissue - Google Patents
System and method of use for treating occluded vessels and diseased tissue Download PDFInfo
- Publication number
- US20040210239A1 US20040210239A1 US10/847,932 US84793204A US2004210239A1 US 20040210239 A1 US20040210239 A1 US 20040210239A1 US 84793204 A US84793204 A US 84793204A US 2004210239 A1 US2004210239 A1 US 2004210239A1
- Authority
- US
- United States
- Prior art keywords
- debris
- catheter
- working head
- lumen
- stent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title abstract description 66
- 239000007788 liquid Substances 0.000 claims abstract description 91
- 238000000605 extraction Methods 0.000 claims abstract description 53
- 239000003814 drug Substances 0.000 claims abstract description 21
- 229940079593 drug Drugs 0.000 claims abstract description 20
- 210000004204 blood vessel Anatomy 0.000 claims description 51
- 239000000463 material Substances 0.000 claims description 51
- 239000008280 blood Substances 0.000 claims description 40
- 210000004369 blood Anatomy 0.000 claims description 40
- 230000002792 vascular Effects 0.000 claims description 16
- 230000000903 blocking effect Effects 0.000 claims description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 239000003102 growth factor Substances 0.000 claims description 6
- 239000011149 active material Substances 0.000 claims description 5
- 239000004005 microsphere Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 abstract description 45
- 230000003116 impacting effect Effects 0.000 abstract description 15
- 208000037260 Atherosclerotic Plaque Diseases 0.000 abstract description 6
- 230000004888 barrier function Effects 0.000 abstract description 5
- 230000001010 compromised effect Effects 0.000 abstract description 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 38
- 230000000250 revascularization Effects 0.000 description 35
- 239000002245 particle Substances 0.000 description 32
- 239000012530 fluid Substances 0.000 description 31
- 210000000709 aorta Anatomy 0.000 description 18
- 210000001367 artery Anatomy 0.000 description 18
- 230000002262 irrigation Effects 0.000 description 18
- 238000003973 irrigation Methods 0.000 description 18
- 230000009471 action Effects 0.000 description 17
- 230000033228 biological regulation Effects 0.000 description 17
- 238000001802 infusion Methods 0.000 description 17
- 238000004891 communication Methods 0.000 description 16
- 238000009826 distribution Methods 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 238000011144 upstream manufacturing Methods 0.000 description 14
- 238000005520 cutting process Methods 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 230000002572 peristaltic effect Effects 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 11
- 238000010276 construction Methods 0.000 description 11
- -1 e.g. Substances 0.000 description 11
- 239000007789 gas Substances 0.000 description 11
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 7
- 210000001105 femoral artery Anatomy 0.000 description 7
- 230000010412 perfusion Effects 0.000 description 7
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 6
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 6
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000006073 displacement reaction Methods 0.000 description 6
- 239000003978 infusion fluid Substances 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000005086 pumping Methods 0.000 description 6
- 239000003351 stiffener Substances 0.000 description 6
- 238000002399 angioplasty Methods 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 210000004351 coronary vessel Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 229920003023 plastic Polymers 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000002966 stenotic effect Effects 0.000 description 5
- 239000010963 304 stainless steel Substances 0.000 description 4
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 4
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 4
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 4
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 4
- 229910000589 SAE 304 stainless steel Inorganic materials 0.000 description 4
- 102100031372 Thymidine phosphorylase Human genes 0.000 description 4
- 108700023160 Thymidine phosphorylases Proteins 0.000 description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
- 206010053648 Vascular occlusion Diseases 0.000 description 4
- 239000002872 contrast media Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 208000037803 restenosis Diseases 0.000 description 4
- 229910000679 solder Inorganic materials 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
- 102000004890 Interleukin-8 Human genes 0.000 description 3
- 108090001007 Interleukin-8 Proteins 0.000 description 3
- 108010025020 Nerve Growth Factor Proteins 0.000 description 3
- 102000015336 Nerve Growth Factor Human genes 0.000 description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 3
- 108010009583 Transforming Growth Factors Proteins 0.000 description 3
- 102000009618 Transforming Growth Factors Human genes 0.000 description 3
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000003143 atherosclerotic effect Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 229940096397 interleukin-8 Drugs 0.000 description 3
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 230000000921 morphogenic effect Effects 0.000 description 3
- 229940053128 nerve growth factor Drugs 0.000 description 3
- 230000003134 recirculating effect Effects 0.000 description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
- 208000021331 vascular occlusion disease Diseases 0.000 description 3
- 239000005541 ACE inhibitor Substances 0.000 description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 2
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 2
- 102100022338 Integrin alpha-M Human genes 0.000 description 2
- 101000962498 Macropis fulvipes Macropin Proteins 0.000 description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 239000000006 Nitroglycerin Substances 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 108010035030 Platelet Membrane Glycoprotein IIb Proteins 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000001349 mammary artery Anatomy 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 2
- 229910001000 nickel titanium Inorganic materials 0.000 description 2
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000006213 oxygenation reaction Methods 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000011236 particulate material Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 238000013151 thrombectomy Methods 0.000 description 2
- 230000002537 thrombolytic effect Effects 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- ZBMRKNMTMPPMMK-UHFFFAOYSA-N 2-amino-4-[hydroxy(methyl)phosphoryl]butanoic acid;azane Chemical compound [NH4+].CP(O)(=O)CCC(N)C([O-])=O ZBMRKNMTMPPMMK-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 102100022987 Angiogenin Human genes 0.000 description 1
- 229940123413 Angiotensin II antagonist Drugs 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 1
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 101100244894 Sus scrofa PR39 gene Proteins 0.000 description 1
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000002942 anti-growth Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000003409 anti-rejection Effects 0.000 description 1
- 230000002769 anti-restenotic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 description 1
- 229960003856 argatroban Drugs 0.000 description 1
- 230000027746 artery morphogenesis Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 210000000269 carotid artery external Anatomy 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 229940039231 contrast media Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940072645 coumadin Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 description 1
- 229960002199 etretinate Drugs 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 229920002457 flexible plastic Polymers 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 108010038082 heparin proteoglycan Proteins 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000002608 intravascular ultrasound Methods 0.000 description 1
- ZCYVEMRRCGMTRW-YPZZEJLDSA-N iodine-125 Chemical compound [125I] ZCYVEMRRCGMTRW-YPZZEJLDSA-N 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- GKOZUEZYRPOHIO-IGMARMGPSA-N iridium-192 Chemical compound [192Ir] GKOZUEZYRPOHIO-IGMARMGPSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- KDLHZDBZIXYQEI-OIOBTWANSA-N palladium-103 Chemical compound [103Pd] KDLHZDBZIXYQEI-OIOBTWANSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108010049224 perlecan Proteins 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 229940028869 ticlid Drugs 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/32—Surgical cutting instruments
- A61B17/3203—Fluid jet cutting instruments
- A61B17/32037—Fluid jet cutting instruments for removing obstructions from inner organs or blood vessels, e.g. for atherectomy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/32—Surgical cutting instruments
- A61B17/3205—Excision instruments
- A61B17/3207—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions
- A61B17/320758—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions with a rotating cutting instrument, e.g. motor driven
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/22—Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for
- A61B17/221—Gripping devices in the form of loops or baskets for gripping calculi or similar types of obstructions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/22—Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for
- A61B2017/22001—Angioplasty, e.g. PCTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/22—Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for
- A61B2017/22038—Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for with a guide wire
- A61B2017/22047—Means for immobilising the guide wire in the patient
- A61B2017/22048—Balloons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/22—Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for
- A61B2017/22051—Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for with an inflatable part, e.g. balloon, for positioning, blocking, or immobilisation
- A61B2017/22065—Functions of balloons
- A61B2017/22067—Blocking; Occlusion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/22—Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for
- A61B2017/22051—Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for with an inflatable part, e.g. balloon, for positioning, blocking, or immobilisation
- A61B2017/22065—Functions of balloons
- A61B2017/22068—Centering
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2217/00—General characteristics of surgical instruments
- A61B2217/002—Auxiliary appliance
- A61B2217/005—Auxiliary appliance with suction drainage system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2217/00—General characteristics of surgical instruments
- A61B2217/002—Auxiliary appliance
- A61B2217/007—Auxiliary appliance with irrigation system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/95—Instruments specially adapted for placement or removal of stents or stent-grafts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/71—Suction drainage systems
- A61M1/77—Suction-irrigation systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/84—Drainage tubes; Aspiration tips
- A61M1/85—Drainage tubes; Aspiration tips with gas or fluid supply means, e.g. for supplying rinsing fluids or anticoagulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/1095—Balloon catheters with special features or adapted for special applications with perfusion means for enabling blood circulation while the balloon is in an inflated state or in a deflated state, e.g. permanent by-pass within catheter shaft
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/05—General characteristics of the apparatus combined with other kinds of therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14212—Pumping with an aspiration and an expulsion action
- A61M5/14232—Roller pumps
Definitions
- This application relates generally to medical instruments and methods of use to remove occlusive material from a vessel, duct or lumen within the body of a living being.
- the rotation of the cutting head is stated as producing a “differential cutting” effect, whereupon relatively hard deposits are cut away from relatively soft tissue.
- Suction ports are provided to pull the hard particles produced by the cutting action into the catheter for removal at the proximal end thereof so that such particles do not flow distally of the catheter where they could have an adverse effect on the patients' body.
- each of those catheters includes a rotary working head having at least one non-sharp impacting surface to effect material removal without cutting.
- those catheters are arranged to eject fluid adjacent the working head to expedite the revascularization procedure.
- the rotation of the working head produces a powerful, toroidal shaped vortex contiguous with the working head which has the effect of recirculating any particles that may have been broken off from the material forming the arterial restriction so that the working head repeatedly impacts those particles to reduce their size.
- rotary atherectomy devices are in use in this country for revascularizing occluded arteries.
- their use is limited to some very selected applications.
- a vascular occlusion of a coronary artery can only be treated by coronary bypass surgery wherein a graft, e.g., a saphenous vein section and/or mammary artery section, is surgically shunted across the occluded coronary artery.
- a graft e.g., a saphenous vein section and/or mammary artery section
- the re-occluded graft has to be either bypassed by another graft (i.e., second bypass surgery), or the re-occluded graft has to be revascularized (i.e., its lumen reopened) by some intravascular procedure.
- balloon angioplasty may be indicated to reopen the graft.
- the graft is totally occluded or heavily occluded by frangible deposits balloon angioplasty is unavailable.
- resort may be to rotary atherectomy.
- One currently available rotary atherectomy device is the ROTOBLATOR® System of Heart Technology, Inc. That system utilizes a catheter having a diamond coated elliptical burr which is rotated at a high rate of speed, e.g., up to 190,000 rpm. The burr serves to break the atherosclerotic plaque into fine particles which are allowed to remain in the patient's body for disposal by the patient's reticuloendothelial system.
- the patents disclose utilizing the momentum of the saline jets to create a local vacuum to entrain any particulate material produced by the revascularization procedure, with the momentum and the local positive pressure being sufficient to carry the saline and debris to a return collection bag.
- Atherectomy device which is currently undergoing clinical trials is the Coronary TEC® System of Interventional Technologies, Inc. That device is believed to be the subject of U.S. Pat. No. 5,224,945, and basically comprises a catheter having a working head with microtome sharp blades for cutting plaque circumferentially. The excised plaque is extracted by suction through a central lumen in the catheter into an exteriorly-located vacuum bottle. No control of the quantity of flow of the debris-carrying fluid from the catheter is disclosed.
- U.S. Pat. No. 5,030,201 discloses a system including an expandable atherectomy catheter arranged to be rotated to cut through an occluded artery to revascularize it.
- the atherectomy catheter includes an expandable cutting head having plural elongated cutting members which are mounted on a flexible torque tube incorporating a vacuum or aspiration system for retrieval of excised material.
- the cutting head is arranged to be rotated to cause the elongated members to cut away atheromatous material or blood clots.
- the atherectomy catheter is arranged to be inserted into the blood vessel through a coaxial delivery catheter, also forming a part of the system.
- the mechanism for aspirating particles of atheromatous material or blood clots removed by the elongated cutting members is disclosed as being in the form of a vacuum port provided at the proximal end of either the delivery catheter, the atherectomy catheter or a “retracting catheter” which also constitutes a part of the system.
- Saline solution or some other irrigant is infused through one of the catheters of the device that is not being used for aspiration.
- the infusion rate of the saline solution is balanced with the aspiration rate to avoid any net removal of fluid from the vessel.
- the patent teaches that by balancing the infusion rate of the saline solution to the aspiration rate, the net removal of fluid from the vessel can be brought close to zero, thereby minimizing blood loss.
- an artery e.g., the femoral artery
- another vessel e.g., the profunda femoris
- diseased tissue e.g., vessels or lumens at least partially occluded with atherosclerotic plaque, or cancerous tissue, etc.
- diseased tissue e.g., deep venous thromboses (DVT) located in the lower leg regions, etc.
- the system of the present invention may be used to support, replace, or augment existing treatment modalities (e.g., thrombolysis, chemotherapy, etc.) in a way that is less tortuous than existing technologies (e.g., the RotoblatorTM atherectomy system manufactured by Boston Scientific, Natick, Mass.).
- a system for opening a lumen in an occluded blood vessel e.g., a coronary bypass graft
- a living being's vascular system located downstream of another blood vessel, e.g., the aorta, from which blood will flow to the occluded blood vessel.
- the system basically comprises a guide catheter, a lumen-opening catheter, a debris blocking member, and a fluid flow system.
- the guide catheter has a distal end portion and at least one blood entrance port located proximally of the distal end portion.
- the lumen-opening catheter extends through the guide catheter to establish a fluid flow passageway therebetween and has a working head, e.g., a rotatable impacting member, for location immediately adjacent the occlusive material within the occluded blood vessel portion.
- the working head is arranged for operating on the occlusive material, e.g., repeatedly impacting it, to open a lumen for the freer flow of blood therethrough. Some debris may be produced by the operation of the working head.
- the debris blocking member is located distally of the working head to prevent debris from flowing distally thereof.
- the fluid flow system is arranged to introduce an infusate liquid at a first flow rate adjacent the working head and to withdraw that liquid through the passageway between the guide catheter and the lumen opening catheter at a second and higher flow rate to create a differential flow adjacent the working head, whereupon debris produced by the operation of the working head is withdrawn by the differential flow and flows with the liquid proximally through the passageway for extraction.
- the blood entrance port in the distal end portion of the guide catheter is in communication with the passageway between the guide catheter and the lumen opening catheter, whereupon blood from the patent blood vessel portion may enter for merger with the liquid and debris flowing through that passageway.
- the debris blocking member is an inflatable balloon is provided at the distal end of the instrument to physically block the egress of any debris downstream of the apparatus.
- Perfusion means is preferably provided to inflate the balloon and to oxygenate downstream tissue when the balloon is inflated.
- the system of the current invention allows for a working head to eject infusate liquid (e.g., through liquid jets), where said infusate may comprise a therapy or additional material (e.g., drugs, biologically active agents, microspheres, etc.).
- the working head may be arranged to be spaced a certain distance from the lumen's interior surface, such that said infusate may penetrate into the lumen or surrounding tissue.
- the working head may be arranged to eject infusate in opposing or impeding directions to cause turbulent flow, which may facilitate diffusion or penetration into tissue.
- the working head may comprise a complicated fluid jet system, or may comprise simple irrigation catheters (as will be discussed in more detail later).
- pump means operates to independently introduce liquid infusate and/or therapy, and after some dwell time, withdraw the liquid. This dwell time will allow said infusate and/or therapy more time to diffuse or penetrate into tissue.
- the liquid withdraw may use the differential flow arrangement of pumping means, as previously described, or may use only the aspiration portion.
- the differential flow system may remain active during the infusing of drugs (whether they are delivered solely or via infusate). This would allow continuous flow against the artery or lumen wall, which may facilitate diffusion of the drug or therapy into the tissue.
- the working head is arranged to contact the interior wall of the lumen, during operation (e.g., ejection of liquid) such that infusate and/or therapy are forced into the interior wall and/or the surrounding tissue.
- working heads may comprise irrigation catheters, diagnostic instruments (e.g., biopsy devices, etc.) or imaging devices (e.g., laser, infra-red optical or ultrasound, etc.)
- diagnostic instruments e.g., biopsy devices, etc.
- imaging devices e.g., laser, infra-red optical or ultrasound, etc.
- vessels and/or lumens are the location of the treatment to be performed; while blood vessels are designated in some embodiments, that is meant to be exemplary, and not limiting.
- FIG. 1 is a schematic diagram, partially in section, of a system of the subject invention shown during the process of opening a lumen in a totally occluded coronary bypass graft so that blood can flow therethrough;
- FIG. 2 is an enlarged view, partially in section, of a portion of the system of FIG. 1 shown during the process of opening a lumen in the occluded coronary bypass graft;
- FIG. 3 is an even more greatly enlarged view, partially in section, of a portion of the system shown in FIG. 2;
- FIG. 4 is a reduced isometric view of the portion of the system shown in FIG. 3;
- FIG. 5 is an illustration showing the apparatus of FIG. 1, partially in section, during the process of revascularizing a totally occluded femoral artery downstream of the profunda femoris;
- FIGS. 6A and 6B together are an illustration of another embodiment of the system of this invention for revascularizing or opening a lumen in a coronary bypass graft;
- FIG. 7 is an enlarged isometric illustration of a portion of an instrument forming a component of the system shown in FIGS. 6A and 6B during the process of revascularizing a diseased bypass graft;
- FIG. 8 is an enlarged longitudinal sectional view of the distal end of the instrument shown in FIG. 7;
- FIG. 9A is an isometric view of a portion of another preferred embodiment of this invention making use of a guide catheter having at least one flow regulation port to ensure that the vessel being revascularized does not collapse during the extraction of the debris produced by the revascularization;
- FIG. 9B is an isometric view of another portion of the embodiment of the system shown in FIG. 9;
- FIG. 10 is an enlarged isometric view of the distal end of the atherectomy catheter, guide catheter and guide wire of the embodiment of FIG. 9A shown during revascularization of a coronary bypass graft, where the guide catheter tightly fits within the bypass graft;
- FIG. 11 is a view similar to FIG. 10 but where the guide catheter fits loosely within the bypass graft;
- FIG. 12 is a greatly enlarged longitudinal sectional view of the distal end of an atherectomy catheter forming a part of the embodiment of the system of FIG. 9A;
- FIG. 13 is an enlarged longitudinal sectional view of the proximal end of the atherectomy catheter of the system of FIG. 9A;
- FIG. 14 is an enlarged longitudinal sectional view similar to FIG. 8, but showing a modified guide wire and distally located balloon for use with the systems of this invention
- FIG. 15 is a graph showing the four potential sizes and numbers of flow regulation ports for the guide catheter and their potential for precluding collapse of the vessel being revascularized;
- FIG. 16 is a view similar to that of FIG. 10 but showing a method of providing a stent in an occluded blood vessel section, e.g., a bypass graft, to revascularize it, and with the debris extraction system making use of a guide catheter tightly engaging the wall of the blood vessel section;
- a stent in an occluded blood vessel section e.g., a bypass graft
- FIG. 17 is a view similar to that of FIG. 11 but showing a method of providing a stent in an occluded blood vessel section, e.g., a bypass graft, to revascularize it, and with the debris extraction system making use of a guide catheter not engaging the wall of the blood vessel section;
- a stent in an occluded blood vessel section e.g., a bypass graft
- FIG. 18 is an isometric view of a portion of one embodiment of the treatment and therapy delivery system shown positioned within a partially sectioned blood vessel which contains a stent;
- FIG. 19 is a view similar to that of FIG. 18 but showing another embodiment of the treatment system that includes a rapid exchange catheter;
- FIG. 20 is a view similar to that of FIG. 19 but showing another embodiment of the treatment system that includes a high velocity agent delivery catheter with a fluid distribution working head;
- FIG. 21 is a view similar to that of FIG. 20 but showing another embodiment of the treatment system that includes a high velocity agent delivery catheter with a centralizing basket positioned proximal of the distribution head;
- FIG. 22 is a view similar to that of FIG. 21 but showing another embodiment of the treatment system that includes a high velocity agent delivery catheter with a distribution head positioned within a centralizing basket;
- FIG. 23 is an isometric view of a portion of one embodiment of the treatment and therapy delivery system containing two distal protection components and a therapy delivery catheter with a distribution head shown positioned within a partially sectioned branched vessel or lumen;
- FIG. 24 is a view similar to that of FIG. 21 but showing the treatment system that includes an agent delivery catheter with centralizing basket positioned to treat a portion of a blood vessel containing a stent.
- FIG. 1 a system for revascularizing or opening a lumen through a coronary bypass graft which has become occluded, such as by the formation of a stenotic lesion or the build-up of plaque therein.
- a coronary bypass graft which has become occluded, such as by the formation of a stenotic lesion or the build-up of plaque therein.
- the term “occluded” is given its broadest interpretation.
- an “occluded” graft or blood vessel may be either totally blocked or only partially blocked (i.e., there is a passageway or lumen through which some blood may flow).
- the system 20 is arranged to be used for forming or enlarging a lumen through any blood vessel within the body of a living being, e.g., an occluded femoral artery downstream of the profunda femoris, not necessarily an occluded coronary bypass graft or an occluded coronary artery.
- the system 20 is arranged to produce a channel or lumen or to enlarge a lumen through the occlusive material within the vessel and to ensure that any particles of that material which are removed or broken away, during the revascularization procedure are prevented from flowing into the contiguous vascular system.
- the debris produced is drawn into the system for extracorporeal removal and is thus prevented from entering the aorta.
- the system 20 basically comprises an “atherectomy” catheter 22 , a guide catheter 24 , an introducer sheath 26 , a drive sub-system 28 , and a debris removal sub-system 30 .
- the atherectomy catheter 22 is in the form of an elongated flexible tubular body member or jacket at the free or distal end of which is located a rotatable working head 32 .
- the working head 32 is generally similar to that described in U.S. Pat. No. 4,747,821. Alternatively, the working head may be constructed in accordance with the teachings of U.S. Pat. Nos.
- the working head may be any device for opening a lumen through at least partially occlusive material.
- the atherectomy catheter 22 is guided through the vascular system of the patient by the guide catheter 24 (which is conventionally placed) to the site of the vascular occlusion that has been determined to exist, so that the rotary working head is located immediately adjacent the upstream end of the occlusion.
- the atherectomy catheter is located within a coronary bypass graft 10 having an upstream end in fluid communication with the aorta 12 .
- the downstream end of the graft is not shown and is in fluid communication with the coronary artery being bypassed or with smaller arteries of the heart.
- the graft 10 is totally occluded by an atherosclerotic lesion or plaque or some other occlusive material 14 (FIG. 2) within the interior of the graft.
- the atherectomy catheter 22 is introduced into the patient's vascular system in a conventional manner, e.g., via the use of the introducer sheath and guide catheter. As shown, this is accomplished via a percutaneous puncture 16 in the femoral artery 18 .
- the sheath 26 and guide catheter 24 are each of conventional construction and thus their details will not be described in the interest of brevity.
- the working head 32 is arranged to rotate about the longitudinal axis of the catheter at a high rate of speed, e.g., from 10,000 rpm to 200,000 rpm to repeatedly mechanically impact the occlusive material.
- a high rate of speed e.g., from 10,000 rpm to 200,000 rpm to repeatedly mechanically impact the occlusive material.
- an infusate liquid (to be described later) is pumped through the atherectomy catheter by a pump (to be described later and forming a portion of the debris removal sub-system 30 ) and out of distal end of the atherectomy catheter adjacent the working head.
- the opening of the occlusion to allow freer flow of blood therethrough is effected by impacting surfaces of the rotating working head impacting the occlusive material 14 , whereupon portions thereof are removed, e.g., broken away.
- the rotation of the working head produces a powerful, toroidal shaped vortex contiguous with the working head.
- This vortex flow has the effect of recirculating particles that are broken off from the occlusive material by the impact of the rotary working head's impacting surfaces back into contact with such surfaces. Accordingly, those particles are repeatedly impacted, with each impaction reducing the size of the particles further until the majority of resulting particle sizes are very small, e.g., less than 200 microns.
- another pump (also to be described later) of the debris removal sub-system 30 is operated to aspirate the particles produced during the revascularization procedure along with the infusate liquid and some blood.
- the debris removal subsystem 30 utilizing a downstream balloon is operative to ensure that debris produced as the working head opens a lumen through the occlusion is not able to flow upstream into the upstream vessel, e.g., the aorta 12 , during the lumen opening procedure, and once the working head breaks through or exits the occlusion on the downstream side, that the debris is not able to flow downstream into the downstream blood vessel(s).
- the upstream vessel e.g., the aorta 12
- the atherectomy catheter includes a jacket 34 which is formed of any suitable material, e.g., plastic, and has a small outside diameter. In the preferred embodiment shown herein, the outside diameter of the jacket 34 is approximately 1.5 mm (5 French). This size catheter is merely exemplary.
- the means for effecting the rotation of the working head is the heretofore identified drive sub-system 28 . That sub-system is similar to the drives disclosed in the aforementioned U.S. Pat. Nos. 4,686,982, and 4,747,821 and basically comprises an air-turbine motor and associated rotary drive cable (to be described later). Other drive systems can be utilized, as well.
- the working head 32 of this embodiment includes an impeller portion 44 and a central shank portion or axle 36 (FIG. 4) projecting proximally therefrom.
- the axle 36 is supported in a central bore of a bushing 38 fixedly mounted at the distal end of the catheter's jacket 34 by an encircling mounting band 40 .
- the shank 36 is fixedly secured to the distal end of a flexible drive cable 42 forming a portion of the drive sub-system 28 .
- the impeller 44 forms the distal portion of the working head and is fixedly secured to the shank 36 so that it will be rotated at a high rate of speed about its longitudinal axis by the concomitant rotation of the drive cable.
- the impeller portion 44 comprises a circular disk or base 52 from which a generally planar tip 54 projects.
- the tip 54 has a pair of generally planar diametrically disposed relieved side surfaces or faces which merge with an arcuate front or distal surface to form a pair of arcuate impacting surfaces 54 A and 54 B.
- Each of the impacting surfaces is radiused in a plane perpendicular to the axis of rotation of the working head so that each is not sharp, e.g., is in the range of approximately 0.001 inch to approximately 0.008 inch, although in the scale of the figures of the drawing they appear to be a sharp line.
- the working head is located within a cylindrical shroud 56 (FIGS. 3 and 4) fixedly mounted on the front of the bushing 38 .
- the shroud 56 includes a cylindrical sidewall portion 58 and a generally conical distal wall portion 60 terminating in a circular opening 62 in the distal end thereof.
- the shroud may be of any suitable outside diameter, e.g., 7 to 8 French.
- the distal arcuate portion of the impeller tip 54 projects out of the central or front opening 62 .
- a side port or open window 64 is located in the sidewall 58 .
- the system 20 utilizes an infusate liquid to expedite the revascularization of the vessel.
- the infusate liquid is pumped at a flow rate Q 1 (to be described later) down through the interior of the catheter jacket 34 through four equidistantly spaced grooves 46 extending down the central bore of the bushing 38 and via radial ports 48 to an annular recess 50 in the front wall of the bushing.
- the annular recess is in fluid communication with the side port or window 64 in the shroud so that the infusate liquid can exit therefrom.
- the direction of flow of the infusate liquid down the atherectomy catheter and out the shroud at its working head is shown clearly in FIG. 4.
- the occlusive material particles which are broken away are progressively reduced in size until they are aspirated by aspiration means forming a portion of the debris removal sub-system 30 . That means will be described later. Suffice it for now to state that the aspiration means withdraws the infusate liquid, the debris particles and some blood at an aspiration flow rate of Q 2 .
- the liquid exiting from the window 64 of the shroud will tend to push the atherectomy catheter's distal end sideways or laterally in the direction opposite to the direction of the liquid exiting that window.
- This hydrodynamic action may be used to aid in steering the catheter to a desired position with respect to an occlusion to be revascularized.
- the atherectomy catheter when negotiating a branch in the artery system to reach the occlusion to be revascularized, the atherectomy catheter can be rotated or twisted about its longitudinal axis so that the shroud's window is facing in the opposite direction to the branch to be entered.
- this action will cause the side directed liquid exiting the window 64 to push the catheter's distal end sideways, whereupon it can enter the desired arterial branch.
- Such “hydrodynamic steering” of the atherectomy catheter can be accomplished in other manners and by other means than by the use of a shroud having a single side window or port.
- this invention contemplates an intravascular catheter instrument, of any type, including any means for producing an asymmetric, e.g., side directed, fluid flow adjacent the distal end of the catheter so that it can be steered into a desired position by appropriate rotation of the catheter about its longitudinal axis.
- the guide catheter 24 is of any conventional construction.
- the Y connector 66 has one input leg including a Touhy-Borst adjustable hemostasis valve 66 A through which the atherectomy catheter 22 passes.
- the other input leg i.e., the angled leg 68 , is connected to the aspiration portion of the debris removal sub-system 30 (to be described later).
- Power for operating the atherectomy catheter is provided by the drive sub-system 28 .
- That system includes an air turbine motor 70 which is coupled to the proximal end of the flexible drive cable 42 .
- the air turbine 70 is provided with compressed air via an input line or conduit 72 .
- Air for the line 72 is provided from a source (not shown) via an associated regulator 74 , and the conventional control valve 76 .
- the control valve is coupled to the input line 72 of the air turbine.
- a pressure gauge 78 is connected between the regulator 74 and the control valve 76 .
- the regulator 74 , the control valve 76 , the pressure gauge 78 and the associated lines or conduits and the air source make up the drive sub-system 28 .
- the control valve 76 is of any conventional construction, be it mechanical or electrical.
- the air turbine motor 70 is also of any conventional construction, as is the regulator 74 and the pressure gauge 78 .
- the air turbine includes an outlet port in communication with the ambient atmosphere, via a line 80 . It must be pointed out at this juncture that the atherectomy catheter 22 need not utilize an air turbine motor to rotate the working head.
- an electric motor can be provided to replace the air turbine to drive the rotating cable and the associated working head.
- the debris removal sub-system 30 basically comprises a source 82 of the infusate liquid “S”, e.g., saline plus a 30% contrast media, a first positive displacement pump 84 , an input line or conduit 86 , an outlet line or conduit 88 , a second positive displacement pump 90 , and a debris collection vessel 92 .
- the input line 86 and its associated components, i.e., the pump 84 and infusate source 82 serve as the “infusion” means for the system 20 .
- the input line 86 is coupled via a connector to the interior of the atherectomy catheter, i.e., to the annular space within the catheter's jacket between it and the drive cable.
- the infusate liquid S is pumped at the flow rate Q 1 by the positive displacement pump 84 through line 86 from the supply or source 82 .
- the infusate liquid S exits the catheter's working head and circulates as described earlier.
- the rate of flow Q 1 of the infusate liquid is established by the positive displacement pump 84 under control of some automatic or manual controller (not shown). In accordance with one exemplary method of use the pump is operated to produce a flow rate Q 1 the range of 5-80 ml. per minute.
- the output line 88 and its associated components, i.e., the pump 90 and debris collector vessel 92 serve as the “aspirating” means for the debris removal sub-system 30 .
- the aspiration line 88 is connected to the leg 68 of the Y connector 66 .
- the pump 90 is arranged to be operated to pump the infusate liquid, the debris produced by the revascularization, and some small amount of blood at the flow rate Q 2 in the proximal direction through the annular space between the atherectomy catheter 22 and the guide catheter 24 and out through the connector leg 68 into the outlet line 88 , and from there to the collector vessel 92 .
- the flow rate Q 2 is selected to be greater than Q 1 .
- the flow rate is selected to be in the range of 5-100 ml. per minute, with the differential between Q 2 and Q 1 being between 5 and 50 percent.
- the use of an aspiration flow rate Q 2 which is higher than the infusion flow rate Q 1 insures that any debris, e.g., particles of the occlusive material making up the graft's lesion, produced from debriding that material is positively prevented from flowing into adjacent vessel portions.
- the aspiration flow rate Q 2 is greater than the infusion flow rate Q 1 , some blood equal to Q 2 ⁇ Q 1 will also be withdrawn from the upstream vessel, e.g., the aorta as shown in FIGS. 1 and 3.
- the withdrawal of some blood from that vessel insures that the debris produced cannot flow upstream to enter into it. Instead the debris particles will be entrained within the infusate liquid and blood which is withdrawn through the aspiration line.
- the rate of blood withdrawn is preferably be kept to a minimum, e.g., 40 ml. per minute in the interests of patient safety.
- the operation of the pumps 84 and 90 are coordinated so that Q 2 is equal to some variable times Q 1 , where that variable is greater than 1 and is adjustable to accommodate the needs of the patient.
- the coordination of the flow rates is preferably accomplished automatically, so that a change in one flow rate automatically results in a proportional change in the other flow rate.
- This coordinated action may be accomplished by a mechanical linkage between the pumps, or by a common electrical controller for the pumps. Manual control of the pumps is also envisioned for some applications.
- any suitable positive displacement pumps can be utilized, e.g., peristaltic pumps or piston pumps, in the system.
- the infusate liquid may be provided with a contrast medium, e.g., 30% contrast medium, so that the revascularization procedure can be viewed using conventional imaging techniques.
- the infusate liquid can, if desired, be oxygenated to eliminate distal ischemia when the catheter is used for arterial restriction opening procedures.
- small amounts of heparin, urokinase, etc., or other drugs can be added to the infusate liquid for the procedure.
- the subject invention provides a viable means for effecting the revascularization of partially or totally occluded coronary bypass grafts, while assuring that any debris particles produced during the revascularization procedure is removed from the patient's body.
- the subject invention is suitable for revascularizing other occluded vessels, as well.
- FIG. 5 the system is shown in use revascularizing a totally occluded femoral artery 18 downstream of the profunda femoris 18 A.
- the system functions to capture the debris created during the lumen opening procedure by preventing it from going along side the catheter and exiting down the profunda to end up in the distal capillary beds.
- a portion Q 4 +Q 1 ⁇ Q 2 of the blood flowing down the femoral artery 18 to the situs of the occlusion will be permitted to flow into the profunda femoris, while the portion Q 2 ⁇ Q 1 of the blood and infusate liquid is diverted and/or withdrawn into the guide catheter to ensure positive debris removal in the same manner as described earlier.
- a femoral artery revascularization procedure is likely to prove beneficial.
- FIGS. 6A and 6B an alternative embodiment 100 of the system of the subject invention is shown.
- the system 100 is similar in most respects to system 20 described heretofore.
- the guide wire includes a debris blocking member, e.g., an inflatable balloon (also to be described later).
- a debris blocking member e.g., an inflatable balloon (also to be described later).
- the balloon is located distally of the working head of the atherectomy catheter and the balloon serves to physically block any debris produced by the system 100 which may tend to escape extraction from flowing distally.
- the atherectomy catheter used in the system 100 is designated by the reference numeral 22 ′ and is identical in most respects to the catheter 22 described heretofore.
- the features common to catheters 22 and 22 ′ will not be reiterated. So too, the features common to systems 100 and 20 will also not be reiterated.
- common components will be given the same reference numerals.
- the system 100 includes a controller or console 102 housing the heretofore identified infusate pump 84 and the extraction pump 90 .
- Each of these pumps is a peristaltic pump.
- the console 102 also includes a flow control section 104 for establishing the various fluid flows of the system, as will be described later, and a speed control section 106 for establishing the operational speed of the working head of the atherectomy catheter. The details of the speed control section 106 will also be described later.
- a perfusate pump 108 is also provided in the console 102 .
- the perfusate pump 108 is also a peristaltic pump and its operation will be described later.
- the pump 108 is arranged to provide a perfusion liquid, e.g., blood or a suitable synthetic oxygenation liquid, downstream of the inflatable balloon to perfuse downstream (distally) located tissue.
- a perfusion liquid e.g., blood or a suitable synthetic oxygenation liquid
- the pump 108 also serves to effect the inflation of the balloon.
- Compressed gas (e.g., air or nitrogen) is provided via line 72 from the console 102 to the catheter's turbine 70 .
- the console receives the compressed gas from a tank 110 via an input line 112 .
- the rotational speed of the turbine is controlled by the speed control section 106 of the console 102 .
- On/off operation of the turbine is controlled by a turbine foot control pedal 114 and an associated gas line 116 connected to the console. This pedal also initiates operation of the infusate pump 84 .
- the speed control section 106 of the console includes a rotary knob for establishing the desired rotational speed of the turbine and an associated digital display for displaying the turbine's speed.
- the console also includes an on/off switch 118 for enabling electrical power to be provided to the system's electrical components when the switch is in the “on” position.
- the foot pedal 114 is used by the operator of the system 100 to initiate operation of the infusate pump to cause the infusation liquid to flow down the guide wire and out its distal end and to start the atherectomy catheter's turbine 70 a short time, e.g., 2 seconds, after the infusate liquid begins to flow.
- the use of the foot pedal frees the operator's hands for other purposes.
- the perfusate pump 108 is connected via an input line to a bag 120 containing the perfusion liquid.
- the output of the perfusate pump 108 is provided via a line 122 to the guide wire of the system 100 .
- the guide wire is designated by the reference numeral 124 and includes the heretofore identified balloon. That balloon is designated by the reference number 126 and, as seen clearly in FIGS. 6B, 7 and 8 , is located adjacent the distal end of the guide wire 124 .
- the atherectomy catheter 22 ′ is an “over-the-wire” type of device. Thus, it includes a central lumen for receipt of the guide wire 124 so that the catheter 22 ′ can be threaded over the guide wire 124 .
- the guide wire 124 serves to perfuse distally located tissue and to inflate its balloon 126 so that the balloon blocks any particulate material (debris) from flowing distally.
- the perfusate liquid in the bag 120 is pumped by the perfusate pump 108 through the line 122 and through the interior of the guide catheter 124 where some of it fills or inflates the balloon and the remainder exits at the distal end of the catheter to perfuse downstream tissue, as will be described later.
- the rate of flow of the infusate, extraction and perfusate liquids is established by the flow control section 104 of the console via its various up/down switches and associated digital displays.
- the ratio of the infusate flow rate to the extraction flow rate is adjustable. This is accomplished by the appropriate setting of the “infusate flow” and “ratio” up/down switches of the flow control section of the console. The desired ratio and the infusate flow rate are displayed by the associated digital displays.
- FIG. 7 there is shown in greater detail the distal end of the atherectomy catheter 22 ′ located within a diseased bypass graft, e.g., a re-occluded mammary artery 10 ′.
- the diseased artery leads to a distal blood vessel 15 , i.e., the vessel to be fed by the graft 10 ′.
- the guide wire 124 is in the form of an elongated flexible member, whose construction will be described later with reference to FIG. 8.
- the distal end of the guide wire 124 is in the form of a somewhat soft or flexible, precurved tip 128 .
- the free end of the catheter's tip is a hemispherical dome 130 .
- the balloon 126 is disposed slightly proximally of the free end 130 of the guide wire 124 .
- FIG. 8 the details of the distal end of the guide wire 124 and balloon are shown (although the tip 128 is shown being linear in the interest of drawing simplicity).
- Most of the length of the guide wire i.e, from its proximal end to the location of the balloon 126 , is in the form of a two start helical spring 132 (see FIG. 8) whose convolutions are in close engagement (abutment) with one another.
- the spring 132 enables the guide wire to be bent through a small radius of curvature to facilitate its intravascular placement via the conventional guide catheter 24 .
- a liquid impervious, e.g., rubber or plastic, flexible liner tube 134 inside the helical spring 132 . This tube prevents the egress of the perfusate liquid through the interface between successive convolutions of the helical spring 132 as that liquid is pumped down the guide wire 124 .
- a perforated support tube 136 is mounted within a distal end helix termination 138 of the spring 132 .
- the support tube 136 is arranged to mount the balloon 126 thereon and includes a plurality of radially located apertures or ports 140 .
- the balloon 136 is an annular member of any conventional construction, e.g., rubber, and is mounted on and is disposed about opposite ends of the perforated support tube 136 .
- the balloon 136 is held in place and sealed to the periphery of the support tube at each end thereof via respective bands 142 .
- Each band 142 extends about one cylindrical end of the balloon.
- the perfusion liquid when the perfusion liquid is pumped down the guide wire 124 by the pump 108 it passes through the apertures or ports 140 (as shown by the arrows in FIG. 8) to fill up, i.e., inflate, the balloon 126 .
- the distal end of the perforated support tube is located within a spring helix termination 144 forming the proximal end of the guide wire tip portion 128 .
- the portion 128 is also formed as a two start helix, like portion 132 .
- no fluid-impervious sleeve is located within the tip portion 128 so that the interface between successive convolutions of the spring forming the tip portion 128 serve as passageways through which the portion of the perfusion liquid which doesn't enter the balloon exits the guide wire as shown by the arrows 146 in FIG. 8.
- the drive cable for rotating its working head is in the form of a spiral spring helix having a central lumen extending down its center.
- the proximal end of the drive cable is connected to the output of the turbine 70 while the distal end is connected to the working head. That working head is designated by the reference number 32 ′ and is shown in FIGS. 6A and 7.
- the central lumen of the spiral helix drive cable forms the passageway for receipt of the guide wire 124 .
- an anti-friction sleeve or some other anti-friction bearing can be provided at the interface between the inner surface of the spiral drive cable and the outer surface of the guide wire.
- the working head 32 ′ is similar in construction to the working head 32 of system 20 except that the working head 32 ′ includes a central bore 148 through which the guide wire 124 extends. As can be seen clearly in FIG. 7, the working head 32 ′ is unshrouded, i.e., is not located within a shroud like the working head 32 of the atherectomy catheter 22 .
- the guide wire 124 with its balloon 126 deflated and with the atherectomy catheter 22 ′ mounted thereon so that the balloon 126 and tip portion 128 extend beyond the working head 32 ′ is threaded through a preplaced guide catheter 24 in the patient's vascular system until it is at a desired situs, such as at the arch of the aorta.
- the guide wire 124 is advanced with respect to the atherectomy catheter 22 ′ so that the guide catheter crosses the lesion or atherosclerotic deposits in the bypass graft 10 ′.
- the precurved tip of the guide wire 124 facilitates the placement of the guide wire.
- the guide wire can be rotated about its longitudinal axis to point the tip 130 in the desired direction.
- the balloon 126 can be inflated and the distally located tissue perfused.
- the exiting perfusion liquid is shown by the arrows in FIG. 7.
- the perfusate liquid is pumped by pump 108 and associated conduit 122 through the hollow interior of the guide wire 124 , so that it passes through the apertures or ports 140 in the support tube 136 to inflate the balloon 126 to the state shown in FIG. 7, while the remainder of that liquid flows out of the open distal end of the support tube 136 , into the hollow interior of guide wire's tip 128 , and out through the interface between the immediately adjacent convolutions of the tip. Accordingly, distally located tissue is oxygenated, notwithstanding the fact that the balloon is inflated and thus blocking the flow of blood through the bypass graft 10 ′.
- the system may utilize an alternative guide-wire mounted debris-blocking balloon. That alternative embodiment of the guide-wire is designated by the reference number 124 ′, is shown clearly in FIG. 14, and will be described in detail later.
- the rate of flow of the infusate liquid is set by the flow control section switch and the ratio of that flow to the extraction flow rate is established by the ratio control switch of the flow control section. Accordingly, when ready the operator presses the foot pedal 114 to start the infusate pump. This action provides the infusate liquid through line 86 and through the associated components of the catheter 22 ′, whereupon the infusate liquid exits from the catheter at the working tip 32 ′ as described earlier.
- the rate of extraction of liquid through the annular space between the inner surface of the guide catheter 24 and the outer surface of the atherectomy catheter 22 ′ is established by the extraction pump 90 under control of the associated flow controls of the console.
- the turbine 70 is arranged to commence operation on a fixed time delay, e.g., 2 seconds, after the infusate pump commences operation in response to the depression of the foot pedal 114 . This action causes the working head to begin rotating at a high rate of speed.
- the desired speed setting for the turbine is established by setting of the rotary knob of the speed control section of the console.
- some restraining means (not shown but like the cradle assembly of the system 200 to be described later) is used to hold or clamp the guide wire in position when the atherectomy catheter is operated to prevent the rotation of the working head 32 ′ from causing the guide wire to rotate.
- the debris particles produced by the rotary working head repeatedly impacting the plaque or other deposit within the diseased graft are withdrawn by the extraction pumps into the collection bag 92 , in the same manner as discussed earlier. Any debris particles which may have otherwise escaped being withdrawn from the patient's body by the extraction subsystem are positively prevented from flowing distally by the barrier established by the inflated balloon 126 . Thus, such particles will eventually be extracted.
- the balloon 136 can be deflated by turning off the infusation pump. Then, the atherectomy catheter 22 ′ and the guide wire 124 can be removed through the guide catheter 24 .
- the atherectomy catheter for producing the lumen through the vascular occlusion need not be a rotary impacting device, like described above.
- a system constructed in accordance with any embodiment of this invention may make use of any instrument having any type of working head, e.g., a reciprocating impacting working head, a combined rotary and reciprocating impacting working head, a rotary cutting head, a reciprocating cutting head, a rotary abrasive head, etc., to open the lumen in the occlusive material in the blood vessel.
- the working head need not be shrouded.
- any of the heretofore identified prior art atherectomy devices can be utilized as part of the system 20 or 100 .
- Some thrombectomy devices may also be utilized as part of the system 20 or 100 (or even as part of the systems 200 and 500 , to be described later).
- One such potential device is the Amplatz Thrombectomy Device designated by the trademark CLOT BUSTER by Microvena Corporation. It should also be pointed out that the working head of the device for forming the lumen need not even engage the occlusive material, so long as its lumen-opening operation produces debris particles to be removed.
- devices making use of liquid jets, laser beams, etc. can be utilized to open the lumen as part of the system of this invention.
- any type of instrument for opening a lumen through the occlusive material and which produces debris can benefit from use in the system of this invention, i.e., a system which establishes a differential flow, wherein the infusate flow is less than the aspiration flow so that particles or pieces of occlusive material removed are positively precluded from flowing into adjacent vessels.
- a system which establishes a differential flow wherein the infusate flow is less than the aspiration flow so that particles or pieces of occlusive material removed are positively precluded from flowing into adjacent vessels.
- the production of a local vortex flow adjacent the working head is desirable to effectuate the lumen opening process and to reduce debris particle size, it is not crucial to this invention.
- FIGS. 1-8 it has been assumed that there will be some blood flow from the patent upstream blood vessel, e.g., the aorta in the case of a revascularization of a bypass graft, which may flow about the exterior of the distal end of the guide catheter 24 to merge with the flow being drawn into the passageway between the guide catheter 24 and the atherectomy catheter 22 . See for example, FIG. 7 wherein blood flow Q 2 ⁇ Q 1 from the aorta flows around the outer surface of the distal end of the guide catheter 24 between the guide catheter and the inner wall of the bypass graft 10 ′.
- the potential for vessel collapse is even more acute.
- the Clement et al. patent positively seals off a space in the vessel to be revascularized between a pair of balloons.
- one balloon is located on the distal end of a guide wire distally of the restriction to be opened and the other balloon is located on the distal end of a guide catheter through which a rotary ablation catheter extends.
- FIGS. 9-13 there is shown another alternative embodiment of a system 200 constructed in accordance with this invention utilizing an atherectomy catheter 22 ′′ for revascularizing occluded vessels, e.g., coronary bypass grafts.
- the system 200 obviates the problem of potential vessel collapse by providing automatic access to blood flow from a patent, upstream vessel, e.g., the aorta 12 , via use of at least one flow control or regulation port in the wall of the guide catheter 24 (or any other tubular member through which the atherectomy catheter 22 ′′ extends and through which the infusate liquid, blood and debris will be aspirated).
- the flow control or regulation port(s) extend(s) through the wall of the guide catheter 24 close to its distal end, yet is(are) located sufficient proximally from the distal end of the guide catheter so that when the guide catheter is in its normal position for enabling an atherectomy catheter 22 ′′ (to be described later) to revascularize the restricted vessel, e.g., a coronary bypass graft 10 ′, the side port(s) is(are) in direct fluid communication with the blood flowing in the patent upstream vessel, e.g., the aorta 12 .
- two such side flow regulation ports 24 A and 24 B are provided near the distal end of the guide catheter 24 .
- the two side ports 24 A and 24 B extend through the wall of the guide catheter 24 , they are in fluid communication with the interior of the guide catheter, and hence with the annular space or passageway between the inner surface of the guide catheter 24 and the outer surface of the atherectomy catheter 22 ′′ which extends through the guide catheter. As described earlier it is through this annular space or passageway that the infusate liquid, blood and any debris, e.g., atherosclerotic plaque produced by the revascularization procedure, is extracted by the extraction subsystem.
- At least one flow regulation or control port ensures that the vessel being revascularized does not collapse as the debris is extracted, even if the guide catheter 24 is tightly fit within the bypass graft 10 , such as shown in FIG. 10, and even if the extraction pump 90 is operating at a much higher rate that the infusate pump 84 .
- This automatic control or regulation provided by the at least one side port(s) will be described after a brief background discussion. To that end, as will be appreciated by those skilled in the art, if the guide catheter 24 (or other tubular member through which the atherectomy catheter extends) does not tightly fit in the bypass graft (such as shown in FIG.
- blood from within the aorta 12 may flow around the outside of the guide catheter 24 (see the arrows A 1 ) to join with the blood, debris particles and infusate fluid flowing into the open end of the guide catheter (see the arrows A 2 ). Accordingly, the action of the extraction pump to remove liquid from the space in the bypass graft section between the end of the guide tube and the distally located blocking balloon 126 ′ (forming a portion of the guide-wire 124 ′ to be described later), will not collapse that vessel section, even if the guide catheter does not make use of any flow control or regulation side port(s). If however, a guide catheter without any flow control or regulation side ports is tightly fit within the bypass graft, the possibility for vessel collapse exists if the extraction rate is not controlled precisely with respect to the infusion rate as discussed earlier.
- This blood then merges with the flow (shown by arrows A 2 ) of blood, infusion liquid and debris particles produced by the action of the rotary working head 32 ′′ in the bypass graft section between the distally located blocking balloon 126 ′ of the guide wire 124 ′ (a variant of guide-wire 124 and which will be described later with reference to FIG. 14) and the distal end of the guide catheter 24 .
- the flow control side port(s) one can ensure that the pressure within the vessel being revascularized, e.g., the bypass graft, is positive, thus ensuring that the vessel section will not collapse.
- a guide catheter 24 having at least one flow control port can be used with any prior art atherectomy catheter system, e.g., the atherectomy system of the heretofore identified Clement et al. U.S. Pat. No. 5,681,336.
- FIGS. 9A, 9B, 12 and 13 there are shown the details of system 200 .
- That system basically comprises the same system as the system 100 shown in FIGS. 6-8 described heretofore, with some slight minor modifications (as will be described later).
- the common components of those systems will be given the same reference numbers and their construction and operation will not be reiterated.
- the system 200 basically comprises a guide catheter 24 , a modified guide wire 124 ′ with a distally located inflatable balloon 126 , an atherectomy catheter 22 ′′ with a distally located rotary working head 32 ′′ disposed over the guide wire and within the guide catheter to be moved longitudinally with respect thereto, a drive sub-system 28 for rotating the working head 32 ′′, a cradle assembly 202 (FIG.
- the guide wire 124 ′ is shown clearly in FIG. 14 and is similar to the guide wire 124 in that it includes an inflatable balloon 126 ′ located immediately adjacent the distal end of the guide wire 124 ′, a flexible distal end portion 128 ′ immediately distally of the balloon 126 ′ and terminating in an atraumatic tip 130 ′ at the distal end of the guide-wire 124 ′.
- the guide wire 124 ′ is not arranged to perfuse downstream tissue, as is the case of the guide wire 124 .
- the guide wire 124 ′ basically comprises an elongated small diameter, flexible, hollow wire or tube 180 , e.g., a “hypo” tube formed of type 304 stainless steel having a 0.010 inch outside diameter and a 0.005 inch inside diameter.
- a central passageway or bore 180 A extends the full length of the guide-wire tube 180 .
- the balloon 126 ′ is formed of any suitable material, e.g., latex of a thickness of approximately 0.006 inch, and is fixedly secured slightly proximally of the distal end portion of the tube 180 via a plurality of loops or lashes of a filament 182 , e.g, polypropylene, wrapped about the tubular proximal end portion 184 of the balloon 126 ′ and similar loops or lashes 182 wrapped about the tubular distal end portion 186 of the balloon 126 ′.
- an inflation gas e.g., carbon dioxide
- plural gas ports 180 B extend through the wall of the guide-wire tube 180 in communication with the interior of the balloon and with the central passageway 180 A in the guide-wire tube 180 .
- the balloon can be any suitable size, depending upon the application.
- the outside diameter of the balloon when deflated may be approximately 0.03 inch, and may be inflated to an outside diameter of up to 0.2 inch (5 mm).
- a tapered, flexible, core wire 188 e.g., type 304 stainless steel, is soldered by any suitable lead-free solder into the distal end of the central passageway 180 A of the guide-wire tube 180 to seal its distal end.
- a tight helix or coil 128 ′ is also soldered by a lead-free solder to the outer surface of the distal end of the tube 180 .
- the coil 128 ′ forms the curved, flexible distal end of the guide-wire and can be fabricated of any suitable radiopaque material, e.g., platinum wire of 0.003 inch diameter.
- the coil 190 extends for a short distance, e.g., approximately 1 inch, from the end of the tube 180 and is of a suitably small outside diameter, e.g, 0.018 inch.
- the distal end of the core 188 extends into a small bore in the atraumatic tip 130 ′ and is soldered in place by a lead-free solder.
- the distal end of the coil 128 ′ is also soldered to the atraumatic tip by a lead-free solder.
- the atraumatic tip 130 ′ is in the form of a hemisphere of any suitable material, e.g., type 300 stainless steel.
- This ring serves as a stop member for the atherectomy catheter 22 ′′.
- the rotating working head 32 ′′ will be prevented from engaging and perforating the distally located balloon by the ring or stop 190 .
- the advancement of the working head along the guide wire to remove the plaque or other restriction-forming material in the vessel will not present any danger of perforating the balloon.
- the console 204 is similar to console 102 described heretofore and includes various electrical and electronic components, e.g., a microprocessor and associated circuitry to accomplish the various functions of the system and to display various system parameters.
- the console 204 includes the heretofore identified peristaltic infusion pump 84 and the peristaltic extraction pump 90 .
- Compressed gas e.g., nitrogen
- the tank provides the compressed nitrogen via heretofore identified regulator 74 and associated valve 76 into line 112 and from there to line 72 .
- the gas pressure is displayed on a dial or meter 78 on the front of the console.
- Control of the turbine's rotational speed is effected by a turbine speed adjustment knob 206 on the front console.
- the turbine's speed is displayed on a digital display panel 208 .
- An optical signal indicative of the turbine's speed is provided via a fiber optic line 210 A.
- This line is connected to a connector 212 A on the console.
- Another fiber optic line 210 B is connected to another connector 212 B on the console, whereupon a beam of light from the console is carried down line 212 B to the turbine rotor where it is broken or chopped up by the rotating blades.
- the chopped up light beam which is indicative of rotor speed is carried back to the console via line 210 A and connector 212 A.
- Control of the turbine is effected via a turbine foot control (or hand control, not shown) 114 connected via line 116 to a connector 214 on the console.
- a pressure transducer 218 (FIG. 9A) is connected in the line 86 coupled from the infusate pump 84 to the atherectomy catheter 22 ′′.
- the pressure transducer provides an output signal via a line 220 to a connector 222 (FIG. 9B) on the console.
- the rate of infusion liquid flow into the atherectomy catheter 22 ′′ is effected by the heretofore identified peristaltic pump 84 .
- the speed of that pump is controlled via an up/down switch 224 on the console.
- the pump's speed in RPM is displayed on a digital readout panel 226 .
- the speed of the extraction pump is controlled by an up/down switch 228 on the console and that pump's speed is displayed on an associated digital readout panel 230 .
- the console also includes an on/off switch 232 for providing electrical power to the system when the switch is in the on position.
- Data from the console e.g., operating parameters, etc.
- any suitable device e.g., a laptop computer 216
- conventional multipin electrical connector 218 e.g., an RS 232 serial port, and associated cable 220 .
- the console 204 may also include various alarm devices to warn operating personnel of certain abnormal conditions.
- the console may include a low battery power warning lamp on the front of the console to warn operating personnel that the battery is low.
- An infusate high pressure warning lamp may also be provided on the console along with an associated audible annunciator to produce respective visible and audible warning signals when a high pressure infusate condition exists.
- the catheter 22 ′′ is similar to catheter 22 ′ in that it includes a jacket 34 having a distal end.
- a rotary working head or tip 32 ′′ is located at the distal end of the jacket.
- the tip 32 is preferably constructed in accordance with the teachings of U.S. Pat. No. 4,747,821.
- tip 32 ′′ unlike the tip of the aforementioned patent includes a central passageway or bore 148 through it (like tip 32 ′). It is through this bore that the guide wire 124 extends.
- the working head 32 ′′ is mounted for rotation within a bushing 302 secured to the distal end of the jacket.
- the bushing 302 is similar in construction to the bushing of the U.S. Pat. No. 4,747,821 and it includes plural passages 46 ′′ extending along its length through which the infusate liquid passes to exit out of the tip.
- it includes plural radial passageways 304 in the thrust pad portion forming the distal end of the bushing and which are in communication with the passages 46 ′′ through which the liquid exits radially.
- the radial passages are constructed similarly to those of U.S. Pat. No. 5,049,124 (Bayles) whose disclosure is incorporated by reference herein.
- the rotary working head 32 ′′ also includes a tubular shank portion through which the central bore 148 extends. Infusate liquid from the passageway 312 is enabled to flow into the open proximal end of the bore 148 and through the annular space or clearance between the inner surface of that bore and the outer surface of the guide wire extending through the bore as shown by the arrows in FIG. 12.
- a sleeve 306 is located immediately proximally of the bushing 302 and extends about the shank portion of the rotary working head 32 ′′.
- the sleeve 306 is welded to the shank portion of the rotary working head.
- the rotary working head 32 ′′ is arranged to be rotated at a high rate of speed within the bushing by a drive cable 308 .
- the cable 308 is a bifilar or double helix formed of any suitable material, e.g., 304 stainless steel or Nitinol, and is flexible so that the atherectomy catheter can be readily bent to follow tortuous paths to the revascularization site, i.e., the coronary bypass graft.
- the distal end helices of the drive cable 308 are welded at 310 to the shank portion of the rotary working head 32 ′′.
- the outer diameter of the drive cable is less than the inner diameter of the catheter jacket 34 to form an annular passageway 312 therebetween. This passageway extends the full length of the atherectomy catheter and serves to carry the infusion liquid to the working head 34 ′′.
- a flexible plastic tube or sleeve 314 is located within the central passageway of the bifilar drive cable 308 and extends for the full length thereof.
- the tube 314 includes a central passageway 316 which is of approximately the same internal diameter as the bore 148 extending through the working head 32 ′′ and is coaxial therewith in order to accommodate the guide wire 124 therethrough.
- the sleeve 314 serves to form a barrier between the metal helices of the drive cable 308 and metal guide wire extending through it, while preventing the helices of the cable 308 from closing up as the drive cable is rotated.
- FIG. 13 there is shown the details of the proximal end of the atherectomy catheter 22 ′′.
- the proximal end of the jacket 34 is flared outward at 318 .
- the flared proximal end of the jacket is connected to the distal end of a turbine housing or body 320 via a capture nut 322 .
- the capture nut 322 includes internal threads 324 which mate with corresponding external threads on the distal end of the turbine housing 320 .
- the free end of the turbine housing is tapered at 326 .
- the capture nut 322 also includes a tapered inner surface 328 merging into a central bore 330 through which the catheter jacket 34 extends.
- the flared end 318 of the jacket is tightly interposed between the surface 330 of the nut and the tapered surface 326 of the turbine housing 320 .
- the distal end portion of the turbine housing 320 also includes a central bore 332 into which the infusate fluid will be injected for flow into the annular passageway 312 in the atherectomy catheter, as will be described later.
- the proximal end of the bifilar drive cable 308 is connected, e.g., welded, to an adaptor sleeve 334 .
- the adaptor is a tubular member which is in turn welded to the turbine rotor drive shaft 336 .
- the turbine drive shaft 336 is an elongated tubular member. Being tubular the turbine drive shaft 336 includes a central passageway. It is through this central passageway that the guide wire is arranged to be extended.
- the turbine rotor drive shaft 336 extends through the central bore 332 in the turbine housing and terminates at its proximal end in a seven-bladed turbine rotor 338 .
- the rotor is located in an enlarged proximally located flanged portion 322 of the turbine housing 320 .
- the flanged portion 322 includes a hollow interior chamber 340 in which the turbine blade 338 is located.
- An enlarged central bore 342 extends distally of the chamber 340 and is axially aligned with the central bore 332 in the distal portion of the turbine housing 320 .
- a sleeve bearing 344 is located within the central bore 342 .
- the turbine rotor shaft 336 extends through a central bore in the bearing with a slight clearance or leakage passageway, e.g., 0.0005 inch, to form a fluid leakage path to facilitate the cooling of the bearing.
- An O-ring 346 is located within an annular recess in the distal portion of the sleeve bearing 344 to form a fluid-tight seal.
- a star washer 348 is located within an enlarged portion of the bore 342 to hold the sleeve bearing in place.
- the proximal end of the turbine drive shaft 336 extends into a ball bearing assembly 350 to center the turbine shaft on the longitudinal axis of the housing.
- a guide-wire centerer and leakage control restrictor member 352 is located within the hollow proximal end of the turbine drive shaft 336 .
- the guide wire 124 is arranged to pass through the restrictor where it is centered and then through the turbine drive shaft, the adaptor 334 , the sleeve 314 , and out through bore 148 in the working head 32 ′′.
- air can pass through the interface of the restrictor 352 to cool and lubricate the adjacent surfaces.
- the ball bearing assembly 350 is held in place via a cap or cover 354 .
- the cap 354 serves to close off the hollow interior of the turbine housing. To that end, the cap is releasably secured to the flanged proximal portion 322 of the turbine housing 320 via plural threaded bolts 356 .
- An enlarged bore hole 358 is located within the cap 354 and is coaxially aligned with the central longitudinal axis of the drive shaft 336 .
- a smaller diameter bore 360 communicates with the bore 358 and with the restrictor 352 .
- the compressed gas e.g., nitrogen
- the pressurized gas enters the turbine housing portion 322 somewhat tangentially and impinges on the angled rotor blades 338 to cause the turbine rotor to rotate about its longitudinal axis at a high rate of speed. This effects the concomitant rotation of the drive shaft 336 , the bifilar cable 308 and hence the rotary working head 32 ′′.
- the infusate fluid e.g., saline and a contrast medium (plus anything else which is desired to be introduced into the vascular system, such as heparin, growth factors, microspheres carrying chemicals, pharmaceuticals or other biologically active materials, etc.) is introduced into the turbine housing 320 so that it gains ingress into the passageway 332 . From that passageway, it flows through the communicating passageway 312 extending within the jacket of the catheter to exit at the distal end of the jacket where the working head 32 ′′ is located.
- the means for introducing infusate liquid into the turbine housing comprises the tubing 86 on which a connector 362 is mounted. The connector 362 is arranged to be connected to the output of the infusate pump.
- An interlock member 366 is located in a transverse bore 368 in the turbine housing 320 so that it perpendicularly intersects the longitudinally extending bore 332 .
- the interlock member is a generally plug-like, tubular body having a thin walled upper end 368 defining an enlarged hollow interior space.
- An opening 370 is provided in the thin walled upper end of the interlock member communicating with the enlarged hollow interior space and into which the distal portion of the sleeve bearing 344 extends.
- Another opening 372 is provided diametrically opposed from the opening 370 so that the turbine drive shaft 336 can extend through the interlock member via the openings 370 and 372 .
- the lower end of the interlock member 366 includes a barb-like tubular projection 374 which extends into the interior of the plastic tube 86 .
- a ring-like ferrule 376 extends about the outer surface of the tube at the upper end thereof to capture the tube on the barb.
- a sealing O-ring 378 is disposed within an annular recess extending about the periphery of the interlock member 366 .
- the barb portion of the interlock member 366 includes a passageway 378 extending through it in communication with the hollow interior at the upper end of the interlock member.
- the rotation of the drive cable 308 creates an Archimedes-like pumping action to aid the infusate pump in carrying the infusate liquid down the annular passageway 312 in the jacket 34 .
- the ability of the helical drive cable 308 to deliver flow is a function of: (1) the rotation speed of the helix, (2) the swept volume of the helix (the swept volume of the helix being the volume of fluid entrapped between the coils of one pitch of the helix), and (3) the leakage of flow back along the helix due to the clearance between the helix and the jacket and the clearance between the helix and the liner.
- the pump can act as a very stiff positive displacement pump, that is, it can deliver flow at a large range of output pressures regardless of the inlet pressure.
- the helix design suitable for transmitting suitable torque with adequate flexibility for navigating the bends of the coronary vasculature, also has the correct swept volume to deliver an appropriate flow, e.g., 30-40 mL/minute, required to keep the catheter and tip abrasion site at a temperature compatible with tissue viability (e.g., not more than 98 deg F.).
- the console provides for independently adjustable peristaltic pump speeds for the infusate and extraction pumps
- the system can provide for any catheter design. The operator can be instructed to select the appropriate pump speed and the appropriate pump tubing for whatever catheter is in use. In some instances it may be advisable to use operator adjustable peristaltic pumps linked electronically that provide for fixed ratios between the infusate and extraction pumps, and in other designs it may be best to provide for the pumps to be preset and not user adjustable.
- the cable 308 is preferably so constructed.
- the drive cable 308 is to act as a pump in addition to the means for effecting the rotation of the working head, the helices of the cable have to have a certain pitch (e.g., 25 coils to the inch) to provide the required swept volume.
- the helices of the cable needs to be approximately of closed coil configuration (e.g., 40 coils to the inch), but not quite closed, because it is best if the coils do not touch each other as the catheter bends since the friction between the abutting coils may cause excessive heat to be generated.
- the variable pitch of the drive cable thus provides for the optimum pumping action, while maintaining optimum flexibility.
- the helix pitch of the drive cable also has an affect on vibration of the catheter, with the coarser or greater spacing between helices resulting in lower vibration.
- the variable pitch drive cable 308 will also help to reduce the vibration level by minimizing the length of closed coil helices at the distal end of the drive cable.
- the system 200 includes a cradle assembly 202 for holding the guide catheter 24 and the guide wire 124 fixed with respect to each other and with respect to the patient's vascular system, while supporting a portion of the atherectomy catheter to enable it to be moved longitudinally with respect to the guide catheter and guide wire in order to advance the working head through the vessel section to be revascularized.
- the cradle assembly 202 will now be described with reference to FIG. 9A.
- the cradle assembly basically comprises a cradle member 400 (shown by phantom lines in the interest of drawing simplicity) and other associated components (some shown by solid lines and others by phantom lines), all to be described later.
- the cradle member 400 itself is a generally tubular member which is arranged to support the turbine body therein and to allow the turbine body to slide longitudinally with respect to the cradle member 400 while fixing the position of the guide catheter 24 and guide wire 124 relative to each other.
- the tubular cradle 400 includes a loading slot 402 extending from its front or distal end to a point close to its rear or proximal end.
- a pair of support feet 404 also shown by phantom lines, are provided on the underside of the cradle tube to support it on any horizontal surface.
- a cup-shaped plug member 406 is mounted in the open rear end of the cradle tube.
- the plug member includes a central passageway 408 extending through it.
- a pair of telescoping tubes 410 and 412 are mounted between the central passageway in the plug member and the proximally located cap 354 of the turbine housing 320 via a ferrule (not shown).
- the central passageway 408 in the plug member and the associated telescoping tubes 410 and 412 provide a passageway through which the guide wire 124 may be extended into the turbine housing and from there through the atherectomy catheter 22 ′′ as described earlier.
- the telescoping tubes are formed of any stiff material, e.g., type 304 stainless steel, to prevent buckling of the guide wire.
- a conventional hemostasis valve e.g., a Tuohy Borst valve 412 , is mounted on the rear side of the plug member via a wing nut mount (not shown).
- the turbine housing assembly is mounted within the cradle tube for sliding movement therealong in order to adjust the distance that the working head 34 ′′ extends from the distal end of the guide tube 24 .
- This feature enables the rotary working head to be advanced in the distal direction to open a lumen through the plaque or other material forming the restriction in the bypass graft to be revascularized.
- a handle 416 is provided for the turbine housing and projects radially outward from the turbine housing portion 322 .
- the handle extends through a longitudinally extending linear slot 418 in the cradle tube 400 .
- the handle and the associated slot are shown on the facing side of the turbine tube (i.e., the visible side in FIG. 9), when in reality they are located on the opposite side.
- the showing of the handle and slot on the facing side of the cradle tube is merely done for drawing convenience.
- a turbine tube housing extension member 420 is mounted, i.e., snap-fit, on the distal portion of the turbine housing.
- the extension member 420 includes a central opening through which the atherectomy catheter 22 ′′ exits the turbine housing.
- a manifold member 422 is mounted within an extension adjustment tube 424 at the front end of the cradle tube 400 .
- the extension adjustment tube is a slotted tube which telescopes within the front end of the cradle tube 400 and whose position can be adjusted so that the manifold 422 can be moved closer or further away from the cradle tube. This feature enables the system 200 to be used with guide catheters of varying lengths.
- a tube extension latch 426 is provided to extend through any selected one of plural longitudinally spaced holes 428 in the extension tube and a single aligned hole not shown in the front end of the cradle tube.
- the manifold 422 is a disk-like member having a longitudinal passageway (not shown) extending therethrough and to which the proximal end of the guide catheter 24 is connected via a swivel connector 430 .
- the swivel connector permits one to adjust the angular orientation of the guide catheter with respect to the cradle tube so that the guide catheter can be revolved to any rotary position necessary to obtain compatibility with the patient's vascular anatomy.
- the longitudinal passageway of the manifold is in fluid communication with the proximal end of the annular passageway 312 extending down the interior of the atherectomy catheter's jacket.
- the manifold also includes a radially extending side port (not shown) in communication with the longitudinal passageway at the proximal end of the guide catheter.
- the extraction (vacuum) tube 88 is arranged to be connected to the radial side port of the manifold via conventional connector 432 to withdraw blood, infusate liquid and debris which has been drawn down the passageway between the guide catheter and the atherectomy catheter by the action of the extraction pump 90 .
- a conventional hemostasis valve 434 is mounted on the rear (proximal) side of the manifold 422 to enable to the atherectomy catheter to extend through the longitudinal passageway in the manifold and into and through the guide catheter 24 .
- a stiffener tube 436 is provided on the atherectomy catheter between the turbine housing and the manifold to prevent the atherectomy catheter's jacket 34 from buckling under axial loads.
- the stiffener tube also facilitates the assembly and loading of the atherectomy catheter into the cradle tube.
- a hook wire 438 is mounted on the stiffener tube 436 to facilitate movement of the stiffener tube.
- a pair of pivotable trunnions 440 project outward from the distal end portion of the stiffener tube for connection to diametrically opposed portions of the extension tube 424 to center the stiffener tube so that it can be lifted to enable loading of the atherectomy catheter.
- the longitudinally extending slot 402 is of sufficient length to enable the turbine housing and hence the atherectomy catheter 22 ′′ to be reciprocated through a 4-5 inch range.
- the subject invention is not limited to atherectomy catheters, and particularly rotary head catheters.
- the subject invention may incorporate an instrument having any other type of working head, e.g., a balloon angioplasty catheter, a catheter for injecting a restriction-removing or dissolving liquid, an ultrasonic catheter, a laser catheter, a stent-delivery catheter, etc., for opening a lumen in an occluded vessel.
- working head as used herein is meant to include any type of device for operating on an occluded vessel to open a lumen in that vessel to the freer flow of blood therethrough.
- FIGS. 16 and 17 there are shown yet another alternative embodiment of a revascularization system 500 of this invention.
- the system 500 is arranged to revascularize an occluded blood vessel, e.g., a bypass graft 10 ′, by introducing a conventional expandable stent 502 into a lumen formed in the restrictive material of the occluded blood vessel section, e.g., the bypass graft.
- the system 500 may also employ the atherectomy catheter and some associated components of the system 200 described heretofore to effect the opening of a lumen through the material forming the restriction, followed by the introduction of a stent-delivery catheter (not shown) for carrying the stent 502 in a collapsed state into the lumen created by the atherectomy catheter, and then to expand the stent 502 in that lumen to the state shown in FIGS. 16 and 17 to ensure that the lumen stays open.
- the stent-delivery catheter used in such an application may be of any conventional type, e.g., a balloon catheter.
- the system 500 may be used without an atherectomy catheter, like the catheters described above or any prior art restriction-opening device, for initially forming the lumen through the material forming the restriction.
- the system 500 makes use of any suitable conventional stent-delivery catheter to carry the collapsed stent 502 over a guide wire, like guide-wire 124 ′ or any other suitable balloon bearing guide-wire, through the restriction in the occluded blood vessel to an operative position, whereupon the stent-delivery catheter is operated, e.g., its balloon inflated, to expand and place the stent in position (like shown in FIGS. 16 and 17).
- the system 500 of this invention makes use of a debris removal sub-system to remove any particles or other debris produced during the revascularization/stenting procedure. That debris removal system may be similar to that described earlier, or any other suitable type. As shown in the embodiments of FIGS.
- the debris removal sub-system used to remove any particles or debris produced during the revascularization/stenting procedure basically comprises a guide catheter 24 having at least one control port, like that described above, and another catheter 504 (to be described later) for delivery of an infusate or irrigation liquid from some pumping means, e.g., an infusate pump 84 , into the occluded vessel section, and some pumping means, e.g., an extraction pump 90 , coupled to the interior of the guide catheter 24 to effect the removal of blood, the infusion liquid and any debris created during the restriction opening procedure from the patient.
- some pumping means e.g., an infusate pump 84
- some pumping means e.g., an extraction pump 90
- the “other catheter 504 ” for delivery of the infusate or irrigation liquid to the situs of the vessel portion being revascularized may comprise an atherectomy catheter 22 ′′ like that described with respect to system 200 when such a system is used to form the lumen into which the stent will be placed, or may comprise a separate catheter, tube, or conduit, or may comprise a lumen or passageway in the guide catheter 24 separate and apart from the central passageway through which the debris, blood and infusate liquid is removed.
- the catheter 504 for carrying the infusion or irrigation liquid into the situs where the stent is to be placed basically comprises a simple irrigation tube or catheter formed of a flexible material, e.g., a plastic, and having a central passageway or lumen extending fully therethrough for carrying the infusate or irrigation liquid from a pump, like pump 84 or any other suitable source of irrigation liquid, down the lumen and out of its open end to the operative situs like shown in FIGS. 16 and 17.
- the procedure to be followed basically comprises the following steps. First the guide catheter 24 is placed in position so that its distal end is located proximally of the restriction to be opened and its control or regulation port(s) 24 A/B is(are) in fluid communication with an upstream patent vessel, e.g., the aorta, like shown in FIGS. 10, 11, 16 and 17 . The guide wire 124 ′ is then extended through the guide catheter 24 and through the restriction to be opened so that the distally located balloon (obturator) 126 on the guide wire is downstream of the restriction.
- an upstream patent vessel e.g., the aorta
- the balloon 126 is then inflated to block the vessel to be revascularized downstream of its restriction.
- the extraction pump 90 is then operated to evacuate any debris particles which may have been produced by the passage of the guide wire 124 and balloon 126 through the restriction and by the inflation of the balloon 126 .
- the atherectomy catheter 22 ′′ is then passed over the guide wire through the guide catheter so that its working head 32 ′′ extends out of the open end of the guide catheter and is at the situs of the restriction to be opened.
- the atherectomy catheter 22 ′′ (or any other catheter having a restriction opening working head) is then operated in a manner like described above to enable the working head to open a lumen through the restriction, while the debris removal sub-system removes the debris created by that operation along with blood and the infusate liquid through the guide catheter.
- the control or regulation ports in the guide catheter ensure that the vessel being revascularized does not collapse during the procedure.
- the atherectomy catheter can be removed, while maintaining the vacuum, i.e., keeping the extraction pump 90 operating. After removal of the atherectomy catheter the extraction pump 90 can be stopped. If it is desired to give the patient some recovery time before deployment of the stent 502 , the distal balloon on the guide wire may be deflated, thereby enabling blood to flow through the newly formed lumen in the revascularized vessel to the downstream vessel, e.g., a coronary artery 15 . Once sufficient time for the patient to recover has elapsed (assuming that any recovery time is desired) the distally located balloon 126 is then re-inflated.
- the stent-delivery catheter (not shown) is then introduced through the guide catheter and over the guide wire until its working head, e.g., the balloon on which the collapsed stent 502 is located, is within the lumen created by the atherectomy catheter 22 ′′.
- the stent-delivery catheter is then operated, e.g., its balloon inflated, to expand the stent 502 radially outward and into seating engagement with the revascularized vessel section, like that shown in FIGS. 16 and 17.
- the debris removal system may be operated to withdraw any debris particles created by the deployment of the stent.
- the stent-delivery catheter can be removed, e.g., its balloon deflated and then the catheter withdrawn proximally along the guide wire. The guide catheter can then be removed.
- an irrigation tube 504 (like that shown in FIGS. 16 and 17) may be introduced over and along the guide wire 124 ′ and through the guide catheter 24 so that its open distal end is in communication with the situs of the stent while the distally located balloon (obturator) 126 ′ remains inflated.
- An irrigant liquid can then be introduced via the irrigation tube to flush out any debris via the passageway between it and the guide catheter under the action of the extraction pump 90 or any other suitable pump or vacuum source.
- the irrigation tube 504 can then be withdrawn over the guide wire, while the vacuum is maintained, e.g., the pump 90 operates, to remove any debris which may be produced by the removal of the irrigation tube.
- the vacuum e.g., pump 90
- the vacuum can then be stopped, the balloon 126 ′ on the distal end of the guide-wire 124 ′ can then be deflated and the guide wire can then be withdrawn through the guide catheter 24 . Then the guide catheter can be removed.
- the procedure to be followed using the system 500 basically comprises the following steps. First the guide catheter 24 is placed in position so that its distal end is located proximally of the restriction to be opened and its control or regulation port(s) 24 A/B is(are) in fluid communication with an upstream patent vessel, e.g., the aorta, like shown in FIGS. 10, 11, 16 and 17 .
- an upstream patent vessel e.g., the aorta, like shown in FIGS. 10, 11, 16 and 17 .
- the guide wire 124 ′ is then extended through the guide catheter 24 and through the restriction to be opened so that the distally located balloon (obturator) 126 ′ on the guide wire is downstream of the restriction.
- the balloon 126 ′ is then inflated to block the vessel to be revascularized downstream of its restriction.
- the stent-delivery catheter (not shown) is then introduced through the guide catheter 24 and over the guide-wire 124 ′ until its working head, e.g., the balloon on which the collapsed stent 502 is located is at the desired position within the vessel to be revascularized.
- the debris removal sub-system, or any other extraction or vacuum system, is then operated to withdraw any debris or particles created when the stent is deployed.
- the stent-delivery catheter can then be operated, e.g., its balloon inflated, to expand the stent 502 radially outward thereby enlarging the lumen through the restriction seating the stent in place against accidental dislodgement within the blood vessel section, like that shown in FIGS. 16 and 17.
- the stent-delivery catheter can be removed, e.g., its balloon deflated, and then the catheter withdrawn, e.g., slid proximally along the guide-wire 124 ‘until it is out of the being’s body.
- An irrigation or infusate liquid is then provided into the operative situs, i.e., the situs of the stent, to flush away any debris created during the stent deployment procedure.
- an irrigation tube 504 is introduced along the guide wire 124 ′ and through the guide catheter 24 so that its open distal end is in communication with the situs of the stent, while the distally located balloon (obturator) 126 remains inflated.
- An irrigant liquid can then be introduced via the irrigation tube 504 to flush out any debris via the passageway between it and the guide catheter 24 under the action of the extraction pump 90 or any other suitable pump or vacuum source.
- the irrigation tube can then be withdrawn from the being by sliding it out over the guide-wire 124 ′, while the vacuum is maintained, e.g., the pump 90 operates, to remove any debris which may be produced by the removal of the irrigation tube.
- the control or regulation port(s) 24 A/B ensure that the vessel section being revascularized does not collapse during the revascularization procedure.
- the vacuum e.g., pump 90
- the balloon 126 on the distal end of the guide-wire can then be deflated and the guide wire can then be withdrawn through the guide catheter. Then the guide catheter can be removed.
- the system of the current invention allows for a working head to eject infusate liquid (e.g., through liquid jets), where said infusate may comprise a therapy (e.g., drugs, biologically active agents, microspheres, etc.).
- the working head may be arranged to be spaced a certain distance from the lumen's interior surface, such that said infusate may penetrate into the lumen tissue.
- FIGS. 18 to 24 further embodiments of the device shown in FIG. 17 are illustrated in FIGS. 18 to 24 .
- the objective with these devices includes the delivery drugs or biologically active agents (together “therapy”) to the lumen wall, either statically or dynamically.
- Such therapy may be used to restore or to help maintain the flow of blood, or other bodily fluid, through the vessel.
- One such treatment would include the delivery of anti-spasm agents, which would prevent closure of the vessel resulting from vascular spasm for a period of time after the vascular intervention.
- Another such treatment would include the delivery of anti-restenosis, or other therapies, that prevent or minimize the future formation of occlusive material.
- Such therapy can be designed to not only reduce or eliminate restenosis of the vessel locally within a stent, but to eliminate restenosis adjacent (e.g., proximally and distally) to the stent and/or to prevent further stenosis anywhere along the vessel walls.
- Such aforementioned therapies might include, but are not limited to, those therapies listed in Table 1. In all the devices shown in FIGS. 17 through 24, it is to be understood that the system permits the delivery of therapy at very high doses that could likely not be tolerated systemically.
- Angiogenic agents Angiotensin Converting Enzyme Inhibitors (ACE inhibitors)
- Angiotensin II antagonists Anti-angiogenic agents
- Antiarrhythmics Anti-bacterial agents
- Antibiotics Erythromycin Penicillin Anti-coagulants
- Heparin Anti-growth factors
- Anti-inflammatory agents Dexamethasone Aspirin Hydrocortisone
- Antioxidants Anti-platelet agents
- Forskolin Anti-proliferation agents
- Rapamycin Anti-restenosis agents Antisense Antispasm agents Lidocaine Nitroglycerin Anti-thrombogenic agents Argatroban Hirudin GP IIb/IIIa inhibitors
- Anti-virus drugs Arteriogenesis agents acidic fibroblast growth factor (aFGF) angiogenin angiotropin basic fibroblast growth factor (bFGF) Bone morphogenic proteins (BMP) epidermal growth factor (EGF) fibrin granulocyte-macro
- the working head may be arranged to eject infusate in opposing or impeding directions to cause turbulent flow, which may facilitate diffusion or penetration into tissue.
- pump means operates to independently introduce infusate and after some dwell time withdraw the infusate. This dwell time will allow infusate and/or therapy more time to diffuse or penetrate into tissue.
- FIG. 18 is similar to FIG. 17 but the components are used differently.
- the therapy is delivered (infused) via catheter 504 to remain as a bolus in the lumen for a significant period of time (i.e., dwell time) with the balloon inflated but with the extraction system turned off.
- the debris extraction means may be operated normally, i.e., extraction is turned on and an infusate is delivered through the catheter 504 to flush the therapy from the vessel.
- the initial pressure of the bolus can also be adjusted to help deliver the therapy to the target tissue.
- a high-pressure bolus could locally stretch the lumen and thereby increase the local permeability of the tissue.
- the fluid containing the therapy flows continuously from catheter 504 and is continuously extracted through the guide catheter 24 .
- This alternative mode has the advantage that the fluid containing the therapy is in motion, which could aid in increasing the rate at which the therapy permeates the vessel wall.
- the temperature of the fluid could be adjusted (e.g., increased) to enhance the delivery of the therapy.
- the catheter 504 is shown as a tube running over a guide wire in FIGS. 17 and 18, but, in another embodiment, the catheter could also be of the rapid exchange type. FIG.
- FIG. 19 shows one kind of rapid exchange catheter at 601 , this embodiment includes a helical cut in the end of the tube, which permits the attachment of the catheter 504 onto a wire without access to the wire ends (this concept is fully described in co-pending application Ser. No. 523,077, which is assigned to the assignee of the present invention, which is incorporated herein by reference).
- a more common rapid exchange concept (not shown) is utilizing a short lumen at the end of the catheter that has a distal port at the distal end of the catheter and a proximal port close to the distal end of the catheter.
- Such rapid exchange concepts reduce the required length of guide wires but still require access to one end of the guide wire to permit attachment of the catheter to the guide wire. Therefore, the delivery of therapy is not limited to the tube-over-wire approach shown in FIG. 18.
- the distal protection component e.g., balloon, filter, etc.
- the distal protection component may be collapsed or avoided entirely. This would allow the concentrated treatment to contact the targeted tissues and then naturally dispense and become more diffuse, for easy systemic toleration.
- the working head is arranged to contact the interior wall of the lumen, during operation (e.g., ejection of liquid) such that infusate and/or therapy are forced into the interior wall and/or the surrounding tissue.
- the distal protection device e.g., balloon, filter, expandable member, etc.
- the offset comprises an offset (i.e., the centerline of the distal protection device is offset from the centerline of the working head), wherein the offset causes the working head to contact the interior wall of the lumen.
- FIGS. 20, 21, and 22 show delivery devices, which should be classified as high velocity delivery devices.
- Several high-pressure therapy delivery devices for delivery of therapy to the myocardium, vessels, and tissue surrounding a lumen are disclosed in a co-pending patent application Ser No. 09/368,410, which is assigned to the same entity as the present application, and which is incorporated herein by reference.
- the devices of FIGS. 20,20, and 21 utilize the guide catheter 24 and distal balloon 126 ′ illustrated in FIG. 16, but additionally provide a medication distribution head 601 (i.e., working head) mounted on the distal portion of catheter 602 .
- the medication distribution type of working head 601 see FIG.
- a high-pressure source 603 drives the therapy through the catheter 602 to the distribution head 601 where the therapy is emitted at sufficiently high velocity to traverse the liquid filled gap between the head and the vessel wall, and impact and penetrate the vessel wall and may go into surrounding tissue (all being referred to as “target tissue”).
- the distribution head is of the order 1 mm in diameter and the multiple distribution jets are each expected to be in the range 0.002 to 0.015 inch diameter. Drive pressures are expected to be approximately 100 psi to 3000 psi. Other embodiments are envisioned, where the size and number of jets will dictate the pressures required.
- catheter 602 is fed over the guide wire, through guide catheter 24 to a point close to the un-inflated distal balloon 126 ′.
- the balloon is then inflated, the therapy delivered through the head 601 and the aspiration activated.
- the catheter 602 is traversed along the vessel to distribute the therapy. Additional components might be necessary to better centralize the distribution head 601 (i.e., working head locating members) (See FIGS. 21 and 22) in the vessel once the head is some distance away from the balloon 126 .
- the centralizing device is a multi filament basket 606 of the type often used in urology.
- the basket is formed from several pre-bent wires 605 (e.g., nitinol), or ribbons, which form a football shaped basket in their relaxed condition as a result of a shape memory property.
- a thin control tube 604 is used to capture and compress the wires 605 to reduce the effective diameter of the basket, although thin pull ribbons (not shown) are also used to control basket shapes in other applications.
- the combined medication distribution head 601 , catheter 602 , and basket and control tube 604 concentric with the catheter 602 are moved through the guide catheter 24 on guide wire 124 (together, the “assembly head”) to a position close to the un-inflated balloon 126 ′.
- the balloon 126 ′ is inflated, axial movement of the control tube 604 adjusts the basket, the high-pressure source 603 is activated and the aspiration commenced.
- the entire assembly head is traversed along the vessel to distribute the therapy.
- the traversing of the assembly head along the vessel length could be automated, such as by a linear actuated drive motor, to provide a uniform, or alternatively variable, distribution of the therapy to the targeted tissue.
- the only difference between FIGS. 21 and 22 is that the medication delivery head 601 is shown distal of the basket in FIG. 21 and within the basket in FIG. 22.
- the in-basket construction may give better centralization and closer action to the guide catheter 24 on reverse travel of the head 601 .
- FIG. 23 A working head, in this example a medication distribution head 601 , is shown on the balloon guide wire 124 in the internal carotid, and a second balloon guide wire 124 is shown in the external carotid.
- a medication distribution head 601 is shown on the balloon guide wire 124 in the internal carotid, and a second balloon guide wire 124 is shown in the external carotid.
- the dose can be allowed to act as a bolus, which rests for a given time before aspiration or as a continuous delivery with aspiration via a guide or other catheter (referred to as “through-flow”).
- the through-flow rate may be different than either of the infusate or aspiration rates used in the differential flow sequence.
- the location of the aspiration catheter with respect to the location of the working head e.g., separation distance
- the normal differential flow system or through-flow system may be used with an infusate (with or without additional material) and the through-flow stage may employ a different infusate or added material.
- the therapy delivery devices can be used in vessels prior to, or post, angioplasty, stent delivery or use of other working heads.
- FIG. 24 shows the use of the medication distribution head in a situation identical to that shown in FIG. 21 with the addition of a stent 610 .
- any of the devices and embodiments disclosed can operate through a stent or other intraluminal prosthesis. They can also be used prior to or post the application of any other working heads such as atherectomy devices, angioplasty balloons, radiation catheters, intravascular ultrasound, infra-red intravascular imaging, or any other diagnostic or imaging head.
- the disclosed drug delivery concepts can be used with any other kind of intravascular therapy where a therapy needs to be delivered onto, into, or through the wall of the vessel.
- Therapy delivery devices e.g., working heads
- This delivery which may be through liquid jets or irrigation-type catheters, may be normal to said interior surface or may be tangential; all of which directions are said to result in therapy ultimately directed toward the vessel's or lumen's interior surface.
- the embodiments disclosed can function in vessels or lumens that are not occluded at all but would benefit from the features of drug delivery in conjunction with (or without) the disclosed barriers and pumping systems.
- these embodiments can be used to treat target tissue, where the target tissue comprises vessels or lumens that contain at least partial occlusions or where the vessel or lumen has surrounding tissue (i.e., tissue in the vicinity of the vessel or lumen, but not necessarily encompassing the vessel or lumen), which is diseased in some fashion.
- this form of drug delivery may be useful as a prophylactic measure, which may be used alone or in conjunction with other treatments and/or devices, to treat vessels, lumens or other targeted tissues
Landscapes
- Health & Medical Sciences (AREA)
- Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Surgical Instruments (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
A system and method for treating diseased target tissue of a living being. The system comprises a working head, e.g., a rotary impacting impeller, a stent delivery catheter, a flush catheter, or liquid jets, a debris extraction sub-system, and may have barrier means in certain embodiments. The working head is arranged to treat diseased tissue, e.g., at least partially occluded with atherosclerotic plaque, or surrounding tissue being compromised by a disease such as cancer, in vessels or lumens, whereupon some debris may be produced. The debris extraction sub-system introduces an infusate liquid adjacent the working head and withdraws that liquid and debris adjacent the working head. The introduction of the infusate liquid may also be used to deliver drugs and other therapies systemically or locally, between the working head and the distal protection barrier.
Description
- This application is a Continuation of U.S. patent application Ser. No. 10/058,556, filed on Jan. 28, 2002 entitled System and Method of Use for Treating Occluded Vessels And Diseased Tissue, which is a Continuation-In-Part of U.S. patent application Ser. No. 09/594,131, filed on Jun. 14, 2000, entitled System and Method of Use for Revascularizing Stenotic Bypass Grafts and Other Occluded Blood Vessels, now U.S. Pat. No. 6,524,323, which is a Continuation of U.S. patent application Ser. No. 09/233,712, filed on Jan. 19, 1999, entitled Improved System And Method Of Use For Revascularizing Stenotic Bypass Grafts And Other Occluded Blood Vessels, now U.S. Pat. No. 6,080,170, which in turn is a Continuation-In-Part of U.S. patent application Ser. No. 08/900,598, filed on Jul. 25, 1997, entitled System And Method Of Use For Revascularizing Stenotic Bypass Grafts And Other Blood Vessels, now U.S. Pat. No. 5,879,361, which in turn is a Continuation-In-Part of U.S. application Ser. No. 08/690,438, filed on Jul. 26, 1996, entitled System And Method Of Use For Revascularizing Stenotic Bypass Grafts And Other Blood Vessels, now U.S. Pat. No. 5,779,721, all of which are assigned to the same assignee as this invention, and whose disclosures are incorporated by reference herein.
- This application relates generally to medical instruments and methods of use to remove occlusive material from a vessel, duct or lumen within the body of a living being.
- Catheter instruments have been suggested or disclosed in the patent literature for effecting non-invasive or minimally invasive revascularization of occluded arteries. For example, in U.S. Pat. No. 4,445,509 there is disclosed a recanalization catheter designed specifically for cutting away hard, abnormal deposits, such as atherosclerotic plaque, from the inside of an artery, while supposedly preserving the soft arterial tissue. That recanalizing catheter includes a sharp-edged, multi-fluted, rotating cutting tip mounted at the distal end of the catheter and arranged to be rotated by a flexible drive shaft extending down the center of the catheter. The rotation of the cutting head is stated as producing a “differential cutting” effect, whereupon relatively hard deposits are cut away from relatively soft tissue. Suction ports are provided to pull the hard particles produced by the cutting action into the catheter for removal at the proximal end thereof so that such particles do not flow distally of the catheter where they could have an adverse effect on the patients' body.
- In U.S. Pat. No. 4,700,705, which is assigned to the same assignee as this invention and whose disclosure is incorporated by reference herein, there are disclosed and claimed catheters and methods of use for effecting the opening of a vessel, duct or lumen, such as the opening of a atherosclerotic restriction (partial or total occlusion) in an artery. These catheters are elongated flexible members of sufficient flexibility to enable them to be readily passed through the body of the patient to the situs of the atherosclerotic plaque in the artery to be opened. A working head is mounted at the distal end of the catheter and is arranged for high-speed rotation about the longitudinal axis of the catheter. In some embodiments the catheter may eject fluid at the working head to expedite the restriction-opening procedure.
- In U.S. Pat. No. 4,747,821, which is also assigned to the same assignee as this invention and whose disclosure is incorporated by reference herein, there is disclosed and claimed other catheters particularly suited for revascularization of arteries. Each of those catheters includes a rotary working head having at least one non-sharp impacting surface to effect material removal without cutting. Moreover, those catheters are arranged to eject fluid adjacent the working head to expedite the revascularization procedure. In particular, the rotation of the working head produces a powerful, toroidal shaped vortex contiguous with the working head which has the effect of recirculating any particles that may have been broken off from the material forming the arterial restriction so that the working head repeatedly impacts those particles to reduce their size.
- In U.S. Pat. No. 5,042,984, which is also assigned to the same assignee as this invention and whose disclosure is incorporated by reference herein, there are disclosed and claimed catheters whose working heads include impacting surfaces of differing aggressiveness which may be selectively brought into engagement with the restriction to be opened. Such catheters also make use of exiting jets of liquid as described above.
- Other atherectomy devices for enlarging an opening in a blood vessel have been disclosed and claimed in the following U.S. Pat. No. 4,589,412 (which is assigned to the same assignee as this invention and whose disclosure is incorporated by reference herein); U.S. Pat. Nos. 4,631,052; 4,686,982 (which is assigned to the same assignee as this invention and whose disclosure is incorporated by reference herein); U.S. Pat. No. 4,749,376 (which is assigned to the same assignee as this invention and whose disclosure is incorporated by reference herein); U.S. Pat. Nos. 4,790,813; 5,009,659; 5,074,841; 5,282,484; 5,366,463; 5,368,603; 5,402,790; 5,423,742; and 5,429,136.
- Some rotary atherectomy devices are in use in this country for revascularizing occluded arteries. However, their use is limited to some very selected applications. Thus, in many instances a vascular occlusion of a coronary artery can only be treated by coronary bypass surgery wherein a graft, e.g., a saphenous vein section and/or mammary artery section, is surgically shunted across the occluded coronary artery. Unfortunately a significant percentage of bypass surgical grafts become re-occluded over time. Thus, the re-occluded graft has to be either bypassed by another graft (i.e., second bypass surgery), or the re-occluded graft has to be revascularized (i.e., its lumen reopened) by some intravascular procedure. If the occluded graft is not totally occluded, balloon angioplasty may be indicated to reopen the graft. Where, however, the graft is totally occluded or heavily occluded by frangible deposits balloon angioplasty is unavailable. Thus, if revascularization of such a graft is desired, resort may be to rotary atherectomy.
- One currently available rotary atherectomy device is the ROTOBLATOR® System of Heart Technology, Inc. That system utilizes a catheter having a diamond coated elliptical burr which is rotated at a high rate of speed, e.g., up to 190,000 rpm. The burr serves to break the atherosclerotic plaque into fine particles which are allowed to remain in the patient's body for disposal by the patient's reticuloendothelial system.
- As is known to those skilled in the art, one problem with a rotary atherectomy device is that unless the debris produced is so small and benign that it can be left within the patient's vascular system there must be some means to ensure that the debris does not flow upstream into the aorta during the procedure or into the downstream artery graft at the break-through point when the device comes out the distal side of a total occlusion, since either action could present a significant hazard to the patient. In particular, the former route risks stroke, the later route risks local ischemia of heart muscle when debris blocks off small arteries.
- Thus, the collection and/or aspiration of debris produced during the revascularization of occluded arterial bypass grafts or other blood vessels is getting considerable attention in the medical arts. For example, Possis Medical, Inc., the assignee of U.S. Pat. Nos. 5,370,609 and 5,496,267, provides catheter devices designated as the ANGIOJET Rapid Thrombolectomy System and the ANGIOJET Rheolytic Thrombolectomy System. These devices are presumably constructed in accordance with those patents and are believed to be presently undergoing clinical trials. The catheter devices disclosed in those patents utilize high velocity jets of saline to abrade the blockage. In particular, the patents disclose utilizing the momentum of the saline jets to create a local vacuum to entrain any particulate material produced by the revascularization procedure, with the momentum and the local positive pressure being sufficient to carry the saline and debris to a return collection bag.
- Another atherectomy device which is currently undergoing clinical trials is the Coronary TEC® System of Interventional Technologies, Inc. That device is believed to be the subject of U.S. Pat. No. 5,224,945, and basically comprises a catheter having a working head with microtome sharp blades for cutting plaque circumferentially. The excised plaque is extracted by suction through a central lumen in the catheter into an exteriorly-located vacuum bottle. No control of the quantity of flow of the debris-carrying fluid from the catheter is disclosed.
- U.S. Pat. No. 5,030,201 (Palestran) discloses a system including an expandable atherectomy catheter arranged to be rotated to cut through an occluded artery to revascularize it. The atherectomy catheter includes an expandable cutting head having plural elongated cutting members which are mounted on a flexible torque tube incorporating a vacuum or aspiration system for retrieval of excised material. The cutting head is arranged to be rotated to cause the elongated members to cut away atheromatous material or blood clots. The atherectomy catheter is arranged to be inserted into the blood vessel through a coaxial delivery catheter, also forming a part of the system. The mechanism for aspirating particles of atheromatous material or blood clots removed by the elongated cutting members is disclosed as being in the form of a vacuum port provided at the proximal end of either the delivery catheter, the atherectomy catheter or a “retracting catheter” which also constitutes a part of the system. Saline solution or some other irrigant is infused through one of the catheters of the device that is not being used for aspiration. The infusion rate of the saline solution is balanced with the aspiration rate to avoid any net removal of fluid from the vessel. In particular, the patent teaches that by balancing the infusion rate of the saline solution to the aspiration rate, the net removal of fluid from the vessel can be brought close to zero, thereby minimizing blood loss.
- While the balancing of the infusion and aspiration flow rates to minimize blood loss may be desirable, such action does not insure positive removal of all debris produced during the revascularization procedure.
- Accordingly, a need exists for apparatus and a method of use to revascularize partially or totally occluded blood vessels, while positively assuring that any particles produced during the revascularization procedure are removed from the patient's body. In the case of partially or totally occluded coronary bypass grafts, a need exists for intravascular atherectomy apparatus and methods of use for effectively producing a lumen through the occlusion for the free flow of blood, without the risk that any debris produced during the lumen opening procedure will enter into the aorta or downstream of the occlusion once it has been crossed or opened.
- Additionally, there exists a need for a single device to revascularize and/or treat occlusive or diseased tissue and/or deliver a therapy to a lumen or artery and the surrounding tissue.
- Accordingly, it is a general object of this invention to provide systems and methods which address those needs.
- It is another object of this invention to provide a system and methods for effectively revascularizing partially or totally occluded blood vessels and for removing any debris produced during the procedure from the patient's body.
- It is another object of this invention to provide a system and methods for safely revascularizing partially or totally occluded blood vessels.
- It is still another object of this invention to provide a system and methods for effectively opening a lumen in a partially or totally occluded arterial bypass graft, without the risk of debris produced during the procedure entering the aorta or from flowing downstream once the lumen through the occlusion has been opened.
- It is yet another object of this invention to provide a system and methods for effectively opening a lumen in a partially or totally occluded portion of an artery, e.g., the femoral artery, downstream of a junction with another vessel, e.g., the profunda femoris, without the risk of debris produced during the procedure entering the other vessel or from flowing downstream in the artery once the lumen through the occlusion has been opened.
- It is yet a further object of this invention to provide a system and methods for revascularizing partially or totally occluded blood vessels utilizing liquid infusion and aspiration means for establishing a differential flow to positively ensure the aspiration of debris produced during the revascularization procedure.
- It is yet a further object of this invention to provide a system and methods for revascularizing partially or totally occluded blood vessels utilizing liquid infusion and aspiration means which is easy to operate to effect the positive removal of debris produced during the revascularization procedure.
- It is yet a further object of this invention to provide a system and methods for revascularizing partially or totally occluded blood vessels utilizing liquid infusion and aspiration means which is adjustable for effectuating the positive removal of debris produced during the revascularization procedure.
- It is yet a further object of this invention to provide a system and methods for revascularizing partially or totally occluded blood vessels utilizing liquid infusion and aspiration (extraction) subsystems which effect positive removal of debris produced during the revascularization procedure but which precludes collapse of the vessel being revascularized.
- It is yet a further object of this invention to provide a system and methods to diagnose or treat diseased tissue (e.g., vessels or lumens at least partially occluded with atherosclerotic plaque, or cancerous tissue, etc.), via the use of catheters, working heads and drug delivery means.
- It is yet a further object of this invention to provide a low profile device to reach small vessels and lumens, perhaps in difficult regions, to treat diseased tissue (e.g., deep venous thromboses (DVT) located in the lower leg regions, etc.), where the system of the present invention may be used to support, replace, or augment existing treatment modalities (e.g., thrombolysis, chemotherapy, etc.) in a way that is less tortuous than existing technologies (e.g., the Rotoblator™ atherectomy system manufactured by Boston Scientific, Natick, Mass.).
- These and other objects of this invention may be achieved by providing a system for opening a lumen in an occluded blood vessel, e.g., a coronary bypass graft, of a living being's vascular system located downstream of another blood vessel, e.g., the aorta, from which blood will flow to the occluded blood vessel. The system basically comprises a guide catheter, a lumen-opening catheter, a debris blocking member, and a fluid flow system.
- The guide catheter has a distal end portion and at least one blood entrance port located proximally of the distal end portion. The lumen-opening catheter extends through the guide catheter to establish a fluid flow passageway therebetween and has a working head, e.g., a rotatable impacting member, for location immediately adjacent the occlusive material within the occluded blood vessel portion. The working head is arranged for operating on the occlusive material, e.g., repeatedly impacting it, to open a lumen for the freer flow of blood therethrough. Some debris may be produced by the operation of the working head.
- The debris blocking member is located distally of the working head to prevent debris from flowing distally thereof.
- The fluid flow system is arranged to introduce an infusate liquid at a first flow rate adjacent the working head and to withdraw that liquid through the passageway between the guide catheter and the lumen opening catheter at a second and higher flow rate to create a differential flow adjacent the working head, whereupon debris produced by the operation of the working head is withdrawn by the differential flow and flows with the liquid proximally through the passageway for extraction.
- The blood entrance port in the distal end portion of the guide catheter is in communication with the passageway between the guide catheter and the lumen opening catheter, whereupon blood from the patent blood vessel portion may enter for merger with the liquid and debris flowing through that passageway.
- In accordance with one preferred embodiment of this invention the debris blocking member is an inflatable balloon is provided at the distal end of the instrument to physically block the egress of any debris downstream of the apparatus. Perfusion means is preferably provided to inflate the balloon and to oxygenate downstream tissue when the balloon is inflated.
- In yet another embodiment the system of the current invention allows for a working head to eject infusate liquid (e.g., through liquid jets), where said infusate may comprise a therapy or additional material (e.g., drugs, biologically active agents, microspheres, etc.). The working head may be arranged to be spaced a certain distance from the lumen's interior surface, such that said infusate may penetrate into the lumen or surrounding tissue.
- In yet another embodiment, the working head may be arranged to eject infusate in opposing or impeding directions to cause turbulent flow, which may facilitate diffusion or penetration into tissue. The working head may comprise a complicated fluid jet system, or may comprise simple irrigation catheters (as will be discussed in more detail later).
- In yet another embodiment, pump means operates to independently introduce liquid infusate and/or therapy, and after some dwell time, withdraw the liquid. This dwell time will allow said infusate and/or therapy more time to diffuse or penetrate into tissue. The liquid withdraw may use the differential flow arrangement of pumping means, as previously described, or may use only the aspiration portion. In a similar embodiment, the differential flow system may remain active during the infusing of drugs (whether they are delivered solely or via infusate). This would allow continuous flow against the artery or lumen wall, which may facilitate diffusion of the drug or therapy into the tissue.
- In yet another embodiment the working head is arranged to contact the interior wall of the lumen, during operation (e.g., ejection of liquid) such that infusate and/or therapy are forced into the interior wall and/or the surrounding tissue.
- In yet another embodiment, working heads may comprise irrigation catheters, diagnostic instruments (e.g., biopsy devices, etc.) or imaging devices (e.g., laser, infra-red optical or ultrasound, etc.)
- In these various embodiments, vessels and/or lumens are the location of the treatment to be performed; while blood vessels are designated in some embodiments, that is meant to be exemplary, and not limiting.
- Other objects and many of the attendant advantages of this invention will readily be appreciated as the same becomes better understood by reference to the following detailed description when considered in connection with the accompanying drawings wherein:
- FIG. 1 is a schematic diagram, partially in section, of a system of the subject invention shown during the process of opening a lumen in a totally occluded coronary bypass graft so that blood can flow therethrough;
- FIG. 2 is an enlarged view, partially in section, of a portion of the system of FIG. 1 shown during the process of opening a lumen in the occluded coronary bypass graft;
- FIG. 3 is an even more greatly enlarged view, partially in section, of a portion of the system shown in FIG. 2;
- FIG. 4 is a reduced isometric view of the portion of the system shown in FIG. 3;
- FIG. 5 is an illustration showing the apparatus of FIG. 1, partially in section, during the process of revascularizing a totally occluded femoral artery downstream of the profunda femoris;
- FIGS. 6A and 6B together are an illustration of another embodiment of the system of this invention for revascularizing or opening a lumen in a coronary bypass graft;
- FIG. 7 is an enlarged isometric illustration of a portion of an instrument forming a component of the system shown in FIGS. 6A and 6B during the process of revascularizing a diseased bypass graft;
- FIG. 8 is an enlarged longitudinal sectional view of the distal end of the instrument shown in FIG. 7;
- FIG. 9A is an isometric view of a portion of another preferred embodiment of this invention making use of a guide catheter having at least one flow regulation port to ensure that the vessel being revascularized does not collapse during the extraction of the debris produced by the revascularization;
- FIG. 9B is an isometric view of another portion of the embodiment of the system shown in FIG. 9;
- FIG. 10 is an enlarged isometric view of the distal end of the atherectomy catheter, guide catheter and guide wire of the embodiment of FIG. 9A shown during revascularization of a coronary bypass graft, where the guide catheter tightly fits within the bypass graft;
- FIG. 11 is a view similar to FIG. 10 but where the guide catheter fits loosely within the bypass graft;
- FIG. 12 is a greatly enlarged longitudinal sectional view of the distal end of an atherectomy catheter forming a part of the embodiment of the system of FIG. 9A;
- FIG. 13 is an enlarged longitudinal sectional view of the proximal end of the atherectomy catheter of the system of FIG. 9A;
- FIG. 14 is an enlarged longitudinal sectional view similar to FIG. 8, but showing a modified guide wire and distally located balloon for use with the systems of this invention;
- FIG. 15 is a graph showing the four potential sizes and numbers of flow regulation ports for the guide catheter and their potential for precluding collapse of the vessel being revascularized;
- FIG. 16 is a view similar to that of FIG. 10 but showing a method of providing a stent in an occluded blood vessel section, e.g., a bypass graft, to revascularize it, and with the debris extraction system making use of a guide catheter tightly engaging the wall of the blood vessel section;
- FIG. 17 is a view similar to that of FIG. 11 but showing a method of providing a stent in an occluded blood vessel section, e.g., a bypass graft, to revascularize it, and with the debris extraction system making use of a guide catheter not engaging the wall of the blood vessel section;
- FIG. 18 is an isometric view of a portion of one embodiment of the treatment and therapy delivery system shown positioned within a partially sectioned blood vessel which contains a stent;
- FIG. 19 is a view similar to that of FIG. 18 but showing another embodiment of the treatment system that includes a rapid exchange catheter;
- FIG. 20 is a view similar to that of FIG. 19 but showing another embodiment of the treatment system that includes a high velocity agent delivery catheter with a fluid distribution working head;
- FIG. 21 is a view similar to that of FIG. 20 but showing another embodiment of the treatment system that includes a high velocity agent delivery catheter with a centralizing basket positioned proximal of the distribution head;
- FIG. 22 is a view similar to that of FIG. 21 but showing another embodiment of the treatment system that includes a high velocity agent delivery catheter with a distribution head positioned within a centralizing basket;
- FIG. 23 is an isometric view of a portion of one embodiment of the treatment and therapy delivery system containing two distal protection components and a therapy delivery catheter with a distribution head shown positioned within a partially sectioned branched vessel or lumen; and
- FIG. 24 is a view similar to that of FIG. 21 but showing the treatment system that includes an agent delivery catheter with centralizing basket positioned to treat a portion of a blood vessel containing a stent.
- Referring now in greater detail to the various figures of the drawings wherein like reference characters refer to like parts, there is shown at20 in FIG. 1 a system for revascularizing or opening a lumen through a coronary bypass graft which has become occluded, such as by the formation of a stenotic lesion or the build-up of plaque therein. As used herein the term “occluded” is given its broadest interpretation. Thus, an “occluded” graft or blood vessel may be either totally blocked or only partially blocked (i.e., there is a passageway or lumen through which some blood may flow).
- The
system 20 is arranged to be used for forming or enlarging a lumen through any blood vessel within the body of a living being, e.g., an occluded femoral artery downstream of the profunda femoris, not necessarily an occluded coronary bypass graft or an occluded coronary artery. In particular, thesystem 20 is arranged to produce a channel or lumen or to enlarge a lumen through the occlusive material within the vessel and to ensure that any particles of that material which are removed or broken away, during the revascularization procedure are prevented from flowing into the contiguous vascular system. When thesystem 20 is used for revascularization of occluded coronary bypass grafts, a primary application for thesystem 20, the debris produced is drawn into the system for extracorporeal removal and is thus prevented from entering the aorta. - As can be seen in FIG. 1, the
system 20 basically comprises an “atherectomy”catheter 22, aguide catheter 24, an introducer sheath 26, adrive sub-system 28, and adebris removal sub-system 30. Theatherectomy catheter 22 is in the form of an elongated flexible tubular body member or jacket at the free or distal end of which is located a rotatable workinghead 32. The workinghead 32 is generally similar to that described in U.S. Pat. No. 4,747,821. Alternatively, the working head may be constructed in accordance with the teachings of U.S. Pat. Nos. 4,679,558, 4,686,982, 4,749,376, 5,042,984, and 5,097,849, all of which are also assigned to the same assignee as this invention, and whose disclosures are also incorporated by reference herein. In fact, the working head may be any device for opening a lumen through at least partially occlusive material. - In use the
atherectomy catheter 22 is guided through the vascular system of the patient by the guide catheter 24 (which is conventionally placed) to the site of the vascular occlusion that has been determined to exist, so that the rotary working head is located immediately adjacent the upstream end of the occlusion. In the embodiment shown in FIG. 1, the atherectomy catheter is located within acoronary bypass graft 10 having an upstream end in fluid communication with theaorta 12. The downstream end of the graft is not shown and is in fluid communication with the coronary artery being bypassed or with smaller arteries of the heart. In the example shown herein thegraft 10 is totally occluded by an atherosclerotic lesion or plaque or some other occlusive material 14 (FIG. 2) within the interior of the graft. - The
atherectomy catheter 22 is introduced into the patient's vascular system in a conventional manner, e.g., via the use of the introducer sheath and guide catheter. As shown, this is accomplished via a percutaneous puncture 16 in thefemoral artery 18. The sheath 26 and guidecatheter 24 are each of conventional construction and thus their details will not be described in the interest of brevity. - The working
head 32 is arranged to rotate about the longitudinal axis of the catheter at a high rate of speed, e.g., from 10,000 rpm to 200,000 rpm to repeatedly mechanically impact the occlusive material. At the same time, an infusate liquid (to be described later) is pumped through the atherectomy catheter by a pump (to be described later and forming a portion of the debris removal sub-system 30) and out of distal end of the atherectomy catheter adjacent the working head. The opening of the occlusion to allow freer flow of blood therethrough is effected by impacting surfaces of the rotating working head impacting theocclusive material 14, whereupon portions thereof are removed, e.g., broken away. In addition, as will be described later, the rotation of the working head produces a powerful, toroidal shaped vortex contiguous with the working head. This vortex flow has the effect of recirculating particles that are broken off from the occlusive material by the impact of the rotary working head's impacting surfaces back into contact with such surfaces. Accordingly, those particles are repeatedly impacted, with each impaction reducing the size of the particles further until the majority of resulting particle sizes are very small, e.g., less than 200 microns. At the same time another pump (also to be described later) of thedebris removal sub-system 30 is operated to aspirate the particles produced during the revascularization procedure along with the infusate liquid and some blood. - Thus, as will be described in detail later, the
debris removal subsystem 30 utilizing a downstream balloon, as will be described later, is operative to ensure that debris produced as the working head opens a lumen through the occlusion is not able to flow upstream into the upstream vessel, e.g., theaorta 12, during the lumen opening procedure, and once the working head breaks through or exits the occlusion on the downstream side, that the debris is not able to flow downstream into the downstream blood vessel(s). - As best seen in FIG. 4 the atherectomy catheter includes a
jacket 34 which is formed of any suitable material, e.g., plastic, and has a small outside diameter. In the preferred embodiment shown herein, the outside diameter of thejacket 34 is approximately 1.5 mm (5 French). This size catheter is merely exemplary. The means for effecting the rotation of the working head is the heretofore identifieddrive sub-system 28. That sub-system is similar to the drives disclosed in the aforementioned U.S. Pat. Nos. 4,686,982, and 4,747,821 and basically comprises an air-turbine motor and associated rotary drive cable (to be described later). Other drive systems can be utilized, as well. - Irrespective of the construction of the drive system, it is coupled to the working
head 32 so that the working head is rotated about its longitudinal axis at the high rate of speed. Many of the details of the working head embodiments will be described later. Suffice it for now to say that the workinghead 32 of this embodiment includes animpeller portion 44 and a central shank portion or axle 36 (FIG. 4) projecting proximally therefrom. Theaxle 36 is supported in a central bore of abushing 38 fixedly mounted at the distal end of the catheter'sjacket 34 by anencircling mounting band 40. Theshank 36 is fixedly secured to the distal end of aflexible drive cable 42 forming a portion of thedrive sub-system 28. - The
impeller 44 forms the distal portion of the working head and is fixedly secured to theshank 36 so that it will be rotated at a high rate of speed about its longitudinal axis by the concomitant rotation of the drive cable. Theimpeller portion 44 comprises a circular disk orbase 52 from which a generallyplanar tip 54 projects. Thetip 54 has a pair of generally planar diametrically disposed relieved side surfaces or faces which merge with an arcuate front or distal surface to form a pair of arcuate impacting surfaces 54A and 54B. Each of the impacting surfaces is radiused in a plane perpendicular to the axis of rotation of the working head so that each is not sharp, e.g., is in the range of approximately 0.001 inch to approximately 0.008 inch, although in the scale of the figures of the drawing they appear to be a sharp line. The working head is located within a cylindrical shroud 56 (FIGS. 3 and 4) fixedly mounted on the front of thebushing 38. Theshroud 56 includes acylindrical sidewall portion 58 and a generally conicaldistal wall portion 60 terminating in acircular opening 62 in the distal end thereof. The shroud may be of any suitable outside diameter, e.g., 7 to 8 French. The distal arcuate portion of theimpeller tip 54 projects out of the central orfront opening 62. A side port oropen window 64 is located in thesidewall 58. - As mentioned earlier the
system 20 utilizes an infusate liquid to expedite the revascularization of the vessel. In particular, the infusate liquid is pumped at a flow rate Q1 (to be described later) down through the interior of thecatheter jacket 34 through four equidistantly spacedgrooves 46 extending down the central bore of thebushing 38 and viaradial ports 48 to anannular recess 50 in the front wall of the bushing. The annular recess is in fluid communication with the side port orwindow 64 in the shroud so that the infusate liquid can exit therefrom. The direction of flow of the infusate liquid down the atherectomy catheter and out the shroud at its working head is shown clearly in FIG. 4. - The rotation of the working head about its longitudinal axis produces a powerful toroidal shaped vortex flow Q3 in the fluid contiguous with the working head. This flow Q3 circulates by entering into the shroud through the central or
front opening 62 and exits out through theside window 64 as shown in FIG. 3. Thus, the flow exiting throughwindow 64 is Q1+Q3. As will be appreciated by those skilled in the art the vortex flow Q3 has the effect of recirculating any particles that are broken off from theocclusive material 14 by the action of the rotating working head back into contact with the working head's impacting surfaces. Thus, the occlusive material particles which are broken away are progressively reduced in size until they are aspirated by aspiration means forming a portion of thedebris removal sub-system 30. That means will be described later. Suffice it for now to state that the aspiration means withdraws the infusate liquid, the debris particles and some blood at an aspiration flow rate of Q2. - As should be appreciated by those skilled in the art the liquid exiting from the
window 64 of the shroud will tend to push the atherectomy catheter's distal end sideways or laterally in the direction opposite to the direction of the liquid exiting that window. This hydrodynamic action may be used to aid in steering the catheter to a desired position with respect to an occlusion to be revascularized. In this regard, for example, when negotiating a branch in the artery system to reach the occlusion to be revascularized, the atherectomy catheter can be rotated or twisted about its longitudinal axis so that the shroud's window is facing in the opposite direction to the branch to be entered. This action will cause the side directed liquid exiting thewindow 64 to push the catheter's distal end sideways, whereupon it can enter the desired arterial branch. Such “hydrodynamic steering” of the atherectomy catheter can be accomplished in other manners and by other means than by the use of a shroud having a single side window or port. Thus, this invention contemplates an intravascular catheter instrument, of any type, including any means for producing an asymmetric, e.g., side directed, fluid flow adjacent the distal end of the catheter so that it can be steered into a desired position by appropriate rotation of the catheter about its longitudinal axis. - As mentioned earlier, the
guide catheter 24 is of any conventional construction. In the preferred embodiment shown in FIG. 1 it is a 10F to 12F catheter having aconventional Y connector 66 at its proximal end. TheY connector 66 has one input leg including a Touhy-Borstadjustable hemostasis valve 66A through which theatherectomy catheter 22 passes. The other input leg, i.e., theangled leg 68, is connected to the aspiration portion of the debris removal sub-system 30 (to be described later). - Power for operating the atherectomy catheter is provided by the
drive sub-system 28. That system includes anair turbine motor 70 which is coupled to the proximal end of theflexible drive cable 42. Theair turbine 70 is provided with compressed air via an input line orconduit 72. Air for theline 72 is provided from a source (not shown) via an associatedregulator 74, and theconventional control valve 76. The control valve is coupled to theinput line 72 of the air turbine. Apressure gauge 78 is connected between theregulator 74 and thecontrol valve 76. Theregulator 74, thecontrol valve 76, thepressure gauge 78 and the associated lines or conduits and the air source make up thedrive sub-system 28. Thecontrol valve 76 is of any conventional construction, be it mechanical or electrical. Theair turbine motor 70 is also of any conventional construction, as is theregulator 74 and thepressure gauge 78. The air turbine includes an outlet port in communication with the ambient atmosphere, via aline 80. It must be pointed out at this juncture that theatherectomy catheter 22 need not utilize an air turbine motor to rotate the working head. For example, an electric motor can be provided to replace the air turbine to drive the rotating cable and the associated working head. - The
debris removal sub-system 30 basically comprises asource 82 of the infusate liquid “S”, e.g., saline plus a 30% contrast media, a firstpositive displacement pump 84, an input line orconduit 86, an outlet line orconduit 88, a secondpositive displacement pump 90, and adebris collection vessel 92. Theinput line 86 and its associated components, i.e., thepump 84 andinfusate source 82 serve as the “infusion” means for thesystem 20. To that end theinput line 86 is coupled via a connector to the interior of the atherectomy catheter, i.e., to the annular space within the catheter's jacket between it and the drive cable. The infusate liquid S is pumped at the flow rate Q1 by thepositive displacement pump 84 throughline 86 from the supply orsource 82. Thus, the infusate liquid S exits the catheter's working head and circulates as described earlier. - The rate of flow Q1 of the infusate liquid is established by the
positive displacement pump 84 under control of some automatic or manual controller (not shown). In accordance with one exemplary method of use the pump is operated to produce a flow rate Q1 the range of 5-80 ml. per minute. - The
output line 88 and its associated components, i.e., thepump 90 anddebris collector vessel 92 serve as the “aspirating” means for thedebris removal sub-system 30. To that end, theaspiration line 88 is connected to theleg 68 of theY connector 66. Thepump 90 is arranged to be operated to pump the infusate liquid, the debris produced by the revascularization, and some small amount of blood at the flow rate Q2 in the proximal direction through the annular space between theatherectomy catheter 22 and theguide catheter 24 and out through theconnector leg 68 into theoutlet line 88, and from there to thecollector vessel 92. - The flow rate Q2 is selected to be greater than Q1. For example, in one exemplary method of use the flow rate is selected to be in the range of 5-100 ml. per minute, with the differential between Q2 and Q1 being between 5 and 50 percent. The use of an aspiration flow rate Q2 which is higher than the infusion flow rate Q1 insures that any debris, e.g., particles of the occlusive material making up the graft's lesion, produced from debriding that material is positively prevented from flowing into adjacent vessel portions. In this regard, as will be appreciated by those skilled in the art, since the aspiration flow rate Q2 is greater than the infusion flow rate Q1, some blood equal to Q2−Q1 will also be withdrawn from the upstream vessel, e.g., the aorta as shown in FIGS. 1 and 3. The withdrawal of some blood from that vessel insures that the debris produced cannot flow upstream to enter into it. Instead the debris particles will be entrained within the infusate liquid and blood which is withdrawn through the aspiration line. The rate of blood withdrawn is preferably be kept to a minimum, e.g., 40 ml. per minute in the interests of patient safety.
- In accordance with a preferred aspect of this invention the operation of the
pumps - In any case, any suitable positive displacement pumps can be utilized, e.g., peristaltic pumps or piston pumps, in the system.
- In order to expedite the revascularization of the bypass graft, the infusate liquid may be provided with a contrast medium, e.g., 30% contrast medium, so that the revascularization procedure can be viewed using conventional imaging techniques. Moreover, the infusate liquid can, if desired, be oxygenated to eliminate distal ischemia when the catheter is used for arterial restriction opening procedures. Also, if desired, small amounts of heparin, urokinase, etc., or other drugs can be added to the infusate liquid for the procedure.
- As should be appreciated from the foregoing the subject invention provides a viable means for effecting the revascularization of partially or totally occluded coronary bypass grafts, while assuring that any debris particles produced during the revascularization procedure is removed from the patient's body. In addition, the subject invention is suitable for revascularizing other occluded vessels, as well. For example, in FIG. 5 the system is shown in use revascularizing a totally occluded
femoral artery 18 downstream of the profunda femoris 18A. In this application the system functions to capture the debris created during the lumen opening procedure by preventing it from going along side the catheter and exiting down the profunda to end up in the distal capillary beds. In this application, a portion Q4+Q1−Q2 of the blood flowing down thefemoral artery 18 to the situs of the occlusion will be permitted to flow into the profunda femoris, while the portion Q2−Q1 of the blood and infusate liquid is diverted and/or withdrawn into the guide catheter to ensure positive debris removal in the same manner as described earlier. For some persons, e.g., diabetics with severely compromised distal capillary beds, a femoral artery revascularization procedure is likely to prove beneficial. - Turning now to FIGS. 6A and 6B, an
alternative embodiment 100 of the system of the subject invention is shown. Thesystem 100 is similar in most respects tosystem 20 described heretofore. One major difference, however, is that the atherectomy catheter is arranged for use over a guide wire (to be described later). The guide wire includes a debris blocking member, e.g., an inflatable balloon (also to be described later). When the atherectomy catheter is in place on the guide wire the balloon is located distally of the working head of the atherectomy catheter and the balloon serves to physically block any debris produced by thesystem 100 which may tend to escape extraction from flowing distally. The atherectomy catheter used in thesystem 100 is designated by thereference numeral 22′ and is identical in most respects to thecatheter 22 described heretofore. In the interests of brevity, the features common tocatheters systems - As can be seen in FIGS. 6A and 6B, the
system 100 includes a controller orconsole 102 housing the heretofore identifiedinfusate pump 84 and theextraction pump 90. Each of these pumps is a peristaltic pump. Theconsole 102 also includes aflow control section 104 for establishing the various fluid flows of the system, as will be described later, and aspeed control section 106 for establishing the operational speed of the working head of the atherectomy catheter. The details of thespeed control section 106 will also be described later. Aperfusate pump 108 is also provided in theconsole 102. Theperfusate pump 108 is also a peristaltic pump and its operation will be described later. Suffice it for now to state that thepump 108 is arranged to provide a perfusion liquid, e.g., blood or a suitable synthetic oxygenation liquid, downstream of the inflatable balloon to perfuse downstream (distally) located tissue. Thepump 108 also serves to effect the inflation of the balloon. - Compressed gas (e.g., air or nitrogen) is provided via
line 72 from theconsole 102 to the catheter'sturbine 70. The console, in turn, receives the compressed gas from atank 110 via aninput line 112. The rotational speed of the turbine is controlled by thespeed control section 106 of theconsole 102. On/off operation of the turbine is controlled by a turbinefoot control pedal 114 and an associatedgas line 116 connected to the console. This pedal also initiates operation of theinfusate pump 84. - The
speed control section 106 of the console includes a rotary knob for establishing the desired rotational speed of the turbine and an associated digital display for displaying the turbine's speed. The console also includes an on/offswitch 118 for enabling electrical power to be provided to the system's electrical components when the switch is in the “on” position. - The
foot pedal 114 is used by the operator of thesystem 100 to initiate operation of the infusate pump to cause the infusation liquid to flow down the guide wire and out its distal end and to start the atherectomy catheter's turbine 70 a short time, e.g., 2 seconds, after the infusate liquid begins to flow. The use of the foot pedal frees the operator's hands for other purposes. - The
perfusate pump 108 is connected via an input line to abag 120 containing the perfusion liquid. The output of theperfusate pump 108 is provided via aline 122 to the guide wire of thesystem 100. The guide wire is designated by thereference numeral 124 and includes the heretofore identified balloon. That balloon is designated by thereference number 126 and, as seen clearly in FIGS. 6B, 7 and 8, is located adjacent the distal end of theguide wire 124. - The
atherectomy catheter 22′ is an “over-the-wire” type of device. Thus, it includes a central lumen for receipt of theguide wire 124 so that thecatheter 22′ can be threaded over theguide wire 124. Theguide wire 124 serves to perfuse distally located tissue and to inflate itsballoon 126 so that the balloon blocks any particulate material (debris) from flowing distally. To accomplish these functions, the perfusate liquid in thebag 120 is pumped by theperfusate pump 108 through theline 122 and through the interior of theguide catheter 124 where some of it fills or inflates the balloon and the remainder exits at the distal end of the catheter to perfuse downstream tissue, as will be described later. - The rate of flow of the infusate, extraction and perfusate liquids is established by the
flow control section 104 of the console via its various up/down switches and associated digital displays. As discussed earlier, the ratio of the infusate flow rate to the extraction flow rate is adjustable. This is accomplished by the appropriate setting of the “infusate flow” and “ratio” up/down switches of the flow control section of the console. The desired ratio and the infusate flow rate are displayed by the associated digital displays. - In FIG. 7 there is shown in greater detail the distal end of the
atherectomy catheter 22′ located within a diseased bypass graft, e.g., a re-occludedmammary artery 10′. The diseased artery leads to adistal blood vessel 15, i.e., the vessel to be fed by thegraft 10′. Theguide wire 124 is in the form of an elongated flexible member, whose construction will be described later with reference to FIG. 8. The distal end of theguide wire 124 is in the form of a somewhat soft or flexible,precurved tip 128. The free end of the catheter's tip is ahemispherical dome 130. Theballoon 126 is disposed slightly proximally of thefree end 130 of theguide wire 124. - In FIG. 8 the details of the distal end of the
guide wire 124 and balloon are shown (although thetip 128 is shown being linear in the interest of drawing simplicity). Most of the length of the guide wire, i.e, from its proximal end to the location of theballoon 126, is in the form of a two start helical spring 132 (see FIG. 8) whose convolutions are in close engagement (abutment) with one another. Thespring 132 enables the guide wire to be bent through a small radius of curvature to facilitate its intravascular placement via theconventional guide catheter 24. Inside thehelical spring 132 is a liquid impervious, e.g., rubber or plastic,flexible liner tube 134. This tube prevents the egress of the perfusate liquid through the interface between successive convolutions of thehelical spring 132 as that liquid is pumped down theguide wire 124. - A perforated
support tube 136 is mounted within a distalend helix termination 138 of thespring 132. Thesupport tube 136 is arranged to mount theballoon 126 thereon and includes a plurality of radially located apertures orports 140. Theballoon 136 is an annular member of any conventional construction, e.g., rubber, and is mounted on and is disposed about opposite ends of theperforated support tube 136. In particular, theballoon 136 is held in place and sealed to the periphery of the support tube at each end thereof viarespective bands 142. Eachband 142 extends about one cylindrical end of the balloon. Thus, when the perfusion liquid is pumped down theguide wire 124 by thepump 108 it passes through the apertures or ports 140 (as shown by the arrows in FIG. 8) to fill up, i.e., inflate, theballoon 126. - The distal end of the perforated support tube is located within a
spring helix termination 144 forming the proximal end of the guidewire tip portion 128. Theportion 128 is also formed as a two start helix, likeportion 132. However, no fluid-impervious sleeve is located within thetip portion 128 so that the interface between successive convolutions of the spring forming thetip portion 128 serve as passageways through which the portion of the perfusion liquid which doesn't enter the balloon exits the guide wire as shown by thearrows 146 in FIG. 8. - Since the
atherectomy catheter 22′ is designed for over-the-wire use, the drive cable for rotating its working head is in the form of a spiral spring helix having a central lumen extending down its center. The proximal end of the drive cable is connected to the output of theturbine 70 while the distal end is connected to the working head. That working head is designated by thereference number 32′ and is shown in FIGS. 6A and 7. The central lumen of the spiral helix drive cable forms the passageway for receipt of theguide wire 124. If desired an anti-friction sleeve or some other anti-friction bearing can be provided at the interface between the inner surface of the spiral drive cable and the outer surface of the guide wire. The workinghead 32′ is similar in construction to the workinghead 32 ofsystem 20 except that the workinghead 32′ includes acentral bore 148 through which theguide wire 124 extends. As can be seen clearly in FIG. 7, the workinghead 32′ is unshrouded, i.e., is not located within a shroud like the workinghead 32 of theatherectomy catheter 22. - Operation of the
system 100 is as follows: - The
guide wire 124 with itsballoon 126 deflated and with theatherectomy catheter 22′ mounted thereon so that theballoon 126 andtip portion 128 extend beyond the workinghead 32′ is threaded through apreplaced guide catheter 24 in the patient's vascular system until it is at a desired situs, such as at the arch of the aorta. At this point theguide wire 124 is advanced with respect to theatherectomy catheter 22′ so that the guide catheter crosses the lesion or atherosclerotic deposits in thebypass graft 10′. The precurved tip of theguide wire 124 facilitates the placement of the guide wire. In this regard, the guide wire can be rotated about its longitudinal axis to point thetip 130 in the desired direction. - Once the
guide wire 124 is at the desired position, such as shown in FIG. 7, theballoon 126 can be inflated and the distally located tissue perfused. The exiting perfusion liquid is shown by the arrows in FIG. 7. In particular, the perfusate liquid is pumped bypump 108 and associatedconduit 122 through the hollow interior of theguide wire 124, so that it passes through the apertures orports 140 in thesupport tube 136 to inflate theballoon 126 to the state shown in FIG. 7, while the remainder of that liquid flows out of the open distal end of thesupport tube 136, into the hollow interior of guide wire'stip 128, and out through the interface between the immediately adjacent convolutions of the tip. Accordingly, distally located tissue is oxygenated, notwithstanding the fact that the balloon is inflated and thus blocking the flow of blood through thebypass graft 10′. - If no perfusion or oxygenation of distally located tissue is desired, the system may utilize an alternative guide-wire mounted debris-blocking balloon. That alternative embodiment of the guide-wire is designated by the
reference number 124′, is shown clearly in FIG. 14, and will be described in detail later. - The rate of flow of the infusate liquid is set by the flow control section switch and the ratio of that flow to the extraction flow rate is established by the ratio control switch of the flow control section. Accordingly, when ready the operator presses the
foot pedal 114 to start the infusate pump. This action provides the infusate liquid throughline 86 and through the associated components of thecatheter 22′, whereupon the infusate liquid exits from the catheter at the workingtip 32′ as described earlier. The rate of extraction of liquid through the annular space between the inner surface of theguide catheter 24 and the outer surface of theatherectomy catheter 22′ is established by theextraction pump 90 under control of the associated flow controls of the console. Theturbine 70 is arranged to commence operation on a fixed time delay, e.g., 2 seconds, after the infusate pump commences operation in response to the depression of thefoot pedal 114. This action causes the working head to begin rotating at a high rate of speed. The desired speed setting for the turbine is established by setting of the rotary knob of the speed control section of the console. Preferably some restraining means (not shown but like the cradle assembly of thesystem 200 to be described later) is used to hold or clamp the guide wire in position when the atherectomy catheter is operated to prevent the rotation of the workinghead 32′ from causing the guide wire to rotate. The compressed gas e.g., nitrogen or air, powering theturbine 70 of theatherectomy catheter 22′ vents to the atmosphere vialine 80. The debris particles produced by the rotary working head repeatedly impacting the plaque or other deposit within the diseased graft are withdrawn by the extraction pumps into thecollection bag 92, in the same manner as discussed earlier. Any debris particles which may have otherwise escaped being withdrawn from the patient's body by the extraction subsystem are positively prevented from flowing distally by the barrier established by theinflated balloon 126. Thus, such particles will eventually be extracted. After the diseased bypass graft has been opened, theballoon 136 can be deflated by turning off the infusation pump. Then, theatherectomy catheter 22′ and theguide wire 124 can be removed through theguide catheter 24. - It must be reiterated that the atherectomy catheter for producing the lumen through the vascular occlusion need not be a rotary impacting device, like described above. Thus, a system constructed in accordance with any embodiment of this invention may make use of any instrument having any type of working head, e.g., a reciprocating impacting working head, a combined rotary and reciprocating impacting working head, a rotary cutting head, a reciprocating cutting head, a rotary abrasive head, etc., to open the lumen in the occlusive material in the blood vessel. Moreover, the working head need not be shrouded. In fact, any of the heretofore identified prior art atherectomy devices can be utilized as part of the
system system 20 or 100 (or even as part of thesystems - In the embodiments described in FIGS. 1-8, it has been assumed that there will be some blood flow from the patent upstream blood vessel, e.g., the aorta in the case of a revascularization of a bypass graft, which may flow about the exterior of the distal end of the
guide catheter 24 to merge with the flow being drawn into the passageway between theguide catheter 24 and theatherectomy catheter 22. See for example, FIG. 7 wherein blood flow Q2−Q1 from the aorta flows around the outer surface of the distal end of theguide catheter 24 between the guide catheter and the inner wall of thebypass graft 10′. In the event that blood flow from the upstream, patent artery, e.g., theaorta 12, is precluded from entering theguide catheter 24, such as by the outer peripheral surface of the distal end of theguide catheter 24 tightly engaging the inner periphery of thebypass graft 10′ to be revascularized, care must be taken to control the ingress and egress flow rates with respect to each other to ensure that the bypass graft does not collapse since the extraction or aspiration rate will exceed the infusion rate. As will be appreciated by those skilled in the art, if the bypass graft does collapse, the rotating workinghead 32 will be forced against the inner surface of the bypass graft wall, which is now in a flatulent state, and the risk of vascular damage will increase. - In prior art devices, such as the Clement et al. U.S. Pat. No. 5,681,336 the potential for vessel collapse is even more acute. In this regard, the Clement et al. patent positively seals off a space in the vessel to be revascularized between a pair of balloons. In particular, one balloon is located on the distal end of a guide wire distally of the restriction to be opened and the other balloon is located on the distal end of a guide catheter through which a rotary ablation catheter extends. Thus, when suction is applied to that space to evacuate the particles produced by the revascularization process, if the extraction rate is not precisely controlled and coordinated to the infusion rate, vessel collapse may occur to bring the vessel wall into the rotating burr.
- This embodiment overcomes this potential vascular collapse problem. In particular, in FIGS. 9-13 there is shown another alternative embodiment of a
system 200 constructed in accordance with this invention utilizing anatherectomy catheter 22″ for revascularizing occluded vessels, e.g., coronary bypass grafts. Thesystem 200 obviates the problem of potential vessel collapse by providing automatic access to blood flow from a patent, upstream vessel, e.g., theaorta 12, via use of at least one flow control or regulation port in the wall of the guide catheter 24 (or any other tubular member through which theatherectomy catheter 22″ extends and through which the infusate liquid, blood and debris will be aspirated). The flow control or regulation port(s) extend(s) through the wall of theguide catheter 24 close to its distal end, yet is(are) located sufficient proximally from the distal end of the guide catheter so that when the guide catheter is in its normal position for enabling anatherectomy catheter 22″ (to be described later) to revascularize the restricted vessel, e.g., acoronary bypass graft 10′, the side port(s) is(are) in direct fluid communication with the blood flowing in the patent upstream vessel, e.g., theaorta 12. In the exemplary embodiment of thesystem 200 shown in FIGS. 9-13 two such sideflow regulation ports guide catheter 24. As will become apparent later the size, location and number of flow regulation side ports used is a matter of choice, depending upon various system parameters. For example, for a system making use of a guide catheter of 9 French (one suitable size for effecting the revascularization of coronary bypass grafts), twoside ports side port 24A of 0.04 inch may be used. Other number(s) and sizes of side port(s) can be used as well. - Since the two
side ports guide catheter 24, they are in fluid communication with the interior of the guide catheter, and hence with the annular space or passageway between the inner surface of theguide catheter 24 and the outer surface of theatherectomy catheter 22″ which extends through the guide catheter. As described earlier it is through this annular space or passageway that the infusate liquid, blood and any debris, e.g., atherosclerotic plaque produced by the revascularization procedure, is extracted by the extraction subsystem. - The use of at least one flow regulation or control port ensures that the vessel being revascularized does not collapse as the debris is extracted, even if the
guide catheter 24 is tightly fit within thebypass graft 10, such as shown in FIG. 10, and even if theextraction pump 90 is operating at a much higher rate that theinfusate pump 84. This automatic control or regulation provided by the at least one side port(s) will be described after a brief background discussion. To that end, as will be appreciated by those skilled in the art, if the guide catheter 24 (or other tubular member through which the atherectomy catheter extends) does not tightly fit in the bypass graft (such as shown in FIG. 11), blood from within theaorta 12 may flow around the outside of the guide catheter 24 (see the arrows A1) to join with the blood, debris particles and infusate fluid flowing into the open end of the guide catheter (see the arrows A2). Accordingly, the action of the extraction pump to remove liquid from the space in the bypass graft section between the end of the guide tube and the distally located blockingballoon 126′ (forming a portion of the guide-wire 124′ to be described later), will not collapse that vessel section, even if the guide catheter does not make use of any flow control or regulation side port(s). If however, a guide catheter without any flow control or regulation side ports is tightly fit within the bypass graft, the possibility for vessel collapse exists if the extraction rate is not controlled precisely with respect to the infusion rate as discussed earlier. - By utilizing at least one flow control or regulation side port this potential hazard can be eliminated since such port(s) will provide automatic access to blood flow in the upstream, patent vessel. In this regard, as can be seen in FIG. 10, with the
guide catheter 24 in place tightly engaging the periphery of thebypass graft section 10′ blood from theaorta 12 is enabled to flow into the flowcontrol regulation ports rotary working head 32″ in the bypass graft section between the distally located blockingballoon 126′ of theguide wire 124′ (a variant of guide-wire 124 and which will be described later with reference to FIG. 14) and the distal end of theguide catheter 24. By appropriate sizing of the flow control side port(s) one can ensure that the pressure within the vessel being revascularized, e.g., the bypass graft, is positive, thus ensuring that the vessel section will not collapse. - The foregoing automatic flow control feature of this invention renders it useful with other revascularization systems than those of the systems disclosed herein. For example, a
guide catheter 24 having at least one flow control port (or any other tubular member through which an atherectomy catheter is extended) can be used with any prior art atherectomy catheter system, e.g., the atherectomy system of the heretofore identified Clement et al. U.S. Pat. No. 5,681,336. - As discussed previously, it is desirable to operate the extraction pump at a rate to pull more fluid out of the vessel section being revascularized than the rate at which infusion liquid is introduced by the infusion pump to ensure that debris is removed even. By the use of a
guide catheter 24 having at least one flow regulation port, like that described above, one can accept a significant mismatch in flow between the infusate flow and the extraction flow and still not risk collapse of the vessel being revascularized. This factor considerably simplifies the amount of coordination between the extraction pump and the infusion pump. - In FIGS. 9A, 9B,12 and 13 there are shown the details of
system 200. That system basically comprises the same system as thesystem 100 shown in FIGS. 6-8 described heretofore, with some slight minor modifications (as will be described later). Thus, in the interest of brevity, the common components of those systems will be given the same reference numbers and their construction and operation will not be reiterated. - The
system 200 basically comprises aguide catheter 24, a modifiedguide wire 124′ with a distally locatedinflatable balloon 126, anatherectomy catheter 22″ with a distally locatedrotary working head 32″ disposed over the guide wire and within the guide catheter to be moved longitudinally with respect thereto, adrive sub-system 28 for rotating the workinghead 32″, a cradle assembly 202 (FIG. 9A) for supporting the turbine and associated portion of the drive sub-system, for fixing the position of theguide wire 124 and guidecatheter 24 and for enabling theatherectomy catheter 22″ to be moved longitudinally with respect to the guide catheter and the guide wire, asource 110 of compressed gas, e.g., nitrogen or air, to power the drive sub-system, adebris removal sub-system 30 made up of anextraction pump 90 and associated components, and acontrol console 204. - The
guide wire 124′ is shown clearly in FIG. 14 and is similar to theguide wire 124 in that it includes aninflatable balloon 126′ located immediately adjacent the distal end of theguide wire 124′, a flexibledistal end portion 128′ immediately distally of theballoon 126′ and terminating in anatraumatic tip 130′ at the distal end of the guide-wire 124′. However, theguide wire 124′ is not arranged to perfuse downstream tissue, as is the case of theguide wire 124. Thus, as can be seen inFin 14 theguide wire 124′ basically comprises an elongated small diameter, flexible, hollow wire ortube 180, e.g., a “hypo” tube formed oftype 304 stainless steel having a 0.010 inch outside diameter and a 0.005 inch inside diameter. A central passageway or bore 180A extends the full length of the guide-wire tube 180. - The
balloon 126′ is formed of any suitable material, e.g., latex of a thickness of approximately 0.006 inch, and is fixedly secured slightly proximally of the distal end portion of thetube 180 via a plurality of loops or lashes of afilament 182, e.g, polypropylene, wrapped about the tubularproximal end portion 184 of theballoon 126′ and similar loops or lashes 182 wrapped about the tubulardistal end portion 186 of theballoon 126′. This creates a confined space within the balloon and into which an inflation gas, e.g., carbon dioxide, is to be provided via the guide-wire tube 180 to inflate the balloon. To that endplural gas ports 180B extend through the wall of the guide-wire tube 180 in communication with the interior of the balloon and with thecentral passageway 180A in the guide-wire tube 180. The balloon can be any suitable size, depending upon the application. For example, for revascularizing a typical bypass graft, the outside diameter of the balloon when deflated may be approximately 0.03 inch, and may be inflated to an outside diameter of up to 0.2 inch (5 mm). - A tapered, flexible,
core wire 188, e.g., type 304 stainless steel, is soldered by any suitable lead-free solder into the distal end of thecentral passageway 180A of the guide-wire tube 180 to seal its distal end. A tight helix orcoil 128′ is also soldered by a lead-free solder to the outer surface of the distal end of thetube 180. Thecoil 128′ forms the curved, flexible distal end of the guide-wire and can be fabricated of any suitable radiopaque material, e.g., platinum wire of 0.003 inch diameter. Thecoil 190 extends for a short distance, e.g., approximately 1 inch, from the end of thetube 180 and is of a suitably small outside diameter, e.g, 0.018 inch. The distal end of thecore 188 extends into a small bore in theatraumatic tip 130′ and is soldered in place by a lead-free solder. The distal end of thecoil 128′ is also soldered to the atraumatic tip by a lead-free solder. Theatraumatic tip 130′ is in the form of a hemisphere of any suitable material, e.g., type 300 stainless steel. - A small sleeve or
ring 190 formed of any suitable material, e.g., plastic or stainless steel, is located on theguide wire 124′ immediately proximally of theballoon 126′. This ring serves as a stop member for theatherectomy catheter 22″. In particular, as theatherectomy catheter 22″ is advanced along theguide wire 124′, with theguide wire 124′ and theguide catheter 24 being held in a fixed position with respect to each other and to the patient's vascular system by a cradle assembly (to be described later), the rotating workinghead 32″ will be prevented from engaging and perforating the distally located balloon by the ring or stop 190. Thus, the advancement of the working head along the guide wire to remove the plaque or other restriction-forming material in the vessel will not present any danger of perforating the balloon. - The
console 204 is similar to console 102 described heretofore and includes various electrical and electronic components, e.g., a microprocessor and associated circuitry to accomplish the various functions of the system and to display various system parameters. Thus, as can be seen clearly in FIG. 9B, theconsole 204 includes the heretofore identifiedperistaltic infusion pump 84 and theperistaltic extraction pump 90. Compressed gas, e.g., nitrogen, is provided vialine 112 from thetank 110. The tank provides the compressed nitrogen via heretofore identifiedregulator 74 and associatedvalve 76 intoline 112 and from there toline 72. The gas pressure is displayed on a dial ormeter 78 on the front of the console. Control of the turbine's rotational speed is effected by a turbinespeed adjustment knob 206 on the front console. The turbine's speed is displayed on adigital display panel 208. An optical signal indicative of the turbine's speed is provided via afiber optic line 210A. This line is connected to aconnector 212A on the console. Anotherfiber optic line 210B is connected to anotherconnector 212B on the console, whereupon a beam of light from the console is carried downline 212B to the turbine rotor where it is broken or chopped up by the rotating blades. The chopped up light beam which is indicative of rotor speed is carried back to the console vialine 210A andconnector 212A. Control of the turbine is effected via a turbine foot control (or hand control, not shown) 114 connected vialine 116 to aconnector 214 on the console. - A pressure transducer218 (FIG. 9A) is connected in the
line 86 coupled from theinfusate pump 84 to theatherectomy catheter 22″. The pressure transducer provides an output signal via aline 220 to a connector 222 (FIG. 9B) on the console. The rate of infusion liquid flow into theatherectomy catheter 22″ is effected by the heretofore identifiedperistaltic pump 84. The speed of that pump is controlled via an up/downswitch 224 on the console. The pump's speed in RPM is displayed on adigital readout panel 226. The speed of the extraction pump is controlled by an up/downswitch 228 on the console and that pump's speed is displayed on an associateddigital readout panel 230. The console also includes an on/offswitch 232 for providing electrical power to the system when the switch is in the on position. - Data from the console, e.g., operating parameters, etc., is arranged to be downloaded to any suitable device, e.g., a
laptop computer 216, via conventional multipinelectrical connector 218, e.g., anRS 232 serial port, and associatedcable 220. - If desired, the
console 204 may also include various alarm devices to warn operating personnel of certain abnormal conditions. For example, the console may include a low battery power warning lamp on the front of the console to warn operating personnel that the battery is low. An infusate high pressure warning lamp may also be provided on the console along with an associated audible annunciator to produce respective visible and audible warning signals when a high pressure infusate condition exists. - Referring now to FIGS. 12 and 13, the details of the
atherectomy catheter 22″ will now be described. As can be seen that thecatheter 22″ is similar tocatheter 22′ in that it includes ajacket 34 having a distal end. A rotary working head ortip 32″ is located at the distal end of the jacket. Thetip 32 is preferably constructed in accordance with the teachings of U.S. Pat. No. 4,747,821. However,tip 32″ unlike the tip of the aforementioned patent includes a central passageway or bore 148 through it (liketip 32′). It is through this bore that theguide wire 124 extends. - The working
head 32″ is mounted for rotation within abushing 302 secured to the distal end of the jacket. Thebushing 302 is similar in construction to the bushing of the U.S. Pat. No. 4,747,821 and it includesplural passages 46″ extending along its length through which the infusate liquid passes to exit out of the tip. In addition it includes pluralradial passageways 304 in the thrust pad portion forming the distal end of the bushing and which are in communication with thepassages 46″ through which the liquid exits radially. The radial passages are constructed similarly to those of U.S. Pat. No. 5,049,124 (Bayles) whose disclosure is incorporated by reference herein. Thus, the exiting liquid from those passages is impacted by the flattened sides of the tip to create a vortex flow in a manner similar to that as shown in FIG. 12. Therotary working head 32″ also includes a tubular shank portion through which thecentral bore 148 extends. Infusate liquid from thepassageway 312 is enabled to flow into the open proximal end of thebore 148 and through the annular space or clearance between the inner surface of that bore and the outer surface of the guide wire extending through the bore as shown by the arrows in FIG. 12. Asleeve 306 is located immediately proximally of thebushing 302 and extends about the shank portion of therotary working head 32″. Thesleeve 306 is welded to the shank portion of the rotary working head. Therotary working head 32″ is arranged to be rotated at a high rate of speed within the bushing by adrive cable 308. As best seen in FIG. 12, thecable 308 is a bifilar or double helix formed of any suitable material, e.g., 304 stainless steel or Nitinol, and is flexible so that the atherectomy catheter can be readily bent to follow tortuous paths to the revascularization site, i.e., the coronary bypass graft. The distal end helices of thedrive cable 308 are welded at 310 to the shank portion of therotary working head 32″. The outer diameter of the drive cable is less than the inner diameter of thecatheter jacket 34 to form anannular passageway 312 therebetween. This passageway extends the full length of the atherectomy catheter and serves to carry the infusion liquid to the workinghead 34″. - A flexible plastic tube or
sleeve 314 is located within the central passageway of thebifilar drive cable 308 and extends for the full length thereof. Thetube 314 includes acentral passageway 316 which is of approximately the same internal diameter as thebore 148 extending through the workinghead 32″ and is coaxial therewith in order to accommodate theguide wire 124 therethrough. Thesleeve 314 serves to form a barrier between the metal helices of thedrive cable 308 and metal guide wire extending through it, while preventing the helices of thecable 308 from closing up as the drive cable is rotated. - In FIG. 13, there is shown the details of the proximal end of the
atherectomy catheter 22″. Thus, it can be seen that the proximal end of thejacket 34 is flared outward at 318. The flared proximal end of the jacket is connected to the distal end of a turbine housing orbody 320 via acapture nut 322. Thecapture nut 322 includesinternal threads 324 which mate with corresponding external threads on the distal end of theturbine housing 320. The free end of the turbine housing is tapered at 326. Thecapture nut 322 also includes a taperedinner surface 328 merging into acentral bore 330 through which thecatheter jacket 34 extends. Thus, when thenut 322 is tightened, the flaredend 318 of the jacket is tightly interposed between thesurface 330 of the nut and thetapered surface 326 of theturbine housing 320. The distal end portion of theturbine housing 320 also includes acentral bore 332 into which the infusate fluid will be injected for flow into theannular passageway 312 in the atherectomy catheter, as will be described later. - The proximal end of the
bifilar drive cable 308 is connected, e.g., welded, to anadaptor sleeve 334. The adaptor is a tubular member which is in turn welded to the turbinerotor drive shaft 336. Theturbine drive shaft 336 is an elongated tubular member. Being tubular theturbine drive shaft 336 includes a central passageway. It is through this central passageway that the guide wire is arranged to be extended. The turbinerotor drive shaft 336 extends through thecentral bore 332 in the turbine housing and terminates at its proximal end in a seven-bladed turbine rotor 338. The rotor is located in an enlarged proximally locatedflanged portion 322 of theturbine housing 320. In particular, theflanged portion 322 includes a hollowinterior chamber 340 in which the turbine blade 338 is located. An enlargedcentral bore 342 extends distally of thechamber 340 and is axially aligned with thecentral bore 332 in the distal portion of theturbine housing 320. Asleeve bearing 344 is located within thecentral bore 342. Theturbine rotor shaft 336 extends through a central bore in the bearing with a slight clearance or leakage passageway, e.g., 0.0005 inch, to form a fluid leakage path to facilitate the cooling of the bearing. An O-ring 346 is located within an annular recess in the distal portion of thesleeve bearing 344 to form a fluid-tight seal. A star washer 348 is located within an enlarged portion of thebore 342 to hold the sleeve bearing in place. - The proximal end of the
turbine drive shaft 336 extends into aball bearing assembly 350 to center the turbine shaft on the longitudinal axis of the housing. A guide-wire centerer and leakage controlrestrictor member 352 is located within the hollow proximal end of theturbine drive shaft 336. Theguide wire 124 is arranged to pass through the restrictor where it is centered and then through the turbine drive shaft, theadaptor 334, thesleeve 314, and out throughbore 148 in the workinghead 32″. Moreover, air can pass through the interface of the restrictor 352 to cool and lubricate the adjacent surfaces. Theball bearing assembly 350 is held in place via a cap orcover 354. Thecap 354 serves to close off the hollow interior of the turbine housing. To that end, the cap is releasably secured to the flangedproximal portion 322 of theturbine housing 320 via plural threadedbolts 356. Anenlarged bore hole 358 is located within thecap 354 and is coaxially aligned with the central longitudinal axis of thedrive shaft 336. A smaller diameter bore 360 communicates with thebore 358 and with therestrictor 352. - The compressed gas, e.g., nitrogen, to effect the rotation of the turbine is provided from the
tank 110 via aninlet port 362. The pressurized gas enters theturbine housing portion 322 somewhat tangentially and impinges on the angled rotor blades 338 to cause the turbine rotor to rotate about its longitudinal axis at a high rate of speed. This effects the concomitant rotation of thedrive shaft 336, thebifilar cable 308 and hence therotary working head 32″. - The infusate fluid, e.g., saline and a contrast medium (plus anything else which is desired to be introduced into the vascular system, such as heparin, growth factors, microspheres carrying chemicals, pharmaceuticals or other biologically active materials, etc.) is introduced into the
turbine housing 320 so that it gains ingress into thepassageway 332. From that passageway, it flows through the communicatingpassageway 312 extending within the jacket of the catheter to exit at the distal end of the jacket where the workinghead 32″ is located. The means for introducing infusate liquid into the turbine housing comprises thetubing 86 on which aconnector 362 is mounted. Theconnector 362 is arranged to be connected to the output of the infusate pump. - An
interlock member 366 is located in atransverse bore 368 in theturbine housing 320 so that it perpendicularly intersects thelongitudinally extending bore 332. The interlock member is a generally plug-like, tubular body having a thin walledupper end 368 defining an enlarged hollow interior space. Anopening 370 is provided in the thin walled upper end of the interlock member communicating with the enlarged hollow interior space and into which the distal portion of thesleeve bearing 344 extends. Anotheropening 372 is provided diametrically opposed from theopening 370 so that theturbine drive shaft 336 can extend through the interlock member via theopenings interlock member 366 includes a barb-liketubular projection 374 which extends into the interior of theplastic tube 86. A ring-like ferrule 376 extends about the outer surface of the tube at the upper end thereof to capture the tube on the barb. A sealing O-ring 378 is disposed within an annular recess extending about the periphery of theinterlock member 366. The barb portion of theinterlock member 366 includes apassageway 378 extending through it in communication with the hollow interior at the upper end of the interlock member. Thus, the infusion liquid introduced into thetube 86 will pass through the communicatingpassageway 378 in the barb member into the hollowupper interior 368 of the interlock member and out throughopening 372 into the passageway or bore 332. Frompassageway 332, the infusate liquid will flow through the hollowannular passageway 312 in the catheter'sjacket 34 and out through its distal end at the workinghead 32″. - As will be appreciated by those skilled in the art, the rotation of the
drive cable 308 creates an Archimedes-like pumping action to aid the infusate pump in carrying the infusate liquid down theannular passageway 312 in thejacket 34. In particular, the ability of thehelical drive cable 308 to deliver flow is a function of: (1) the rotation speed of the helix, (2) the swept volume of the helix (the swept volume of the helix being the volume of fluid entrapped between the coils of one pitch of the helix), and (3) the leakage of flow back along the helix due to the clearance between the helix and the jacket and the clearance between the helix and the liner. If the clearances are reduced to zero (leakage reduced to zero) the pump can act as a very stiff positive displacement pump, that is, it can deliver flow at a large range of output pressures regardless of the inlet pressure. For example, with a 5F diameter catheter having bifilar drive cable with 0.008 inch wire diameter and pitch of 0.040 inch running at speeds between 100,000 and 160,000 RPM, the helix design suitable for transmitting suitable torque, with adequate flexibility for navigating the bends of the coronary vasculature, also has the correct swept volume to deliver an appropriate flow, e.g., 30-40 mL/minute, required to keep the catheter and tip abrasion site at a temperature compatible with tissue viability (e.g., not more than 98 deg F.). These facts make it possible for a 5F catheter system to use thehelical drive cable 308 as the infusate metering pump while theperistaltic infusate pump 84 serves as a priming pump. This arrangement, can deliver pressure rather than flow by the use of soft pump tubing, i.e., tubing, that leaks back under thepump 84 rollers, if the delivery pressure becomes excessive, e.g., approximately 30 psi or greater. If different size catheters are used, such as 8F or 4F, the helical drive cable design may not provide the ideal flow, and the peristaltic infusate pump 84 characteristics might well have to be changed to obtain the correct flow. This can be accomplished by changing the peristaltic pump speeds, changing the stiffness of the peristaltic pumps by using tubing of different softness, and partially disabling the helix drive cable pump by increasing the clearances around the helix. Thus, if the console provides for independently adjustable peristaltic pump speeds for the infusate and extraction pumps, the system can provide for any catheter design. The operator can be instructed to select the appropriate pump speed and the appropriate pump tubing for whatever catheter is in use. In some instances it may be advisable to use operator adjustable peristaltic pumps linked electronically that provide for fixed ratios between the infusate and extraction pumps, and in other designs it may be best to provide for the pumps to be preset and not user adjustable. - It has also been found that there is an advantage to having a variable pitch helix for the
drive cable 308. Thus, thecable 308 is preferably so constructed. As will be appreciated if thedrive cable 308 is to act as a pump in addition to the means for effecting the rotation of the working head, the helices of the cable have to have a certain pitch (e.g., 25 coils to the inch) to provide the required swept volume. If the bending stiffness of the atherectomy catheter is to be minimized (e.g., to enable the catheter to freely negotiate tortuous paths to the site of the occluded vessel section) the helices of the cable needs to be approximately of closed coil configuration (e.g., 40 coils to the inch), but not quite closed, because it is best if the coils do not touch each other as the catheter bends since the friction between the abutting coils may cause excessive heat to be generated. It has been found that if the distal end portion of thehelical drive cable 308 is almost close wound for a short distance (e.g., 0.5 to 4.0 inches), as is the case in the embodiment shown herein, the remainder of the cable, (i.e., the portion located proximally of the distal end portion and which may be approximately 50 inches or longer) can force the infusate liquid past the close coils at the distal end and out of the catheter. The variable pitch of the drive cable thus provides for the optimum pumping action, while maintaining optimum flexibility. As will also be appreciated the helix pitch of the drive cable also has an affect on vibration of the catheter, with the coarser or greater spacing between helices resulting in lower vibration. Thus, the variablepitch drive cable 308 will also help to reduce the vibration level by minimizing the length of closed coil helices at the distal end of the drive cable. - As mentioned earlier, the
system 200 includes acradle assembly 202 for holding theguide catheter 24 and theguide wire 124 fixed with respect to each other and with respect to the patient's vascular system, while supporting a portion of the atherectomy catheter to enable it to be moved longitudinally with respect to the guide catheter and guide wire in order to advance the working head through the vessel section to be revascularized. Thecradle assembly 202 will now be described with reference to FIG. 9A. As can be seen therein, the cradle assembly basically comprises a cradle member 400 (shown by phantom lines in the interest of drawing simplicity) and other associated components (some shown by solid lines and others by phantom lines), all to be described later. Thecradle member 400 itself is a generally tubular member which is arranged to support the turbine body therein and to allow the turbine body to slide longitudinally with respect to thecradle member 400 while fixing the position of theguide catheter 24 andguide wire 124 relative to each other. - The
tubular cradle 400 includes aloading slot 402 extending from its front or distal end to a point close to its rear or proximal end. A pair ofsupport feet 404, also shown by phantom lines, are provided on the underside of the cradle tube to support it on any horizontal surface. A cup-shapedplug member 406 is mounted in the open rear end of the cradle tube. The plug member includes acentral passageway 408 extending through it. A pair oftelescoping tubes 410 and 412, are mounted between the central passageway in the plug member and the proximally locatedcap 354 of theturbine housing 320 via a ferrule (not shown). Thecentral passageway 408 in the plug member and the associatedtelescoping tubes 410 and 412 provide a passageway through which theguide wire 124 may be extended into the turbine housing and from there through theatherectomy catheter 22″ as described earlier. The telescoping tubes are formed of any stiff material, e.g., type 304 stainless steel, to prevent buckling of the guide wire. - In order to fix or clamp the longitudinal position of the guide wire with respect to the cradle assembly while also forming a fluid tight seal about the guide wire where it enters the
plug member 406, a conventional hemostasis valve, e.g., a Tuohy Borst valve 412, is mounted on the rear side of the plug member via a wing nut mount (not shown). - The turbine housing assembly is mounted within the cradle tube for sliding movement therealong in order to adjust the distance that the working
head 34″ extends from the distal end of theguide tube 24. This feature enables the rotary working head to be advanced in the distal direction to open a lumen through the plaque or other material forming the restriction in the bypass graft to be revascularized. To achieve that end, ahandle 416 is provided for the turbine housing and projects radially outward from theturbine housing portion 322. The handle extends through a longitudinally extendinglinear slot 418 in thecradle tube 400. It should be pointed out at this juncture that the handle and the associated slot are shown on the facing side of the turbine tube (i.e., the visible side in FIG. 9), when in reality they are located on the opposite side. The showing of the handle and slot on the facing side of the cradle tube is merely done for drawing convenience. - In order to increase the “wheel base” of turbine housing so that it slides easily within the
cradle tube 400 in a longitudinal direction without tilting or canting, a turbine tubehousing extension member 420 is mounted, i.e., snap-fit, on the distal portion of the turbine housing. Theextension member 420 includes a central opening through which theatherectomy catheter 22″ exits the turbine housing. - A
manifold member 422 is mounted within anextension adjustment tube 424 at the front end of thecradle tube 400. The extension adjustment tube is a slotted tube which telescopes within the front end of thecradle tube 400 and whose position can be adjusted so that the manifold 422 can be moved closer or further away from the cradle tube. This feature enables thesystem 200 to be used with guide catheters of varying lengths. In order to fix the position of the extension adjustment tube with respect to thecradle tube 400, atube extension latch 426 is provided to extend through any selected one of plural longitudinally spacedholes 428 in the extension tube and a single aligned hole not shown in the front end of the cradle tube. - The
manifold 422 is a disk-like member having a longitudinal passageway (not shown) extending therethrough and to which the proximal end of theguide catheter 24 is connected via aswivel connector 430. The swivel connector permits one to adjust the angular orientation of the guide catheter with respect to the cradle tube so that the guide catheter can be revolved to any rotary position necessary to obtain compatibility with the patient's vascular anatomy. The longitudinal passageway of the manifold is in fluid communication with the proximal end of theannular passageway 312 extending down the interior of the atherectomy catheter's jacket. The manifold also includes a radially extending side port (not shown) in communication with the longitudinal passageway at the proximal end of the guide catheter. The extraction (vacuum)tube 88 is arranged to be connected to the radial side port of the manifold viaconventional connector 432 to withdraw blood, infusate liquid and debris which has been drawn down the passageway between the guide catheter and the atherectomy catheter by the action of theextraction pump 90. - Since the
atherectomy catheter 22″ extends through theguide catheter 24, aconventional hemostasis valve 434 is mounted on the rear (proximal) side of the manifold 422 to enable to the atherectomy catheter to extend through the longitudinal passageway in the manifold and into and through theguide catheter 24. - A
stiffener tube 436 is provided on the atherectomy catheter between the turbine housing and the manifold to prevent the atherectomy catheter'sjacket 34 from buckling under axial loads. The stiffener tube also facilitates the assembly and loading of the atherectomy catheter into the cradle tube. To that end, ahook wire 438 is mounted on thestiffener tube 436 to facilitate movement of the stiffener tube. A pair of pivotable trunnions 440 project outward from the distal end portion of the stiffener tube for connection to diametrically opposed portions of theextension tube 424 to center the stiffener tube so that it can be lifted to enable loading of the atherectomy catheter. - In accordance with one preferred embodiment of the invention, the
longitudinally extending slot 402 is of sufficient length to enable the turbine housing and hence theatherectomy catheter 22″ to be reciprocated through a 4-5 inch range. - It must be pointed out again that the subject invention is not limited to atherectomy catheters, and particularly rotary head catheters. In particular, the subject invention may incorporate an instrument having any other type of working head, e.g., a balloon angioplasty catheter, a catheter for injecting a restriction-removing or dissolving liquid, an ultrasonic catheter, a laser catheter, a stent-delivery catheter, etc., for opening a lumen in an occluded vessel. To that end the term “working head” as used herein is meant to include any type of device for operating on an occluded vessel to open a lumen in that vessel to the freer flow of blood therethrough.
- In FIGS. 16 and 17 there are shown yet another alternative embodiment of a
revascularization system 500 of this invention. Thesystem 500 is arranged to revascularize an occluded blood vessel, e.g., abypass graft 10′, by introducing a conventionalexpandable stent 502 into a lumen formed in the restrictive material of the occluded blood vessel section, e.g., the bypass graft. If desired, thesystem 500 may also employ the atherectomy catheter and some associated components of thesystem 200 described heretofore to effect the opening of a lumen through the material forming the restriction, followed by the introduction of a stent-delivery catheter (not shown) for carrying thestent 502 in a collapsed state into the lumen created by the atherectomy catheter, and then to expand thestent 502 in that lumen to the state shown in FIGS. 16 and 17 to ensure that the lumen stays open. The stent-delivery catheter used in such an application may be of any conventional type, e.g., a balloon catheter. - It must be pointed out at this juncture that the
system 500 may be used without an atherectomy catheter, like the catheters described above or any prior art restriction-opening device, for initially forming the lumen through the material forming the restriction. In such an alternative application, as will be described later, thesystem 500 makes use of any suitable conventional stent-delivery catheter to carry thecollapsed stent 502 over a guide wire, like guide-wire 124′ or any other suitable balloon bearing guide-wire, through the restriction in the occluded blood vessel to an operative position, whereupon the stent-delivery catheter is operated, e.g., its balloon inflated, to expand and place the stent in position (like shown in FIGS. 16 and 17). - Irrespective of the manner in which the lumen is created into which the
stent 502 is placed, thesystem 500 of this invention makes use of a debris removal sub-system to remove any particles or other debris produced during the revascularization/stenting procedure. That debris removal system may be similar to that described earlier, or any other suitable type. As shown in the embodiments of FIGS. 16 and 17, the debris removal sub-system used to remove any particles or debris produced during the revascularization/stenting procedure basically comprises aguide catheter 24 having at least one control port, like that described above, and another catheter 504 (to be described later) for delivery of an infusate or irrigation liquid from some pumping means, e.g., aninfusate pump 84, into the occluded vessel section, and some pumping means, e.g., anextraction pump 90, coupled to the interior of theguide catheter 24 to effect the removal of blood, the infusion liquid and any debris created during the restriction opening procedure from the patient. It should be noted that the “other catheter 504” for delivery of the infusate or irrigation liquid to the situs of the vessel portion being revascularized, may comprise anatherectomy catheter 22″ like that described with respect tosystem 200 when such a system is used to form the lumen into which the stent will be placed, or may comprise a separate catheter, tube, or conduit, or may comprise a lumen or passageway in theguide catheter 24 separate and apart from the central passageway through which the debris, blood and infusate liquid is removed. In the embodiment shown thecatheter 504 for carrying the infusion or irrigation liquid into the situs where the stent is to be placed basically comprises a simple irrigation tube or catheter formed of a flexible material, e.g., a plastic, and having a central passageway or lumen extending fully therethrough for carrying the infusate or irrigation liquid from a pump, likepump 84 or any other suitable source of irrigation liquid, down the lumen and out of its open end to the operative situs like shown in FIGS. 16 and 17. - If it is desired to utilize a
system 500 to apply thestent 502 into a lumen formed by an atherectomy catheter, e.g.,atherectomy catheter 22″, the procedure to be followed basically comprises the following steps. First theguide catheter 24 is placed in position so that its distal end is located proximally of the restriction to be opened and its control or regulation port(s) 24A/B is(are) in fluid communication with an upstream patent vessel, e.g., the aorta, like shown in FIGS. 10, 11, 16 and 17. Theguide wire 124′ is then extended through theguide catheter 24 and through the restriction to be opened so that the distally located balloon (obturator) 126 on the guide wire is downstream of the restriction. Theballoon 126 is then inflated to block the vessel to be revascularized downstream of its restriction. Theextraction pump 90 is then operated to evacuate any debris particles which may have been produced by the passage of theguide wire 124 andballoon 126 through the restriction and by the inflation of theballoon 126. Theatherectomy catheter 22″ is then passed over the guide wire through the guide catheter so that its workinghead 32″ extends out of the open end of the guide catheter and is at the situs of the restriction to be opened. - The
atherectomy catheter 22″ (or any other catheter having a restriction opening working head) is then operated in a manner like described above to enable the working head to open a lumen through the restriction, while the debris removal sub-system removes the debris created by that operation along with blood and the infusate liquid through the guide catheter. The control or regulation ports in the guide catheter ensure that the vessel being revascularized does not collapse during the procedure. - Once the lumen has been created through the restriction, the atherectomy catheter can be removed, while maintaining the vacuum, i.e., keeping the
extraction pump 90 operating. After removal of the atherectomy catheter theextraction pump 90 can be stopped. If it is desired to give the patient some recovery time before deployment of thestent 502, the distal balloon on the guide wire may be deflated, thereby enabling blood to flow through the newly formed lumen in the revascularized vessel to the downstream vessel, e.g., acoronary artery 15. Once sufficient time for the patient to recover has elapsed (assuming that any recovery time is desired) the distally locatedballoon 126 is then re-inflated. - The stent-delivery catheter (not shown) is then introduced through the guide catheter and over the guide wire until its working head, e.g., the balloon on which the
collapsed stent 502 is located, is within the lumen created by theatherectomy catheter 22″. The stent-delivery catheter is then operated, e.g., its balloon inflated, to expand thestent 502 radially outward and into seating engagement with the revascularized vessel section, like that shown in FIGS. 16 and 17. If desired, the debris removal system may be operated to withdraw any debris particles created by the deployment of the stent. Once the stent has been deployed the stent-delivery catheter can be removed, e.g., its balloon deflated and then the catheter withdrawn proximally along the guide wire. The guide catheter can then be removed. - In some applications it may be desirable to provide an irrigation or infusate liquid into the lumen in which the stent is to be deployed during or immediately after the stent deployment the procedure. To that end, an irrigation tube504 (like that shown in FIGS. 16 and 17) may be introduced over and along the
guide wire 124′ and through theguide catheter 24 so that its open distal end is in communication with the situs of the stent while the distally located balloon (obturator) 126′ remains inflated. An irrigant liquid can then be introduced via the irrigation tube to flush out any debris via the passageway between it and the guide catheter under the action of theextraction pump 90 or any other suitable pump or vacuum source. Once this has been accomplished theirrigation tube 504 can then be withdrawn over the guide wire, while the vacuum is maintained, e.g., thepump 90 operates, to remove any debris which may be produced by the removal of the irrigation tube. The vacuum (e.g., pump 90) can then be stopped, theballoon 126′ on the distal end of the guide-wire 124′ can then be deflated and the guide wire can then be withdrawn through theguide catheter 24. Then the guide catheter can be removed. - If it is desired to place a
stent 502 within an occluded blood vessel section, without having first opened a lumen through it with an atherectomy catheter, likecatheter 22″ or any other lumen-opening catheter, the procedure to be followed using thesystem 500 basically comprises the following steps. First theguide catheter 24 is placed in position so that its distal end is located proximally of the restriction to be opened and its control or regulation port(s) 24A/B is(are) in fluid communication with an upstream patent vessel, e.g., the aorta, like shown in FIGS. 10, 11, 16 and 17. Theguide wire 124′ is then extended through theguide catheter 24 and through the restriction to be opened so that the distally located balloon (obturator) 126′ on the guide wire is downstream of the restriction. Theballoon 126′ is then inflated to block the vessel to be revascularized downstream of its restriction. The stent-delivery catheter (not shown) is then introduced through theguide catheter 24 and over the guide-wire 124′ until its working head, e.g., the balloon on which thecollapsed stent 502 is located is at the desired position within the vessel to be revascularized. The debris removal sub-system, or any other extraction or vacuum system, is then operated to withdraw any debris or particles created when the stent is deployed. Thus, once the debris removal sub-system is operating the stent-delivery catheter can then be operated, e.g., its balloon inflated, to expand thestent 502 radially outward thereby enlarging the lumen through the restriction seating the stent in place against accidental dislodgement within the blood vessel section, like that shown in FIGS. 16 and 17. Once the stent has been deployed the stent-delivery catheter can be removed, e.g., its balloon deflated, and then the catheter withdrawn, e.g., slid proximally along the guide-wire 124‘until it is out of the being’s body. An irrigation or infusate liquid is then provided into the operative situs, i.e., the situs of the stent, to flush away any debris created during the stent deployment procedure. To that end, anirrigation tube 504 is introduced along theguide wire 124′ and through theguide catheter 24 so that its open distal end is in communication with the situs of the stent, while the distally located balloon (obturator) 126 remains inflated. An irrigant liquid can then be introduced via theirrigation tube 504 to flush out any debris via the passageway between it and theguide catheter 24 under the action of theextraction pump 90 or any other suitable pump or vacuum source. - Once the stent is deployed and all debris removed, the irrigation tube can then be withdrawn from the being by sliding it out over the guide-
wire 124′, while the vacuum is maintained, e.g., thepump 90 operates, to remove any debris which may be produced by the removal of the irrigation tube. As described earlier, the control or regulation port(s) 24A/B ensure that the vessel section being revascularized does not collapse during the revascularization procedure. - After removal of all remaining debris, the vacuum (e.g., pump90) can then be stopped, the
balloon 126 on the distal end of the guide-wire can then be deflated and the guide wire can then be withdrawn through the guide catheter. Then the guide catheter can be removed. - Irrespective of the type of revascularization procedure utilized, it may be desirable before removal of the
guide catheter 24 to inject a dye through it to the operative situs to enable one to fluoroscope or otherwise visualize the bypass vessel to ensure that it has been be properly revascularized. - In yet another embodiment the system of the current invention allows for a working head to eject infusate liquid (e.g., through liquid jets), where said infusate may comprise a therapy (e.g., drugs, biologically active agents, microspheres, etc.). The working head may be arranged to be spaced a certain distance from the lumen's interior surface, such that said infusate may penetrate into the lumen tissue.
- To this end, further embodiments of the device shown in FIG. 17 are illustrated in FIGS.18 to 24. The objective with these devices includes the delivery drugs or biologically active agents (together “therapy”) to the lumen wall, either statically or dynamically. Such therapy may be used to restore or to help maintain the flow of blood, or other bodily fluid, through the vessel. One such treatment would include the delivery of anti-spasm agents, which would prevent closure of the vessel resulting from vascular spasm for a period of time after the vascular intervention. Another such treatment would include the delivery of anti-restenosis, or other therapies, that prevent or minimize the future formation of occlusive material. Such therapy can be designed to not only reduce or eliminate restenosis of the vessel locally within a stent, but to eliminate restenosis adjacent (e.g., proximally and distally) to the stent and/or to prevent further stenosis anywhere along the vessel walls. Such aforementioned therapies might include, but are not limited to, those therapies listed in Table 1. In all the devices shown in FIGS. 17 through 24, it is to be understood that the system permits the delivery of therapy at very high doses that could likely not be tolerated systemically.
TABLE 1 Examples of Biological, Pharmaceutical, and other Therapies Deliverable via the Present Invention Adenovirus with or without genetic material Angiogenic agents Angiotensin Converting Enzyme Inhibitors (ACE inhibitors) Angiotensin II antagonists Anti-angiogenic agents Antiarrhythmics Anti-bacterial agents Antibiotics Erythromycin Penicillin Anti-coagulants Heparin Anti-growth factors Anti-inflammatory agents Dexamethasone Aspirin Hydrocortisone Antioxidants Anti-platelet agents Forskolin Anti-proliferation agents Anti-rejection agents Rapamycin Anti-restenosis agents Antisense Antispasm agents Lidocaine Nitroglycerin Anti-thrombogenic agents Argatroban Hirudin GP IIb/IIIa inhibitors Anti-virus drugs Arteriogenesis agents acidic fibroblast growth factor (aFGF) angiogenin angiotropin basic fibroblast growth factor (bFGF) Bone morphogenic proteins (BMP) epidermal growth factor (EGF) fibrin granulocyte-macrophage colony stimulating factor (GM-CSF) hepatocyte growth factor (HGF) HIF-1 insulin growth factor-1 (IGF-1) interleukin-8 (IL-8) MAC-1 nicotinamide platelet-derived endothelial cell growth factor (PD-ECGF) platelet-derived growth factor (PDGF) transforming growth factors alpha & beta (TGF-.alpha., TGF-beta.) tumor necrosis factor alpha (TNF-.alpha.) vascular endothelial growth factor (VEGF) vascular permeability factor (VPF) Bacteria Beta blocker Blood clotting factor Bone morphogenic proteins (BMP) Calcium channel blockers Carcinogens Cells Chemotherapeutic agents (e.g., Ceramide, Taxol, Cisplatin) Cholesterol reducers Chondroitin Collagen Inhibitors Colony stimulating factors Coumadin Cytokines prostaglandins Dentin Etretinate Genetic material Glucosamine Glycosaminoglycans GP IIb/IIIa inhibitors L-703,081 Granulocyte-macrophage colony stimulating factor (GM-CSF) Growth factor antagonists or inhibitors Growth factors Bone morphogenic proteins (BMPs) Endothelial Cell Growth Factor (ECGF) Epidermal growth factor (EGF) Fibroblast Growth Factors (FGF) Hepatocyte growth factor (HGF) Insulin-like Growth Factors (e.g., IGF-I) Nerve growth factor (NGF) Platelet Derived Growth Factor (PDGF) Recombinant NGF (rhNGF) Tissue necrosis factor (TNF) Transforming growth factors alpha (TGF-alpha) Transforming growth factors beta (TGF-beta) Vascular Endothelial Growth Factor (VEGF) Vascular permeability factor (UPF) Acidic fibroblast growth factor (aFGF) Basic fibroblast growth factor (bFGF) Epidermal growth factor (EGF) Hepatocyte growth factor (HGF) Insulin growth factor-1 (IGF-1) Platelet-derived endothelial cell growth factor (PD-ECGF) Tumor necrosis factor alpha (TNF-.alpha.) Growth hormones Heparin sulfate proteoglycan HMC-CoA reductase inhibitors (statins) Hormones Erythropoietin Immoxidal Immunosuppressant agents inflammatory mediator Insulin Interleukins Interlukin-8 (IL-8) Interlukins Lipid lowering agents Lipo-proteins Low-molecular weight heparin Lymphocites Lysine MAC-1 Morphogens Nitric oxide (NO) Nucleotides Peptides Polyphenol PR39 Proteins Prostaglandins Proteoglycans Perlecan Radioactive materials Iodine - 125 Iodine - 131 Iridium - 192 Palladium 103 Radio-pharmaceuticals Secondary Messengers Ceramide Somatomedins Statins Stem Cells Steroids Thrombin Thrombin inhibitor Thrombolytics Ticlid Tyrosine kinase Inhibitors ST638 AG-17 Vasodilator Histamine Forskolin Nitroglycerin Vitamins E C Yeast - The inclusion of groups and subgroups in Table 2 is for convenience only. The grouping does not indicate the preferred use or limited use of any drug therein. That is, the groupings are for reference only and not meant to be limiting in any way (e.g., it is recognized that the Taxol formulations are used for chemotherapeutic applications as well as for anti-restenotic coatings).
- In yet another embodiment, the working head may be arranged to eject infusate in opposing or impeding directions to cause turbulent flow, which may facilitate diffusion or penetration into tissue.
- It should be noted that the effects of drugs and contrast are highlighted herein, but water is also realized to have a material removing, or flushing, effect (e.g., devices such as the Hydrolyzer, manufactured by Cordis Corporation).
- In yet another embodiment, pump means operates to independently introduce infusate and after some dwell time withdraw the infusate. This dwell time will allow infusate and/or therapy more time to diffuse or penetrate into tissue.
- FIG. 18 is similar to FIG. 17 but the components are used differently. In one mode the therapy is delivered (infused) via
catheter 504 to remain as a bolus in the lumen for a significant period of time (i.e., dwell time) with the balloon inflated but with the extraction system turned off. During this time the drug permeates the lumen wall, and, at the end of the predetermined period, the debris extraction means may be operated normally, i.e., extraction is turned on and an infusate is delivered through thecatheter 504 to flush the therapy from the vessel. The initial pressure of the bolus can also be adjusted to help deliver the therapy to the target tissue. For example, a high-pressure bolus could locally stretch the lumen and thereby increase the local permeability of the tissue. In an alternative embodiment, the fluid containing the therapy flows continuously fromcatheter 504 and is continuously extracted through theguide catheter 24. This alternative mode has the advantage that the fluid containing the therapy is in motion, which could aid in increasing the rate at which the therapy permeates the vessel wall. It is also contemplated that the temperature of the fluid could be adjusted (e.g., increased) to enhance the delivery of the therapy. Thecatheter 504 is shown as a tube running over a guide wire in FIGS. 17 and 18, but, in another embodiment, the catheter could also be of the rapid exchange type. FIG. 19 shows one kind of rapid exchange catheter at 601, this embodiment includes a helical cut in the end of the tube, which permits the attachment of thecatheter 504 onto a wire without access to the wire ends (this concept is fully described in co-pending application Ser. No. 523,077, which is assigned to the assignee of the present invention, which is incorporated herein by reference). A more common rapid exchange concept (not shown) is utilizing a short lumen at the end of the catheter that has a distal port at the distal end of the catheter and a proximal port close to the distal end of the catheter. Such rapid exchange concepts reduce the required length of guide wires but still require access to one end of the guide wire to permit attachment of the catheter to the guide wire. Therefore, the delivery of therapy is not limited to the tube-over-wire approach shown in FIG. 18. - In yet another embodiment of the present invention, the distal protection component (e.g., balloon, filter, etc.) may be collapsed or avoided entirely. This would allow the concentrated treatment to contact the targeted tissues and then naturally dispense and become more diffuse, for easy systemic toleration.
- In yet another embodiment the working head is arranged to contact the interior wall of the lumen, during operation (e.g., ejection of liquid) such that infusate and/or therapy are forced into the interior wall and/or the surrounding tissue. In one such embodiment, the distal protection device (e.g., balloon, filter, expandable member, etc.) comprises an offset (i.e., the centerline of the distal protection device is offset from the centerline of the working head), wherein the offset causes the working head to contact the interior wall of the lumen.
- The therapy delivery concepts discussed thus far might be classified as static or low velocity delivery systems. FIGS. 20, 21, and22 however show delivery devices, which should be classified as high velocity delivery devices. Several high-pressure therapy delivery devices for delivery of therapy to the myocardium, vessels, and tissue surrounding a lumen are disclosed in a co-pending patent application Ser No. 09/368,410, which is assigned to the same entity as the present application, and which is incorporated herein by reference. The devices of FIGS. 20,20, and 21 utilize the
guide catheter 24 anddistal balloon 126′ illustrated in FIG. 16, but additionally provide a medication distribution head 601 (i.e., working head) mounted on the distal portion ofcatheter 602. The medication distribution type of working head 601 (see FIG. 20) passes through theguide catheter 24 along the balloon guide wire and can be positioned anywhere between theballoon 126′and the distal end of theguide catheter 24. A high-pressure source 603 (not shown) drives the therapy through thecatheter 602 to thedistribution head 601 where the therapy is emitted at sufficiently high velocity to traverse the liquid filled gap between the head and the vessel wall, and impact and penetrate the vessel wall and may go into surrounding tissue (all being referred to as “target tissue”). In one preferred embodiment, the distribution head is of the order 1 mm in diameter and the multiple distribution jets are each expected to be in the range 0.002 to 0.015 inch diameter. Drive pressures are expected to be approximately 100 psi to 3000 psi. Other embodiments are envisioned, where the size and number of jets will dictate the pressures required. - In one embodiment,
catheter 602 is fed over the guide wire, throughguide catheter 24 to a point close to the un-inflateddistal balloon 126′. The balloon is then inflated, the therapy delivered through thehead 601 and the aspiration activated. Thecatheter 602 is traversed along the vessel to distribute the therapy. Additional components might be necessary to better centralize the distribution head 601 (i.e., working head locating members) (See FIGS. 21 and 22) in the vessel once the head is some distance away from theballoon 126. - In one embodiment, the centralizing device is a
multi filament basket 606 of the type often used in urology. The basket is formed from several pre-bent wires 605 (e.g., nitinol), or ribbons, which form a football shaped basket in their relaxed condition as a result of a shape memory property. Athin control tube 604 is used to capture and compress thewires 605 to reduce the effective diameter of the basket, although thin pull ribbons (not shown) are also used to control basket shapes in other applications. In use, the combinedmedication distribution head 601,catheter 602, and basket andcontrol tube 604 concentric with thecatheter 602, are moved through theguide catheter 24 on guide wire 124 (together, the “assembly head”) to a position close to theun-inflated balloon 126′. Theballoon 126′ is inflated, axial movement of thecontrol tube 604 adjusts the basket, the high-pressure source 603 is activated and the aspiration commenced. The entire assembly head is traversed along the vessel to distribute the therapy. The traversing of the assembly head along the vessel length (or at least well beyond the ends of the stent, if any) could be automated, such as by a linear actuated drive motor, to provide a uniform, or alternatively variable, distribution of the therapy to the targeted tissue. The only difference between FIGS. 21 and 22 is that themedication delivery head 601 is shown distal of the basket in FIG. 21 and within the basket in FIG. 22. The in-basket construction may give better centralization and closer action to theguide catheter 24 on reverse travel of thehead 601. - Previous embodiments herein have shown use of the devices in single un-branched vessels, however, applications of the embodiments may be used in a branched vessel (See FIG. 23), in this example the internal and external carotid arteries, but other hollow organs and lumens could benefit from these embodiments as well. A working head, in this example a
medication distribution head 601, is shown on theballoon guide wire 124 in the internal carotid, and a secondballoon guide wire 124 is shown in the external carotid. This arrangement allows the isolation of the two branches and the use of a strong dose of therapy to be introduced via amedication distribution head 601 to one of the branches at a time. The dose can be allowed to act as a bolus, which rests for a given time before aspiration or as a continuous delivery with aspiration via a guide or other catheter (referred to as “through-flow”). The through-flow rate may be different than either of the infusate or aspiration rates used in the differential flow sequence. The location of the aspiration catheter with respect to the location of the working head (e.g., separation distance) could be adjusted to determine the effective treatment area in the vessel. - Additionally, the normal differential flow system or through-flow system may be used with an infusate (with or without additional material) and the through-flow stage may employ a different infusate or added material.
- In these various embodiments, the therapy delivery devices can be used in vessels prior to, or post, angioplasty, stent delivery or use of other working heads. FIG. 24 shows the use of the medication distribution head in a situation identical to that shown in FIG. 21 with the addition of a
stent 610. Clearly any of the devices and embodiments disclosed can operate through a stent or other intraluminal prosthesis. They can also be used prior to or post the application of any other working heads such as atherectomy devices, angioplasty balloons, radiation catheters, intravascular ultrasound, infra-red intravascular imaging, or any other diagnostic or imaging head. In short, the disclosed drug delivery concepts can be used with any other kind of intravascular therapy where a therapy needs to be delivered onto, into, or through the wall of the vessel. - Therapy delivery devices (e.g., working heads) are used to deliver therapy to the artery or lumen, or to the interior surface of same. This delivery, which may be through liquid jets or irrigation-type catheters, may be normal to said interior surface or may be tangential; all of which directions are said to result in therapy ultimately directed toward the vessel's or lumen's interior surface.
- Additionally, it is self evident that the embodiments disclosed can function in vessels or lumens that are not occluded at all but would benefit from the features of drug delivery in conjunction with (or without) the disclosed barriers and pumping systems. Thus, these embodiments can be used to treat target tissue, where the target tissue comprises vessels or lumens that contain at least partial occlusions or where the vessel or lumen has surrounding tissue (i.e., tissue in the vicinity of the vessel or lumen, but not necessarily encompassing the vessel or lumen), which is diseased in some fashion. Notwithstanding the above, it is also recognized that this form of drug delivery may be useful as a prophylactic measure, which may be used alone or in conjunction with other treatments and/or devices, to treat vessels, lumens or other targeted tissues
- Without further elaboration the foregoing will so fully illustrate our invention that others may, by applying current or future knowledge, adopt the same for use under various conditions of service.
Claims (20)
1. An intravascular system for opening a lumen in an occluded blood vessel portion of a living being's vascular system, the occluded blood vessel portion being occluded by an occlusive material, said system comprising a stent, an instrument for deploying said stent and a debris extraction system, said debris extraction system being arranged for introducing an infusate liquid comprising at least one material, said instrument being arranged to be extended into the living being's vascular system to deploy said stent to the interior of the occluded blood vessel portion to open a lumen therein for the flow of blood therethrough, whereupon some debris may be produced, said debris extraction system being arranged for removing debris.
2. The system of claim 1 , wherein said at least one material comprises at least one of saline, contrast, a drug, pharmaceutical, a biologically active material, or microspheres carrying chemicals.
3. The system of claim 2 , wherein said biologically active material comprises a growth factor.
4. The intravascular system of claim 1 , wherein said system additionally comprises a working head.
5. The intravascular system of claim 4 , wherein said working head is arranged to remove occlusive material from the occluded blood vessel portion.
6. The intravascular system of claim 5 , additionally comprising a debris blocking member for preventing the debris from flowing into downstream blood vessels.
7. The intravascular system of claim 6 , wherein said debris blocking member comprises a balloon.
8. The intravascular system of claim 4 , wherein said working head is rotatable.
9. The intravascular system of claim 4 , wherein debris may be produced during the operation of said working head, and wherein said debris extraction system is arranged for removing said debris.
10. The intravascular system of claim 1 , additionally comprising a catheter through which said instrument extends to form a passageway therebetween, the debris being withdrawn through said passageway for collection remote from the occluded blood vessel.
11. The intravascular system of claim 10 , additionally comprising a debris blocking member for preventing the debris from flowing into downstream blood vessels.
12. The intravascular system of claim 11 , wherein said debris blocking member comprises a balloon.
13. An intravascular system for opening a lumen in an occluded blood vessel portion of a living being's vascular system and for handling debris that may be produced thereby, the occluded blood vessel portion being occluded by an occlusive material, said system comprising a stent, an instrument for deploying said stent, a debris extraction system, and a debris blocking member, said instrument being arranged to be extended into the living being's vascular system to deploy said stent to the interior of the occluded blood vessel portion to open a lumen therein for the flow of blood therethrough, said debris extraction system being arranged for introducing an infusate liquid comprising at least one material, and said debris extraction system being further arranged for removing the debris, said debris blocking member being arranged for preventing the debris from flowing into a downstream blood vessel during deployment of said stent.
14. The system of claim 13 wherein said at least one material comprises at least one of saline, contrast, a drug, pharmaceutical, a biologically active material, or microspheres carrying chemicals.
15. The system of claim 14 wherein said biologically active material comprises a growth factor.
16. The intravascular system of claim 13 wherein said debris blocking member comprises a balloon.
17. The intravascular system of claim 13 wherein said system additionally comprises a working head.
18. The intravascular system of claim 17 wherein said working head is rotatable.
19. The intravascular system of claim 17 wherein debris may be produced during the operation of said working head, and wherein said debris extraction system is arranged for removing the debris produced by the operation of said working head.
20. An intravascular system for opening a lumen in an occluded blood vessel portion of a living being's vascular system, the occluded blood vessel portion being occluded by an occlusive material, said system comprising a stent, an instrument for deploying said stent and a debris extraction system, said debris extraction system being arranged for introducing an infusate liquid comprising at least one material, said instrument being arranged to be extended into the lumen to deploy said stent to the occlusive material in the interior of the occluded blood vessel portion to open a lumen therein for the flow of blood therethrough, whereupon some debris may be produced, said debris extraction system being arranged for removing debris produced during the deployment of said stent.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/847,932 US20040210239A1 (en) | 1996-07-26 | 2004-05-18 | System and method of use for treating occluded vessels and diseased tissue |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/690,438 US5779721A (en) | 1996-07-26 | 1996-07-26 | System and method of use for revascularizing stenotic bypass grafts and other blood vessels |
US08/900,598 US5879361A (en) | 1996-07-26 | 1997-07-25 | System and method of use for revascularizing stenotic bypass grafts and other blood vessels |
US09/233,712 US6080170A (en) | 1996-07-26 | 1999-01-19 | System and method of use for revascularizing stenotic bypass grafts and other occluded blood vessels |
US09/594,131 US6524323B1 (en) | 1996-07-26 | 2000-06-14 | System and method of use for revascularizing stenotic bypass grafts and other occluded blood vessels |
US10/058,556 US6830577B2 (en) | 1996-07-26 | 2002-01-28 | System and method of use for treating occluded vessels and diseased tissue |
US10/847,932 US20040210239A1 (en) | 1996-07-26 | 2004-05-18 | System and method of use for treating occluded vessels and diseased tissue |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/058,556 Continuation US6830577B2 (en) | 1996-07-26 | 2002-01-28 | System and method of use for treating occluded vessels and diseased tissue |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040210239A1 true US20040210239A1 (en) | 2004-10-21 |
Family
ID=46278749
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/058,556 Expired - Lifetime US6830577B2 (en) | 1996-07-26 | 2002-01-28 | System and method of use for treating occluded vessels and diseased tissue |
US10/847,932 Abandoned US20040210239A1 (en) | 1996-07-26 | 2004-05-18 | System and method of use for treating occluded vessels and diseased tissue |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/058,556 Expired - Lifetime US6830577B2 (en) | 1996-07-26 | 2002-01-28 | System and method of use for treating occluded vessels and diseased tissue |
Country Status (1)
Country | Link |
---|---|
US (2) | US6830577B2 (en) |
Cited By (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070016244A1 (en) * | 2005-07-06 | 2007-01-18 | Percutaneous Systems, Inc. | Methods and apparatus for deploying ureteral stents |
US20070060907A1 (en) * | 2004-02-26 | 2007-03-15 | Shapland James E | Regional cardiac tissue treatment |
US20070073268A1 (en) * | 2002-08-12 | 2007-03-29 | Goble E M | Integrated Infusion and Aspiration System and Method |
GB2444171A (en) * | 2006-11-23 | 2008-05-28 | Leonid Shturman | Fluid supply coupling for a rotational atherectomy device |
US20080177277A1 (en) * | 2004-07-07 | 2008-07-24 | Percutaneous Systems, Inc. | Methods for removing kidney stones from the ureter |
US20090287238A1 (en) * | 2004-07-07 | 2009-11-19 | Percutaneous Systems, Inc. | Methods and apparatus for deploying short length ureteral stents |
US20100041984A1 (en) * | 2008-08-12 | 2010-02-18 | James Edward Shapland | Impedance sensing device and catheter system |
US20100042069A1 (en) * | 2008-08-12 | 2010-02-18 | James Edward Shapland | Remote sensing catheter system and methods |
US20100082004A1 (en) * | 2006-11-07 | 2010-04-01 | Osprey Medical Inc. | Collection catheter and kit |
US20110015558A1 (en) * | 2004-02-26 | 2011-01-20 | Osprey Medical Inc. | Isolating cardiac circulation |
US20110144576A1 (en) * | 2009-12-14 | 2011-06-16 | Voyage Medical, Inc. | Catheter orientation control system mechanisms |
US7963947B2 (en) | 2008-01-16 | 2011-06-21 | Pressure Products Medical Supplies, Inc. | Apparatus, system, and method of shielding the sharp tip of a transseptal guidewire |
US20110172558A1 (en) * | 2009-12-09 | 2011-07-14 | Osprey Medical, Inc. | Catheter with distal and proximal ports |
US8050746B2 (en) | 2005-02-02 | 2011-11-01 | Voyage Medical, Inc. | Tissue visualization device and method variations |
US8078266B2 (en) | 2005-10-25 | 2011-12-13 | Voyage Medical, Inc. | Flow reduction hood systems |
US8131350B2 (en) | 2006-12-21 | 2012-03-06 | Voyage Medical, Inc. | Stabilization of visualization catheters |
US8137333B2 (en) | 2005-10-25 | 2012-03-20 | Voyage Medical, Inc. | Delivery of biological compounds to ischemic and/or infarcted tissue |
US8221310B2 (en) | 2005-10-25 | 2012-07-17 | Voyage Medical, Inc. | Tissue visualization device and method variations |
US8235985B2 (en) | 2007-08-31 | 2012-08-07 | Voyage Medical, Inc. | Visualization and ablation system variations |
US20120277847A1 (en) * | 2008-07-01 | 2012-11-01 | Endologix, Inc. | Catheter system and methods of using same |
US8333012B2 (en) | 2008-10-10 | 2012-12-18 | Voyage Medical, Inc. | Method of forming electrode placement and connection systems |
US8500697B2 (en) | 2007-10-19 | 2013-08-06 | Pressure Products Medical Supplies, Inc. | Transseptal guidewire |
US20130310823A1 (en) * | 2012-04-24 | 2013-11-21 | Mark Gelfand | Endovascular Catheters and Methods for Carotid Body Ablation |
US8657805B2 (en) | 2007-05-08 | 2014-02-25 | Intuitive Surgical Operations, Inc. | Complex shape steerable tissue visualization and manipulation catheter |
US8694071B2 (en) | 2010-02-12 | 2014-04-08 | Intuitive Surgical Operations, Inc. | Image stabilization techniques and methods |
US8709008B2 (en) | 2007-05-11 | 2014-04-29 | Intuitive Surgical Operations, Inc. | Visual electrode ablation systems |
US8758229B2 (en) | 2006-12-21 | 2014-06-24 | Intuitive Surgical Operations, Inc. | Axial visualization systems |
US8858609B2 (en) * | 2008-02-07 | 2014-10-14 | Intuitive Surgical Operations, Inc. | Stent delivery under direct visualization |
US8894643B2 (en) | 2008-10-10 | 2014-11-25 | Intuitive Surgical Operations, Inc. | Integral electrode placement and connection systems |
US8934962B2 (en) | 2005-02-02 | 2015-01-13 | Intuitive Surgical Operations, Inc. | Electrophysiology mapping and visualization system |
US9055906B2 (en) | 2006-06-14 | 2015-06-16 | Intuitive Surgical Operations, Inc. | In-vivo visualization systems |
US9089700B2 (en) | 2008-08-11 | 2015-07-28 | Cibiem, Inc. | Systems and methods for treating dyspnea, including via electrical afferent signal blocking |
US9101735B2 (en) | 2008-07-07 | 2015-08-11 | Intuitive Surgical Operations, Inc. | Catheter control systems |
US9155452B2 (en) | 2007-04-27 | 2015-10-13 | Intuitive Surgical Operations, Inc. | Complex shape steerable tissue visualization and manipulation catheter |
US9211372B2 (en) | 2011-08-11 | 2015-12-15 | Osprey Medical, Inc. | Systems and methods for limb treatment |
US9283033B2 (en) | 2012-06-30 | 2016-03-15 | Cibiem, Inc. | Carotid body ablation via directed energy |
US9398930B2 (en) | 2012-06-01 | 2016-07-26 | Cibiem, Inc. | Percutaneous methods and devices for carotid body ablation |
US9402677B2 (en) | 2012-06-01 | 2016-08-02 | Cibiem, Inc. | Methods and devices for cryogenic carotid body ablation |
US9468364B2 (en) | 2008-11-14 | 2016-10-18 | Intuitive Surgical Operations, Inc. | Intravascular catheter with hood and image processing systems |
US9510732B2 (en) | 2005-10-25 | 2016-12-06 | Intuitive Surgical Operations, Inc. | Methods and apparatus for efficient purging |
US9814522B2 (en) | 2010-04-06 | 2017-11-14 | Intuitive Surgical Operations, Inc. | Apparatus and methods for ablation efficacy |
US9955946B2 (en) | 2014-03-12 | 2018-05-01 | Cibiem, Inc. | Carotid body ablation with a transvenous ultrasound imaging and ablation catheter |
US10004388B2 (en) | 2006-09-01 | 2018-06-26 | Intuitive Surgical Operations, Inc. | Coronary sinus cannulation |
US10064540B2 (en) | 2005-02-02 | 2018-09-04 | Intuitive Surgical Operations, Inc. | Visualization apparatus for transseptal access |
US10070772B2 (en) | 2006-09-01 | 2018-09-11 | Intuitive Surgical Operations, Inc. | Precision control systems for tissue visualization and manipulation assemblies |
US10335131B2 (en) | 2006-10-23 | 2019-07-02 | Intuitive Surgical Operations, Inc. | Methods for preventing tissue migration |
US10441136B2 (en) | 2006-12-18 | 2019-10-15 | Intuitive Surgical Operations, Inc. | Systems and methods for unobstructed visualization and ablation |
US11406250B2 (en) | 2005-02-02 | 2022-08-09 | Intuitive Surgical Operations, Inc. | Methods and apparatus for treatment of atrial fibrillation |
US11478152B2 (en) | 2005-02-02 | 2022-10-25 | Intuitive Surgical Operations, Inc. | Electrophysiology mapping and visualization system |
Families Citing this family (160)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6582392B1 (en) | 1998-05-01 | 2003-06-24 | Ekos Corporation | Ultrasound assembly for use with a catheter |
US6723063B1 (en) | 1998-06-29 | 2004-04-20 | Ekos Corporation | Sheath for use with an ultrasound element |
US7713279B2 (en) | 2000-12-20 | 2010-05-11 | Fox Hollow Technologies, Inc. | Method and devices for cutting tissue |
US8328829B2 (en) | 1999-08-19 | 2012-12-11 | Covidien Lp | High capacity debulking catheter with razor edge cutting window |
US7708749B2 (en) | 2000-12-20 | 2010-05-04 | Fox Hollow Technologies, Inc. | Debulking catheters and methods |
US6299622B1 (en) | 1999-08-19 | 2001-10-09 | Fox Hollow Technologies, Inc. | Atherectomy catheter with aligned imager |
ATE499054T1 (en) | 2000-12-20 | 2011-03-15 | Fox Hollow Technologies Inc | REDUCTION CATHETER |
US7604612B2 (en) | 2001-05-01 | 2009-10-20 | St. Jude Medical, Cardiology Division, Inc. | Emboli protection devices and related methods of use |
US7422579B2 (en) | 2001-05-01 | 2008-09-09 | St. Jude Medical Cardiology Divison, Inc. | Emboli protection devices and related methods of use |
EP1453425B1 (en) | 2001-12-03 | 2006-03-08 | Ekos Corporation | Catheter with multiple ultrasound radiating members |
US8226629B1 (en) | 2002-04-01 | 2012-07-24 | Ekos Corporation | Ultrasonic catheter power control |
US7241257B1 (en) * | 2002-06-28 | 2007-07-10 | Abbott Cardiovascular Systems, Inc. | Devices and methods to perform minimally invasive surgeries |
US8246640B2 (en) | 2003-04-22 | 2012-08-21 | Tyco Healthcare Group Lp | Methods and devices for cutting tissue at a vascular location |
JP2007525263A (en) | 2004-01-29 | 2007-09-06 | イコス コーポレイション | Method and apparatus for detecting blood vessel state by catheter |
US20080262467A1 (en) * | 2005-02-16 | 2008-10-23 | Humphrey Joseph A C | Blood Flow Bypass Catheters and Methods for the Delivery of Medium to the Vasculature and Body Ducts |
US7252834B2 (en) * | 2005-04-25 | 2007-08-07 | Clemson University Research Foundation (Curf) | Elastin stabilization of connective tissue |
US8343040B2 (en) | 2005-05-04 | 2013-01-01 | Olympus Endo Technology America Inc. | Rotate-to-advance catheterization system |
US8414477B2 (en) | 2005-05-04 | 2013-04-09 | Olympus Endo Technology America Inc. | Rotate-to-advance catheterization system |
US8235942B2 (en) | 2005-05-04 | 2012-08-07 | Olympus Endo Technology America Inc. | Rotate-to-advance catheterization system |
US7780650B2 (en) * | 2005-05-04 | 2010-08-24 | Spirus Medical, Inc. | Rotate-to-advance catheterization system |
US7731654B2 (en) | 2005-05-13 | 2010-06-08 | Merit Medical Systems, Inc. | Delivery device with viewing window and associated method |
US20060282133A1 (en) * | 2005-06-10 | 2006-12-14 | Cao Group, Inc. | Method of Marking Biological Tissues for Enhanced Destruction by Applied Radiant Energy |
US8221348B2 (en) | 2005-07-07 | 2012-07-17 | St. Jude Medical, Cardiology Division, Inc. | Embolic protection device and methods of use |
US20070060878A1 (en) | 2005-09-01 | 2007-03-15 | Possis Medical, Inc. | Occlusive guidewire system having an ergonomic handheld control mechanism and torqueable kink-resistant guidewire |
US8025655B2 (en) | 2005-09-12 | 2011-09-27 | Bridgepoint Medical, Inc. | Endovascular devices and methods |
US7918870B2 (en) | 2005-09-12 | 2011-04-05 | Bridgepoint Medical, Inc. | Endovascular devices and methods |
US8083727B2 (en) | 2005-09-12 | 2011-12-27 | Bridgepoint Medical, Inc. | Endovascular devices and methods for exploiting intramural space |
EP3650074B1 (en) | 2005-09-12 | 2023-10-25 | Boston Scientific Scimed, Inc. | Endovascular devices |
US11020141B2 (en) | 2005-09-12 | 2021-06-01 | Bridgepoint Medical, Inc. | Endovascular devices and methods |
US8608703B2 (en) | 2007-06-12 | 2013-12-17 | Medrad, Inc. | Infusion flow guidewire system |
US8435229B2 (en) | 2006-02-28 | 2013-05-07 | Olympus Endo Technology America Inc. | Rotate-to-advance catheterization system |
US8574220B2 (en) | 2006-02-28 | 2013-11-05 | Olympus Endo Technology America Inc. | Rotate-to-advance catheterization system |
WO2007127176A2 (en) | 2006-04-24 | 2007-11-08 | Ekos Corporation | Ultrasound therapy system |
US7951161B2 (en) * | 2006-05-09 | 2011-05-31 | Medrad, Inc. | Atherectomy system having a variably exposed cutter |
US20070276419A1 (en) | 2006-05-26 | 2007-11-29 | Fox Hollow Technologies, Inc. | Methods and devices for rotating an active element and an energy emitter on a catheter |
US20080004645A1 (en) | 2006-06-30 | 2008-01-03 | Atheromed, Inc. | Atherectomy devices and methods |
US8361094B2 (en) | 2006-06-30 | 2013-01-29 | Atheromed, Inc. | Atherectomy devices and methods |
US8007506B2 (en) | 2006-06-30 | 2011-08-30 | Atheromed, Inc. | Atherectomy devices and methods |
US9492192B2 (en) | 2006-06-30 | 2016-11-15 | Atheromed, Inc. | Atherectomy devices, systems, and methods |
US20080045986A1 (en) | 2006-06-30 | 2008-02-21 | Atheromed, Inc. | Atherectomy devices and methods |
US9314263B2 (en) | 2006-06-30 | 2016-04-19 | Atheromed, Inc. | Atherectomy devices, systems, and methods |
CN102327139A (en) | 2006-06-30 | 2012-01-25 | 阿瑟罗迈德公司 | Atherectomy device |
US20090018566A1 (en) | 2006-06-30 | 2009-01-15 | Artheromed, Inc. | Atherectomy devices, systems, and methods |
US8628549B2 (en) | 2006-06-30 | 2014-01-14 | Atheromed, Inc. | Atherectomy devices, systems, and methods |
US7674253B2 (en) * | 2006-08-18 | 2010-03-09 | Kensey Nash Corporation | Catheter for conducting a procedure within a lumen, duct or organ of a living being |
US11298511B2 (en) | 2006-11-21 | 2022-04-12 | Bridgepoint Medical, Inc. | Endovascular devices and methods for exploiting intramural space |
US9060802B2 (en) | 2006-11-21 | 2015-06-23 | Bridgepoint Medical, Inc. | Endovascular devices and methods for exploiting intramural space |
US10888354B2 (en) | 2006-11-21 | 2021-01-12 | Bridgepoint Medical, Inc. | Endovascular devices and methods for exploiting intramural space |
US10182833B2 (en) | 2007-01-08 | 2019-01-22 | Ekos Corporation | Power parameters for ultrasonic catheter |
US10188410B2 (en) | 2007-01-08 | 2019-01-29 | Ekos Corporation | Power parameters for ultrasonic catheter |
EP2120737B1 (en) | 2007-02-05 | 2020-04-01 | Boston Scientific Limited | Thrombectomy apparatus |
US8870755B2 (en) | 2007-05-18 | 2014-10-28 | Olympus Endo Technology America Inc. | Rotate-to-advance catheterization system |
WO2009002881A1 (en) | 2007-06-22 | 2008-12-31 | Ekos Corporation | Method and apparatus for treatment of intracranial hemorrhages |
US9034007B2 (en) | 2007-09-21 | 2015-05-19 | Insera Therapeutics, Inc. | Distal embolic protection devices with a variable thickness microguidewire and methods for their use |
US8632556B2 (en) | 2007-10-22 | 2014-01-21 | Bridgepoint Medical, Inc. | Methods and devices for crossing chronic total occlusions |
US8236016B2 (en) | 2007-10-22 | 2012-08-07 | Atheromed, Inc. | Atherectomy devices and methods |
US8070762B2 (en) | 2007-10-22 | 2011-12-06 | Atheromed Inc. | Atherectomy devices and methods |
US20090155337A1 (en) * | 2007-11-12 | 2009-06-18 | Endologix, Inc. | Method and agent for in-situ stabilization of vascular tissue |
US9717896B2 (en) | 2007-12-18 | 2017-08-01 | Gearbox, Llc | Treatment indications informed by a priori implant information |
US8636670B2 (en) | 2008-05-13 | 2014-01-28 | The Invention Science Fund I, Llc | Circulatory monitoring systems and methods |
US20090287120A1 (en) | 2007-12-18 | 2009-11-19 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Circulatory monitoring systems and methods |
WO2009100129A2 (en) | 2008-02-05 | 2009-08-13 | Chad John Kugler | Crossing occlusions in blood vessels |
US8337425B2 (en) | 2008-02-05 | 2012-12-25 | Bridgepoint Medical, Inc. | Endovascular device with a tissue piercing distal probe and associated methods |
US11992238B2 (en) | 2008-02-05 | 2024-05-28 | Boston Scientific Scimed, Inc. | Endovascular device with a tissue piercing distal probe and associated methods |
US8784440B2 (en) | 2008-02-25 | 2014-07-22 | Covidien Lp | Methods and devices for cutting tissue |
US8062316B2 (en) | 2008-04-23 | 2011-11-22 | Avinger, Inc. | Catheter system and method for boring through blocked vascular passages |
US8548571B2 (en) | 2009-12-08 | 2013-10-01 | Avinger, Inc. | Devices and methods for predicting and preventing restenosis |
US20100125253A1 (en) * | 2008-11-17 | 2010-05-20 | Avinger | Dual-tip Catheter System for Boring through Blocked Vascular Passages |
US9498600B2 (en) | 2009-07-01 | 2016-11-22 | Avinger, Inc. | Atherectomy catheter with laterally-displaceable tip |
US8696695B2 (en) | 2009-04-28 | 2014-04-15 | Avinger, Inc. | Guidewire positioning catheter |
US9125562B2 (en) | 2009-07-01 | 2015-09-08 | Avinger, Inc. | Catheter-based off-axis optical coherence tomography imaging system |
WO2009134346A2 (en) | 2008-04-28 | 2009-11-05 | David Bryan Robinson | Methods and apparatus for crossing occlusions in blood vessels |
WO2010045226A2 (en) | 2008-10-13 | 2010-04-22 | Fox Hollow Technologies, Inc. | Devices and methods for manipulating a catheter shaft |
WO2010064222A2 (en) | 2008-12-01 | 2010-06-10 | University College Cork, National University Of Ireland, Cork | Igf1 for myocardial repair |
RU2509537C2 (en) | 2009-04-29 | 2014-03-20 | ТАЙКО ХЕЛСКЕА ГРУП эЛПи | Methods and devices for tissue cutting and cleansing |
CN102458276B (en) | 2009-05-14 | 2014-05-21 | 泰科保健集团有限合伙公司 | Easily cleaned atherectomy catheters and methods of use |
JP6101078B2 (en) | 2009-05-28 | 2017-03-29 | アビンガー・インコーポレイテッドAvinger, Inc. | Optical coherence tomography for bioimaging |
US8137337B2 (en) * | 2009-06-24 | 2012-03-20 | Hakky Said I | Indwelling urinary catheter with self-retaining mechanism |
WO2011003031A1 (en) | 2009-07-03 | 2011-01-06 | Ekos Corporation | Power parameters for ultrasonic catheter |
EP2485687A1 (en) * | 2009-10-09 | 2012-08-15 | Vatrix Medical, Inc. | In vivo chemical stabilization of vulnerable plaque |
FR2952802A1 (en) * | 2009-11-20 | 2011-05-27 | Alain Lebet | Medical device for use in medical field to extract fragments of urinary tract segments in urethra track of patient, has irrigation equipment projecting irrigation liquid against expansible element to extract fragments |
BR112012013389A2 (en) | 2009-12-02 | 2018-03-06 | Tyco Healthcare | methods and devices for cutting a fabric |
EP2509519B1 (en) | 2009-12-11 | 2019-08-07 | Covidien LP | Material removal device having improved material capture efficiency |
WO2011091275A1 (en) * | 2010-01-23 | 2011-07-28 | Duke University | Jetless intravenous catheters and mechanical assist devices for hand-injection of contrast media during dynamic computer tomography and methods of using same |
US8740835B2 (en) | 2010-02-17 | 2014-06-03 | Ekos Corporation | Treatment of vascular occlusions using ultrasonic energy and microbubbles |
US8551130B2 (en) | 2010-02-18 | 2013-10-08 | Cardiovascular Systems, Inc. | Therapeutic agent delivery system, device and method for localized application of therapeutic substances to a biological conduit |
US9050414B2 (en) | 2010-02-19 | 2015-06-09 | Cardiovascular Systems, Inc. | Systems and methods for mixing therapeutic agents before and/or during administration |
US8663259B2 (en) | 2010-05-13 | 2014-03-04 | Rex Medical L.P. | Rotational thrombectomy wire |
US9023070B2 (en) | 2010-05-13 | 2015-05-05 | Rex Medical, L.P. | Rotational thrombectomy wire coupler |
US9795406B2 (en) | 2010-05-13 | 2017-10-24 | Rex Medical, L.P. | Rotational thrombectomy wire |
US8764779B2 (en) | 2010-05-13 | 2014-07-01 | Rex Medical, L.P. | Rotational thrombectomy wire |
EP2579791B1 (en) | 2010-06-14 | 2014-04-23 | Covidien LP | Material removal device |
US10548478B2 (en) | 2010-07-01 | 2020-02-04 | Avinger, Inc. | Balloon atherectomy catheters with imaging |
WO2012003430A2 (en) | 2010-07-01 | 2012-01-05 | Avinger, Inc. | Atherectomy catheters with longitudinally displaceable drive shafts |
US11382653B2 (en) | 2010-07-01 | 2022-07-12 | Avinger, Inc. | Atherectomy catheter |
WO2014039096A1 (en) | 2012-09-06 | 2014-03-13 | Avinger, Inc. | Re-entry stylet for catheter |
US9238119B2 (en) | 2010-08-12 | 2016-01-19 | Boston Scientific Limited | Infusion flow system and fluid coupling |
JP6291253B2 (en) | 2010-08-27 | 2018-03-14 | イーコス・コーポレイシヨン | Ultrasound catheter |
EP2632352B1 (en) | 2010-10-28 | 2017-04-12 | Covidien LP | Material removal device |
CN103281964B (en) | 2010-11-11 | 2015-09-30 | 科维蒂恩有限合伙公司 | The flexibility possessing imaging capability subtracts the method for go out conduit and manufacture conduit |
US8911468B2 (en) | 2011-01-31 | 2014-12-16 | Vatrix Medical, Inc. | Devices, therapeutic compositions and corresponding percutaneous treatment methods for aortic dissection |
US9949754B2 (en) | 2011-03-28 | 2018-04-24 | Avinger, Inc. | Occlusion-crossing devices |
JP6205344B2 (en) | 2011-03-28 | 2017-09-27 | アビンガー・インコーポレイテッドAvinger, Inc. | Occlusion crossing device, imaging device and atherectomy device |
US11458290B2 (en) | 2011-05-11 | 2022-10-04 | Ekos Corporation | Ultrasound system |
US9937255B2 (en) | 2011-05-18 | 2018-04-10 | Nectero Medical, Inc. | Coated balloons for blood vessel stabilization |
WO2013033426A2 (en) | 2011-09-01 | 2013-03-07 | Covidien Lp | Catheter with helical drive shaft and methods of manufacture |
EP2765930B1 (en) | 2011-10-13 | 2018-09-26 | Atheromed, Inc. | Atherectomy apparatus |
EP2768406B1 (en) | 2011-10-17 | 2019-12-04 | Avinger, Inc. | Atherectomy catheters and non-contact actuation mechanism for catheters |
US9345406B2 (en) | 2011-11-11 | 2016-05-24 | Avinger, Inc. | Occlusion-crossing devices, atherectomy devices, and imaging |
EP2849660B1 (en) | 2012-05-14 | 2021-08-25 | Avinger, Inc. | Atherectomy catheter drive assemblies |
EP2849661B1 (en) | 2012-05-14 | 2020-12-09 | Avinger, Inc. | Atherectomy catheters with imaging |
WO2013172972A1 (en) | 2012-05-14 | 2013-11-21 | Avinger, Inc. | Optical coherence tomography with graded index fiber for biological imaging |
CN102698327A (en) * | 2012-06-08 | 2012-10-03 | 李广成 | Hematoma remover |
US9050127B2 (en) * | 2012-06-27 | 2015-06-09 | Boston Scientific Limited | Consolidated atherectomy and thrombectomy catheter |
US9283241B2 (en) | 2012-07-10 | 2016-03-15 | Clemson University | Treatment to render implants resistant to diabetes |
US11284916B2 (en) | 2012-09-06 | 2022-03-29 | Avinger, Inc. | Atherectomy catheters and occlusion crossing devices |
US9498247B2 (en) | 2014-02-06 | 2016-11-22 | Avinger, Inc. | Atherectomy catheters and occlusion crossing devices |
US9532844B2 (en) | 2012-09-13 | 2017-01-03 | Covidien Lp | Cleaning device for medical instrument and method of use |
US9943329B2 (en) | 2012-11-08 | 2018-04-17 | Covidien Lp | Tissue-removing catheter with rotatable cutter |
EP2943232A1 (en) | 2013-01-10 | 2015-11-18 | The Cleveland Clinic Foundation | Deployable joint infection treatment system |
BR112015022067A2 (en) | 2013-03-14 | 2017-07-18 | Ekos Corp | method and apparatus for administering drug to a target site |
US8715314B1 (en) | 2013-03-15 | 2014-05-06 | Insera Therapeutics, Inc. | Vascular treatment measurement methods |
CA2901443A1 (en) | 2013-03-15 | 2014-09-25 | Insera Therapeutics, Inc. | Vascular treatment devices and methods |
US10932670B2 (en) | 2013-03-15 | 2021-03-02 | Avinger, Inc. | Optical pressure sensor assembly |
US8679150B1 (en) | 2013-03-15 | 2014-03-25 | Insera Therapeutics, Inc. | Shape-set textile structure based mechanical thrombectomy methods |
EP2967507B1 (en) | 2013-03-15 | 2018-09-05 | Avinger, Inc. | Tissue collection device for catheter |
US9854979B2 (en) | 2013-03-15 | 2018-01-02 | Avinger, Inc. | Chronic total occlusion crossing devices with imaging |
US8690907B1 (en) | 2013-03-15 | 2014-04-08 | Insera Therapeutics, Inc. | Vascular treatment methods |
JP6517198B2 (en) | 2013-07-08 | 2019-05-22 | アビンガー・インコーポレイテッドAvinger, Inc. | Identification of elastic layers guiding interventions |
EP3102127B1 (en) | 2014-02-06 | 2019-10-09 | Avinger, Inc. | Atherectomy catheter |
US10271869B2 (en) | 2014-03-01 | 2019-04-30 | Rex Medical, L.P. | Atherectomy device |
WO2015200702A1 (en) | 2014-06-27 | 2015-12-30 | Covidien Lp | Cleaning device for catheter and catheter including the same |
US10357277B2 (en) | 2014-07-08 | 2019-07-23 | Avinger, Inc. | High speed chronic total occlusion crossing devices |
US10092742B2 (en) | 2014-09-22 | 2018-10-09 | Ekos Corporation | Catheter system |
US10463389B2 (en) | 2014-12-27 | 2019-11-05 | Rex Medical, L.P. | Atherectomy device |
US10433868B2 (en) | 2014-12-27 | 2019-10-08 | Rex Medical, L.P. | Artherectomy device |
US10314667B2 (en) | 2015-03-25 | 2019-06-11 | Covidien Lp | Cleaning device for cleaning medical instrument |
CN107708581B (en) | 2015-06-10 | 2021-11-19 | Ekos公司 | Ultrasonic wave guide tube |
EP3322338A4 (en) | 2015-07-13 | 2019-03-13 | Avinger, Inc. | MICRO-MOLDED ANAMORPHOSING REFLECTIVE LENS FOR IMAGERY-GUIDED DIAGNOSTIC / THERAPEUTIC CATHETERS |
US10292721B2 (en) | 2015-07-20 | 2019-05-21 | Covidien Lp | Tissue-removing catheter including movable distal tip |
US10561440B2 (en) | 2015-09-03 | 2020-02-18 | Vesatek, Llc | Systems and methods for manipulating medical devices |
US11253292B2 (en) | 2015-09-13 | 2022-02-22 | Rex Medical, L.P. | Atherectomy device |
US10314664B2 (en) | 2015-10-07 | 2019-06-11 | Covidien Lp | Tissue-removing catheter and tissue-removing element with depth stop |
US10226263B2 (en) | 2015-12-23 | 2019-03-12 | Incuvate, Llc | Aspiration monitoring system and method |
CN108882857A (en) | 2016-01-25 | 2018-11-23 | 阿维格公司 | With the modified OCT image conduit of lag |
CN108697423A (en) | 2016-02-16 | 2018-10-23 | 伊瑟拉医疗公司 | The part flow arrangement of suction unit and anchoring |
US10307175B2 (en) | 2016-03-26 | 2019-06-04 | Rex Medical, L.P | Atherectomy device |
JP6959255B2 (en) | 2016-04-01 | 2021-11-02 | アビンガー・インコーポレイテッドAvinger, Inc. | Catheter device for porridge resection |
EP3463123A4 (en) | 2016-06-03 | 2020-01-08 | Avinger, Inc. | Catheter device with detachable distal end |
CN109414273B (en) | 2016-06-30 | 2023-02-17 | 阿维格公司 | Atherectomy catheter with shapeable distal tip |
US10751485B2 (en) | 2016-08-29 | 2020-08-25 | Cephea Valve Technologies, Inc. | Methods, systems, and devices for sealing and flushing a delivery system |
US11678905B2 (en) | 2018-07-19 | 2023-06-20 | Walk Vascular, Llc | Systems and methods for removal of blood and thrombotic material |
EP4461253A2 (en) | 2018-07-24 | 2024-11-13 | Penumbra, Inc. | Apparatus and methods for controlled clot aspiration |
CN109350178B (en) * | 2018-12-05 | 2024-10-01 | 上海蓝脉医疗科技有限公司 | Thrombolysis device |
DE102019203714B4 (en) * | 2019-03-19 | 2020-10-22 | Siemens Healthcare Gmbh | Method and data processing system for providing decision support data |
JP2022553223A (en) | 2019-10-18 | 2022-12-22 | アビンガー・インコーポレイテッド | occlusion crossing device |
US20210404459A1 (en) * | 2020-06-25 | 2021-12-30 | Bard Peripheral Vascular, Inc. | Peristaltic pump apparatus for use with biopsy sampling devices |
US11304723B1 (en) | 2020-12-17 | 2022-04-19 | Avantec Vascular Corporation | Atherectomy devices that are self-driving with controlled deflection |
CN114642475A (en) * | 2020-12-18 | 2022-06-21 | 上海蓝脉医疗科技有限公司 | Thrombus removing device |
EP4371507A1 (en) | 2022-11-18 | 2024-05-22 | Penumbra, Inc. | Aspiration thrombectomy system for dynamic system state detection |
Citations (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4445509A (en) * | 1982-02-04 | 1984-05-01 | Auth David C | Method and apparatus for removal of enclosed abnormal deposits |
US4589412A (en) * | 1984-01-03 | 1986-05-20 | Intravascular Surgical Instruments, Inc. | Method and apparatus for surgically removing remote deposits |
US4631052A (en) * | 1984-01-03 | 1986-12-23 | Intravascular Surgical Instruments, Inc. | Method and apparatus for surgically removing remote deposits |
US4679558A (en) * | 1985-08-12 | 1987-07-14 | Intravascular Surgical Instruments, Inc. | Catheter based surgical methods and apparatus therefor |
US4686982A (en) * | 1985-06-19 | 1987-08-18 | John Nash | Spiral wire bearing for rotating wire drive catheter |
US4696667A (en) * | 1986-03-20 | 1987-09-29 | Helmut Masch | Intravascular catheter and method |
US4700705A (en) * | 1985-08-12 | 1987-10-20 | Intravascular Surgical Instruments, Inc. | Catheter based surgical methods and apparatus therefor |
US4747821A (en) * | 1986-10-22 | 1988-05-31 | Intravascular Surgical Instruments, Inc. | Catheter with high speed moving working head |
US4749376A (en) * | 1986-10-24 | 1988-06-07 | Intravascular Surgical Instruments, Inc. | Reciprocating working head catheter |
US4762129A (en) * | 1984-11-23 | 1988-08-09 | Tassilo Bonzel | Dilatation catheter |
US4775371A (en) * | 1986-09-02 | 1988-10-04 | Advanced Cardiovascular Systems, Inc. | Stiffened dilatation catheter and method of manufacture |
US4790813A (en) * | 1984-12-17 | 1988-12-13 | Intravascular Surgical Instruments, Inc. | Method and apparatus for surgically removing remote deposits |
US4842579A (en) * | 1984-05-14 | 1989-06-27 | Surgical Systems & Instruments, Inc. | Atherectomy device |
US4857045A (en) * | 1987-04-30 | 1989-08-15 | Schneider (Usa) Inc., A Pfizer Company | Atherectomy catheter |
US4883458A (en) * | 1987-02-24 | 1989-11-28 | Surgical Systems & Instruments, Inc. | Atherectomy system and method of using the same |
US4898575A (en) * | 1987-08-31 | 1990-02-06 | Medinnovations, Inc. | Guide wire following tunneling catheter system and method for transluminal arterial atherectomy |
US4957482A (en) * | 1988-12-19 | 1990-09-18 | Surgical Systems & Instruments, Inc. | Atherectomy device with a positive pump means |
US5009659A (en) * | 1989-10-30 | 1991-04-23 | Schneider (Usa) Inc. | Fiber tip atherectomy catheter |
US5022553A (en) * | 1990-05-29 | 1991-06-11 | Pontius Jeffrey S | Temporary diaper storage container |
US5030201A (en) * | 1989-11-24 | 1991-07-09 | Aubrey Palestrant | Expandable atherectomy catheter device |
US5042984A (en) * | 1989-08-17 | 1991-08-27 | Kensey Nash Corporation | Catheter with working head having selectable impacting surfaces and method of using the same |
US5047040A (en) * | 1987-11-05 | 1991-09-10 | Devices For Vascular Intervention, Inc. | Atherectomy device and method |
US5049124A (en) * | 1989-10-14 | 1991-09-17 | Dow Corning Wright Corporation | Catheter drive apparatus having fluid delivery bearing |
US5074841A (en) * | 1990-01-30 | 1991-12-24 | Microcision, Inc. | Atherectomy device with helical cutter |
US5087265A (en) * | 1989-02-17 | 1992-02-11 | American Biomed, Inc. | Distal atherectomy catheter |
US5097849A (en) * | 1989-08-17 | 1992-03-24 | Kensey Nash Corporation | Method of use of catheter with working head having selectable impacting surfaces |
US5114399A (en) * | 1990-10-01 | 1992-05-19 | Intramed Laboratories | Surgical device |
US5120308A (en) * | 1989-05-03 | 1992-06-09 | Progressive Angioplasty Systems, Inc. | Catheter with high tactile guide wire |
US5135483A (en) * | 1991-07-22 | 1992-08-04 | Dow Corning Wright Corporation | Atherectomy device with a removable drive system |
US5195956A (en) * | 1988-01-19 | 1993-03-23 | Uwe Stockmeier | Medical catheter with a cutting device |
US5209727A (en) * | 1992-01-29 | 1993-05-11 | Interventional Technologies, Inc. | Guide wire with integral angioplasty balloon |
US5224945A (en) * | 1992-01-13 | 1993-07-06 | Interventional Technologies, Inc. | Compressible/expandable atherectomy cutter |
US5267955A (en) * | 1990-05-10 | 1993-12-07 | Lake Region Manufacturing Company, Inc. | Atherectomy device |
US5273526A (en) * | 1991-06-21 | 1993-12-28 | Lake Region Manufacturing Company, Inc. | Vascular occulusion removal devices and method |
US5282484A (en) * | 1989-08-18 | 1994-02-01 | Endovascular Instruments, Inc. | Method for performing a partial atherectomy |
US5284468A (en) * | 1991-08-19 | 1994-02-08 | M-Pact Worldwide Management Corporation | Orthopedic splinting article |
US5314407A (en) * | 1986-11-14 | 1994-05-24 | Heart Technology, Inc. | Clinically practical rotational angioplasty system |
US5358472A (en) * | 1992-01-13 | 1994-10-25 | Schneider (Usa) Inc. | Guidewire atherectomy catheter and method of using the same |
US5366463A (en) * | 1990-05-02 | 1994-11-22 | Ryan William J | Atherectomy catheter for the removal of atherosclerosis from within blood vessels |
US5368603A (en) * | 1990-06-05 | 1994-11-29 | Halliburton; Alexander G. | Endarterectomy catheter, and method of use thereof |
US5370609A (en) * | 1990-08-06 | 1994-12-06 | Possis Medical, Inc. | Thrombectomy device |
US5385152A (en) * | 1990-11-09 | 1995-01-31 | Boston Scientific Corporation | Guidewire for crossing occlusions in blood vessels |
US5395311A (en) * | 1990-05-14 | 1995-03-07 | Andrews; Winston A. | Atherectomy catheter |
US5402790A (en) * | 1990-05-21 | 1995-04-04 | Cardiovascular Imaging Systems, Inc. | Intravascular catheter having combined imaging abrasion head |
US5409454A (en) * | 1991-02-19 | 1995-04-25 | Arrow International Investment Corp. | Apparatus for atherectomy |
US5423742A (en) * | 1989-09-12 | 1995-06-13 | Schneider Europe | Method for the widening of strictures in vessels carrying body fluid |
US5429136A (en) * | 1993-04-21 | 1995-07-04 | Devices For Vascular Intervention, Inc. | Imaging atherectomy apparatus |
US5462529A (en) * | 1993-09-29 | 1995-10-31 | Technology Development Center | Adjustable treatment chamber catheter |
US5496267A (en) * | 1990-11-08 | 1996-03-05 | Possis Medical, Inc. | Asymmetric water jet atherectomy |
US5632755A (en) * | 1992-11-09 | 1997-05-27 | Endo Vascular Intruments, Inc. | Intra-artery obstruction clearing apparatus and methods |
US5665098A (en) * | 1992-11-09 | 1997-09-09 | Endovascular Instruments, Inc. | Unitary removal of plaque |
US5665103A (en) * | 1996-03-07 | 1997-09-09 | Scimed Life Systems, Inc. | Stent locating device |
US5679558A (en) * | 1992-04-15 | 1997-10-21 | Plant Genetic Systems, N.V. | Transformation of monocot cells |
US5681336A (en) * | 1995-09-07 | 1997-10-28 | Boston Scientific Corporation | Therapeutic device for treating vien graft lesions |
US5779721A (en) * | 1996-07-26 | 1998-07-14 | Kensey Nash Corporation | System and method of use for revascularizing stenotic bypass grafts and other blood vessels |
US5833650A (en) * | 1995-06-05 | 1998-11-10 | Percusurge, Inc. | Catheter apparatus and method for treating occluded vessels |
US5836892A (en) * | 1995-10-30 | 1998-11-17 | Cordis Corporation | Guidewire with radiopaque markers |
US5868767A (en) * | 1994-12-23 | 1999-02-09 | Devices For Vascular Intervention | Universal catheter with interchangeable work element |
US5882329A (en) * | 1997-02-12 | 1999-03-16 | Prolifix Medical, Inc. | Apparatus and method for removing stenotic material from stents |
US5900246A (en) * | 1993-03-18 | 1999-05-04 | Cedars-Sinai Medical Center | Drug incorporating and releasing polymeric coating for bioprosthesis |
US5947985A (en) * | 1997-11-12 | 1999-09-07 | Imran; Mir A. | Apparatus and method for cleaning diseased vein grafts |
US5954745A (en) * | 1997-05-16 | 1999-09-21 | Gertler; Jonathan | Catheter-filter set having a compliant seal |
US5976153A (en) * | 1997-03-31 | 1999-11-02 | Fischell; Robert E. | Stent delivery catheter system |
US6017319A (en) * | 1996-05-24 | 2000-01-25 | Precision Vascular Systems, Inc. | Hybrid tubular guide wire for catheters |
US6074407A (en) * | 1997-10-14 | 2000-06-13 | Target Therapeutics, Inc. | Delivery catheter for occlusive implants |
US6080170A (en) * | 1996-07-26 | 2000-06-27 | Kensey Nash Corporation | System and method of use for revascularizing stenotic bypass grafts and other occluded blood vessels |
US6093157A (en) * | 1997-10-22 | 2000-07-25 | Scimed Life Systems, Inc. | Radiopaque guide wire |
US6126667A (en) * | 1999-10-01 | 2000-10-03 | Scimed Life Systems, Inc. | Articulated ablation device |
US6135991A (en) * | 1997-03-06 | 2000-10-24 | Percusurge, Inc. | Aspiration method |
US6217567B1 (en) * | 1997-03-06 | 2001-04-17 | Percusurge, Inc. | Hollow medical wires and methods of constructing same |
US6235042B1 (en) * | 1998-09-21 | 2001-05-22 | Arteria Medical Science, Inc. | Atherectomy device |
US6264672B1 (en) * | 1999-10-25 | 2001-07-24 | Biopsy Sciences, Llc | Emboli capturing device |
US6296616B1 (en) * | 1997-11-18 | 2001-10-02 | Advanced Cardiovascular Systems, Inc. | Guidewire with shaped intermediate portion |
US6319244B2 (en) * | 1999-03-16 | 2001-11-20 | Chase Medical, L.P. | Catheter with flexible and rigid reinforcements |
US6344049B1 (en) * | 1999-08-17 | 2002-02-05 | Scion Cardio-Vascular, Inc. | Filter for embolic material mounted on expandable frame and associated deployment system |
US6436056B1 (en) * | 1996-02-28 | 2002-08-20 | Boston Scientific Corporation | Polymeric implements for torque transmission |
US6482217B1 (en) * | 1998-04-10 | 2002-11-19 | Endicor Medical, Inc. | Neuro thrombectomy catheter |
US6544276B1 (en) * | 1996-05-20 | 2003-04-08 | Medtronic Ave. Inc. | Exchange method for emboli containment |
US6652480B1 (en) * | 1997-03-06 | 2003-11-25 | Medtronic Ave., Inc. | Methods for reducing distal embolization |
-
2002
- 2002-01-28 US US10/058,556 patent/US6830577B2/en not_active Expired - Lifetime
-
2004
- 2004-05-18 US US10/847,932 patent/US20040210239A1/en not_active Abandoned
Patent Citations (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4445509A (en) * | 1982-02-04 | 1984-05-01 | Auth David C | Method and apparatus for removal of enclosed abnormal deposits |
US4589412A (en) * | 1984-01-03 | 1986-05-20 | Intravascular Surgical Instruments, Inc. | Method and apparatus for surgically removing remote deposits |
US4631052A (en) * | 1984-01-03 | 1986-12-23 | Intravascular Surgical Instruments, Inc. | Method and apparatus for surgically removing remote deposits |
US4842579A (en) * | 1984-05-14 | 1989-06-27 | Surgical Systems & Instruments, Inc. | Atherectomy device |
US4842579B1 (en) * | 1984-05-14 | 1995-10-31 | Surgical Systems & Instr Inc | Atherectomy device |
US4762129A (en) * | 1984-11-23 | 1988-08-09 | Tassilo Bonzel | Dilatation catheter |
US4762129B1 (en) * | 1984-11-23 | 1991-07-02 | Tassilo Bonzel | |
US4790813A (en) * | 1984-12-17 | 1988-12-13 | Intravascular Surgical Instruments, Inc. | Method and apparatus for surgically removing remote deposits |
US4686982A (en) * | 1985-06-19 | 1987-08-18 | John Nash | Spiral wire bearing for rotating wire drive catheter |
US4679558A (en) * | 1985-08-12 | 1987-07-14 | Intravascular Surgical Instruments, Inc. | Catheter based surgical methods and apparatus therefor |
US4700705A (en) * | 1985-08-12 | 1987-10-20 | Intravascular Surgical Instruments, Inc. | Catheter based surgical methods and apparatus therefor |
US4696667A (en) * | 1986-03-20 | 1987-09-29 | Helmut Masch | Intravascular catheter and method |
US4775371A (en) * | 1986-09-02 | 1988-10-04 | Advanced Cardiovascular Systems, Inc. | Stiffened dilatation catheter and method of manufacture |
US4747821A (en) * | 1986-10-22 | 1988-05-31 | Intravascular Surgical Instruments, Inc. | Catheter with high speed moving working head |
US4749376A (en) * | 1986-10-24 | 1988-06-07 | Intravascular Surgical Instruments, Inc. | Reciprocating working head catheter |
US5314407A (en) * | 1986-11-14 | 1994-05-24 | Heart Technology, Inc. | Clinically practical rotational angioplasty system |
US4883458A (en) * | 1987-02-24 | 1989-11-28 | Surgical Systems & Instruments, Inc. | Atherectomy system and method of using the same |
US4857045A (en) * | 1987-04-30 | 1989-08-15 | Schneider (Usa) Inc., A Pfizer Company | Atherectomy catheter |
US4898575A (en) * | 1987-08-31 | 1990-02-06 | Medinnovations, Inc. | Guide wire following tunneling catheter system and method for transluminal arterial atherectomy |
US5047040A (en) * | 1987-11-05 | 1991-09-10 | Devices For Vascular Intervention, Inc. | Atherectomy device and method |
US5195956A (en) * | 1988-01-19 | 1993-03-23 | Uwe Stockmeier | Medical catheter with a cutting device |
US4957482A (en) * | 1988-12-19 | 1990-09-18 | Surgical Systems & Instruments, Inc. | Atherectomy device with a positive pump means |
US5370651A (en) * | 1989-02-17 | 1994-12-06 | Summers; David P. | Distal atherectomy catheter |
US5087265A (en) * | 1989-02-17 | 1992-02-11 | American Biomed, Inc. | Distal atherectomy catheter |
US5120308A (en) * | 1989-05-03 | 1992-06-09 | Progressive Angioplasty Systems, Inc. | Catheter with high tactile guide wire |
US5042984A (en) * | 1989-08-17 | 1991-08-27 | Kensey Nash Corporation | Catheter with working head having selectable impacting surfaces and method of using the same |
US5097849A (en) * | 1989-08-17 | 1992-03-24 | Kensey Nash Corporation | Method of use of catheter with working head having selectable impacting surfaces |
US5282484A (en) * | 1989-08-18 | 1994-02-01 | Endovascular Instruments, Inc. | Method for performing a partial atherectomy |
US5423742A (en) * | 1989-09-12 | 1995-06-13 | Schneider Europe | Method for the widening of strictures in vessels carrying body fluid |
US5049124A (en) * | 1989-10-14 | 1991-09-17 | Dow Corning Wright Corporation | Catheter drive apparatus having fluid delivery bearing |
US5009659A (en) * | 1989-10-30 | 1991-04-23 | Schneider (Usa) Inc. | Fiber tip atherectomy catheter |
US5030201A (en) * | 1989-11-24 | 1991-07-09 | Aubrey Palestrant | Expandable atherectomy catheter device |
US5074841A (en) * | 1990-01-30 | 1991-12-24 | Microcision, Inc. | Atherectomy device with helical cutter |
US5366463A (en) * | 1990-05-02 | 1994-11-22 | Ryan William J | Atherectomy catheter for the removal of atherosclerosis from within blood vessels |
US5267955A (en) * | 1990-05-10 | 1993-12-07 | Lake Region Manufacturing Company, Inc. | Atherectomy device |
US5395311A (en) * | 1990-05-14 | 1995-03-07 | Andrews; Winston A. | Atherectomy catheter |
US5402790A (en) * | 1990-05-21 | 1995-04-04 | Cardiovascular Imaging Systems, Inc. | Intravascular catheter having combined imaging abrasion head |
US5022553A (en) * | 1990-05-29 | 1991-06-11 | Pontius Jeffrey S | Temporary diaper storage container |
US5368603A (en) * | 1990-06-05 | 1994-11-29 | Halliburton; Alexander G. | Endarterectomy catheter, and method of use thereof |
US5370609A (en) * | 1990-08-06 | 1994-12-06 | Possis Medical, Inc. | Thrombectomy device |
US5114399A (en) * | 1990-10-01 | 1992-05-19 | Intramed Laboratories | Surgical device |
US5496267A (en) * | 1990-11-08 | 1996-03-05 | Possis Medical, Inc. | Asymmetric water jet atherectomy |
US5385152A (en) * | 1990-11-09 | 1995-01-31 | Boston Scientific Corporation | Guidewire for crossing occlusions in blood vessels |
US5409454A (en) * | 1991-02-19 | 1995-04-25 | Arrow International Investment Corp. | Apparatus for atherectomy |
US5273526A (en) * | 1991-06-21 | 1993-12-28 | Lake Region Manufacturing Company, Inc. | Vascular occulusion removal devices and method |
US5135483A (en) * | 1991-07-22 | 1992-08-04 | Dow Corning Wright Corporation | Atherectomy device with a removable drive system |
US5284468A (en) * | 1991-08-19 | 1994-02-08 | M-Pact Worldwide Management Corporation | Orthopedic splinting article |
US5224945A (en) * | 1992-01-13 | 1993-07-06 | Interventional Technologies, Inc. | Compressible/expandable atherectomy cutter |
US5358472A (en) * | 1992-01-13 | 1994-10-25 | Schneider (Usa) Inc. | Guidewire atherectomy catheter and method of using the same |
US5209727A (en) * | 1992-01-29 | 1993-05-11 | Interventional Technologies, Inc. | Guide wire with integral angioplasty balloon |
US5679558A (en) * | 1992-04-15 | 1997-10-21 | Plant Genetic Systems, N.V. | Transformation of monocot cells |
US5632755A (en) * | 1992-11-09 | 1997-05-27 | Endo Vascular Intruments, Inc. | Intra-artery obstruction clearing apparatus and methods |
US5665098A (en) * | 1992-11-09 | 1997-09-09 | Endovascular Instruments, Inc. | Unitary removal of plaque |
US5900246A (en) * | 1993-03-18 | 1999-05-04 | Cedars-Sinai Medical Center | Drug incorporating and releasing polymeric coating for bioprosthesis |
US5429136A (en) * | 1993-04-21 | 1995-07-04 | Devices For Vascular Intervention, Inc. | Imaging atherectomy apparatus |
US5462529A (en) * | 1993-09-29 | 1995-10-31 | Technology Development Center | Adjustable treatment chamber catheter |
US5868767A (en) * | 1994-12-23 | 1999-02-09 | Devices For Vascular Intervention | Universal catheter with interchangeable work element |
US5833650A (en) * | 1995-06-05 | 1998-11-10 | Percusurge, Inc. | Catheter apparatus and method for treating occluded vessels |
US5681336A (en) * | 1995-09-07 | 1997-10-28 | Boston Scientific Corporation | Therapeutic device for treating vien graft lesions |
US5836892A (en) * | 1995-10-30 | 1998-11-17 | Cordis Corporation | Guidewire with radiopaque markers |
US6436056B1 (en) * | 1996-02-28 | 2002-08-20 | Boston Scientific Corporation | Polymeric implements for torque transmission |
US5665103A (en) * | 1996-03-07 | 1997-09-09 | Scimed Life Systems, Inc. | Stent locating device |
US6544276B1 (en) * | 1996-05-20 | 2003-04-08 | Medtronic Ave. Inc. | Exchange method for emboli containment |
US6017319A (en) * | 1996-05-24 | 2000-01-25 | Precision Vascular Systems, Inc. | Hybrid tubular guide wire for catheters |
US5879361A (en) * | 1996-07-26 | 1999-03-09 | Kensey Nash Corporation | System and method of use for revascularizing stenotic bypass grafts and other blood vessels |
US6080170A (en) * | 1996-07-26 | 2000-06-27 | Kensey Nash Corporation | System and method of use for revascularizing stenotic bypass grafts and other occluded blood vessels |
US5779721A (en) * | 1996-07-26 | 1998-07-14 | Kensey Nash Corporation | System and method of use for revascularizing stenotic bypass grafts and other blood vessels |
US5882329A (en) * | 1997-02-12 | 1999-03-16 | Prolifix Medical, Inc. | Apparatus and method for removing stenotic material from stents |
US6217567B1 (en) * | 1997-03-06 | 2001-04-17 | Percusurge, Inc. | Hollow medical wires and methods of constructing same |
US6652480B1 (en) * | 1997-03-06 | 2003-11-25 | Medtronic Ave., Inc. | Methods for reducing distal embolization |
US6135991A (en) * | 1997-03-06 | 2000-10-24 | Percusurge, Inc. | Aspiration method |
US5976153A (en) * | 1997-03-31 | 1999-11-02 | Fischell; Robert E. | Stent delivery catheter system |
US5954745A (en) * | 1997-05-16 | 1999-09-21 | Gertler; Jonathan | Catheter-filter set having a compliant seal |
US6074407A (en) * | 1997-10-14 | 2000-06-13 | Target Therapeutics, Inc. | Delivery catheter for occlusive implants |
US6093157A (en) * | 1997-10-22 | 2000-07-25 | Scimed Life Systems, Inc. | Radiopaque guide wire |
US5947985A (en) * | 1997-11-12 | 1999-09-07 | Imran; Mir A. | Apparatus and method for cleaning diseased vein grafts |
US6296616B1 (en) * | 1997-11-18 | 2001-10-02 | Advanced Cardiovascular Systems, Inc. | Guidewire with shaped intermediate portion |
US6482217B1 (en) * | 1998-04-10 | 2002-11-19 | Endicor Medical, Inc. | Neuro thrombectomy catheter |
US6235042B1 (en) * | 1998-09-21 | 2001-05-22 | Arteria Medical Science, Inc. | Atherectomy device |
US6319244B2 (en) * | 1999-03-16 | 2001-11-20 | Chase Medical, L.P. | Catheter with flexible and rigid reinforcements |
US6344049B1 (en) * | 1999-08-17 | 2002-02-05 | Scion Cardio-Vascular, Inc. | Filter for embolic material mounted on expandable frame and associated deployment system |
US6126667A (en) * | 1999-10-01 | 2000-10-03 | Scimed Life Systems, Inc. | Articulated ablation device |
US6264672B1 (en) * | 1999-10-25 | 2001-07-24 | Biopsy Sciences, Llc | Emboli capturing device |
Cited By (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070073268A1 (en) * | 2002-08-12 | 2007-03-29 | Goble E M | Integrated Infusion and Aspiration System and Method |
US8292871B2 (en) * | 2004-02-26 | 2012-10-23 | Osprey Medical, Inc. | Regional cardiac tissue treatment |
US20070060907A1 (en) * | 2004-02-26 | 2007-03-15 | Shapland James E | Regional cardiac tissue treatment |
US20110015558A1 (en) * | 2004-02-26 | 2011-01-20 | Osprey Medical Inc. | Isolating cardiac circulation |
US20100274173A1 (en) * | 2004-02-26 | 2010-10-28 | Osprey Medical, Inc. | Regional cardiac tissue treatment |
US7722596B2 (en) * | 2004-02-26 | 2010-05-25 | Osprey Medical, Inc. | Regional cardiac tissue treatment |
US8911450B2 (en) | 2004-07-07 | 2014-12-16 | Percutaneous Systems, Inc. | Methods and apparatus for deploying ureteral stents |
US8753351B2 (en) | 2004-07-07 | 2014-06-17 | Percutaneous Systems, Inc. | Methods for removing kidney stones from the ureter |
US8080019B2 (en) | 2004-07-07 | 2011-12-20 | Percutaneous Systems, Inc. | Apparatus for deploying occluding structures in body lumens |
US20090287238A1 (en) * | 2004-07-07 | 2009-11-19 | Percutaneous Systems, Inc. | Methods and apparatus for deploying short length ureteral stents |
US20110098690A1 (en) * | 2004-07-07 | 2011-04-28 | Percutaneous Systems, Inc. | Methods for removing kidney stones from the ureter |
US20080177277A1 (en) * | 2004-07-07 | 2008-07-24 | Percutaneous Systems, Inc. | Methods for removing kidney stones from the ureter |
US7883516B2 (en) * | 2004-07-07 | 2011-02-08 | Percutaneous Systems, Inc. | Methods for removing kidney stones from the ureter |
US8417321B2 (en) | 2005-02-02 | 2013-04-09 | Voyage Medical, Inc | Flow reduction hood systems |
US8934962B2 (en) | 2005-02-02 | 2015-01-13 | Intuitive Surgical Operations, Inc. | Electrophysiology mapping and visualization system |
US10368729B2 (en) | 2005-02-02 | 2019-08-06 | Intuitive Surgical Operations, Inc. | Methods and apparatus for efficient purging |
US11819190B2 (en) | 2005-02-02 | 2023-11-21 | Intuitive Surgical Operations, Inc. | Methods and apparatus for efficient purging |
US9332893B2 (en) | 2005-02-02 | 2016-05-10 | Intuitive Surgical Operations, Inc. | Delivery of biological compounds to ischemic and/or infarcted tissue |
US10463237B2 (en) | 2005-02-02 | 2019-11-05 | Intuitive Surgical Operations, Inc. | Delivery of biological compounds to ischemic and/or infarcted tissue |
US8050746B2 (en) | 2005-02-02 | 2011-11-01 | Voyage Medical, Inc. | Tissue visualization device and method variations |
US10278588B2 (en) | 2005-02-02 | 2019-05-07 | Intuitive Surgical Operations, Inc. | Electrophysiology mapping and visualization system |
US10064540B2 (en) | 2005-02-02 | 2018-09-04 | Intuitive Surgical Operations, Inc. | Visualization apparatus for transseptal access |
US8814845B2 (en) | 2005-02-02 | 2014-08-26 | Intuitive Surgical Operations, Inc. | Delivery of biological compounds to ischemic and/or infarcted tissue |
US11889982B2 (en) | 2005-02-02 | 2024-02-06 | Intuitive Surgical Operations, Inc. | Electrophysiology mapping and visualization system |
US10772492B2 (en) | 2005-02-02 | 2020-09-15 | Intuitive Surgical Operations, Inc. | Methods and apparatus for efficient purging |
US9526401B2 (en) | 2005-02-02 | 2016-12-27 | Intuitive Surgical Operations, Inc. | Flow reduction hood systems |
US8419613B2 (en) | 2005-02-02 | 2013-04-16 | Voyage Medical, Inc. | Tissue visualization device |
US11406250B2 (en) | 2005-02-02 | 2022-08-09 | Intuitive Surgical Operations, Inc. | Methods and apparatus for treatment of atrial fibrillation |
US11478152B2 (en) | 2005-02-02 | 2022-10-25 | Intuitive Surgical Operations, Inc. | Electrophysiology mapping and visualization system |
US20070016244A1 (en) * | 2005-07-06 | 2007-01-18 | Percutaneous Systems, Inc. | Methods and apparatus for deploying ureteral stents |
US7972292B2 (en) | 2005-07-06 | 2011-07-05 | Percutaneous Systems, Inc. | Methods and apparatus for deploying ureteral stents |
US9192287B2 (en) | 2005-10-25 | 2015-11-24 | Intuitive Surgical Operations, Inc. | Tissue visualization device and method variations |
US9510732B2 (en) | 2005-10-25 | 2016-12-06 | Intuitive Surgical Operations, Inc. | Methods and apparatus for efficient purging |
US8078266B2 (en) | 2005-10-25 | 2011-12-13 | Voyage Medical, Inc. | Flow reduction hood systems |
US8221310B2 (en) | 2005-10-25 | 2012-07-17 | Voyage Medical, Inc. | Tissue visualization device and method variations |
US8137333B2 (en) | 2005-10-25 | 2012-03-20 | Voyage Medical, Inc. | Delivery of biological compounds to ischemic and/or infarcted tissue |
US9055906B2 (en) | 2006-06-14 | 2015-06-16 | Intuitive Surgical Operations, Inc. | In-vivo visualization systems |
US10470643B2 (en) | 2006-06-14 | 2019-11-12 | Intuitive Surgical Operations, Inc. | In-vivo visualization systems |
US11882996B2 (en) | 2006-06-14 | 2024-01-30 | Intuitive Surgical Operations, Inc. | In-vivo visualization systems |
US10004388B2 (en) | 2006-09-01 | 2018-06-26 | Intuitive Surgical Operations, Inc. | Coronary sinus cannulation |
US11779195B2 (en) | 2006-09-01 | 2023-10-10 | Intuitive Surgical Operations, Inc. | Precision control systems for tissue visualization and manipulation assemblies |
US10070772B2 (en) | 2006-09-01 | 2018-09-11 | Intuitive Surgical Operations, Inc. | Precision control systems for tissue visualization and manipulation assemblies |
US11337594B2 (en) | 2006-09-01 | 2022-05-24 | Intuitive Surgical Operations, Inc. | Coronary sinus cannulation |
US11369356B2 (en) | 2006-10-23 | 2022-06-28 | Intuitive Surgical Operations, Inc. | Methods and apparatus for preventing tissue migration |
US10335131B2 (en) | 2006-10-23 | 2019-07-02 | Intuitive Surgical Operations, Inc. | Methods for preventing tissue migration |
US20100082004A1 (en) * | 2006-11-07 | 2010-04-01 | Osprey Medical Inc. | Collection catheter and kit |
US8708986B2 (en) | 2006-11-07 | 2014-04-29 | Osprey Medical Inc. | Collection catheter and kit |
GB2444171A (en) * | 2006-11-23 | 2008-05-28 | Leonid Shturman | Fluid supply coupling for a rotational atherectomy device |
US10441136B2 (en) | 2006-12-18 | 2019-10-15 | Intuitive Surgical Operations, Inc. | Systems and methods for unobstructed visualization and ablation |
US10390685B2 (en) | 2006-12-21 | 2019-08-27 | Intuitive Surgical Operations, Inc. | Off-axis visualization systems |
US11559188B2 (en) | 2006-12-21 | 2023-01-24 | Intuitive Surgical Operations, Inc. | Off-axis visualization systems |
US8131350B2 (en) | 2006-12-21 | 2012-03-06 | Voyage Medical, Inc. | Stabilization of visualization catheters |
US8758229B2 (en) | 2006-12-21 | 2014-06-24 | Intuitive Surgical Operations, Inc. | Axial visualization systems |
US9226648B2 (en) | 2006-12-21 | 2016-01-05 | Intuitive Surgical Operations, Inc. | Off-axis visualization systems |
US12133631B2 (en) | 2006-12-21 | 2024-11-05 | Intuitive Surgical Operations, Inc. | Off-axis visualization systems |
US12193638B2 (en) | 2007-04-27 | 2025-01-14 | Intuitive Surgical Operations, Inc. | Complex shape steerable tissue visualization and manipulation catheter |
US9155452B2 (en) | 2007-04-27 | 2015-10-13 | Intuitive Surgical Operations, Inc. | Complex shape steerable tissue visualization and manipulation catheter |
US10092172B2 (en) | 2007-05-08 | 2018-10-09 | Intuitive Surgical Operations, Inc. | Complex shape steerable tissue visualization and manipulation catheter |
US8657805B2 (en) | 2007-05-08 | 2014-02-25 | Intuitive Surgical Operations, Inc. | Complex shape steerable tissue visualization and manipulation catheter |
US9155587B2 (en) | 2007-05-11 | 2015-10-13 | Intuitive Surgical Operations, Inc. | Visual electrode ablation systems |
US10624695B2 (en) | 2007-05-11 | 2020-04-21 | Intuitive Surgical Operations, Inc. | Visual electrode ablation systems |
US8709008B2 (en) | 2007-05-11 | 2014-04-29 | Intuitive Surgical Operations, Inc. | Visual electrode ablation systems |
US8235985B2 (en) | 2007-08-31 | 2012-08-07 | Voyage Medical, Inc. | Visualization and ablation system variations |
US8500697B2 (en) | 2007-10-19 | 2013-08-06 | Pressure Products Medical Supplies, Inc. | Transseptal guidewire |
US9585692B2 (en) | 2007-10-19 | 2017-03-07 | Pressure Products Medical Supplies Inc. | Transseptal guidewire |
US7963947B2 (en) | 2008-01-16 | 2011-06-21 | Pressure Products Medical Supplies, Inc. | Apparatus, system, and method of shielding the sharp tip of a transseptal guidewire |
US8858609B2 (en) * | 2008-02-07 | 2014-10-14 | Intuitive Surgical Operations, Inc. | Stent delivery under direct visualization |
US11986409B2 (en) | 2008-02-07 | 2024-05-21 | Intuitive Surgical Operations, Inc. | Stent delivery under direct visualization |
US11241325B2 (en) | 2008-02-07 | 2022-02-08 | Intuitive Surgical Operations, Inc. | Stent delivery under direct visualization |
US10278849B2 (en) | 2008-02-07 | 2019-05-07 | Intuitive Surgical Operations, Inc. | Stent delivery under direct visualization |
US11938284B2 (en) | 2008-07-01 | 2024-03-26 | Endologix Llc | Catheter system and methods of using same |
US9700701B2 (en) * | 2008-07-01 | 2017-07-11 | Endologix, Inc. | Catheter system and methods of using same |
US20120277847A1 (en) * | 2008-07-01 | 2012-11-01 | Endologix, Inc. | Catheter system and methods of using same |
US10512758B2 (en) | 2008-07-01 | 2019-12-24 | Endologix, Inc. | Catheter system and methods of using same |
US11350815B2 (en) | 2008-07-07 | 2022-06-07 | Intuitive Surgical Operations, Inc. | Catheter control systems |
US9101735B2 (en) | 2008-07-07 | 2015-08-11 | Intuitive Surgical Operations, Inc. | Catheter control systems |
US9795784B2 (en) | 2008-08-11 | 2017-10-24 | Cibiem, Inc. | Systems and methods for treating dyspnea, including via electrical afferent signal blocking |
US9433784B2 (en) | 2008-08-11 | 2016-09-06 | Cibiem, Inc. | Systems and methods for treating dyspnea, including via electrical afferent signal blocking |
US9089700B2 (en) | 2008-08-11 | 2015-07-28 | Cibiem, Inc. | Systems and methods for treating dyspnea, including via electrical afferent signal blocking |
US9050400B2 (en) | 2008-08-12 | 2015-06-09 | Osprey Medical, Inc. | Remote sensing catheter system and methods |
US8409161B2 (en) | 2008-08-12 | 2013-04-02 | Osprey Medical, Inc. | Remote sensing catheter system and methods |
US20100041984A1 (en) * | 2008-08-12 | 2010-02-18 | James Edward Shapland | Impedance sensing device and catheter system |
US20100042069A1 (en) * | 2008-08-12 | 2010-02-18 | James Edward Shapland | Remote sensing catheter system and methods |
US20100168564A1 (en) * | 2008-08-12 | 2010-07-01 | Osprey Medical, Inc. | Remote sensing catheter system and methods |
US11950838B2 (en) | 2008-10-10 | 2024-04-09 | Intuitive Surgical Operations, Inc. | Integral electrode placement and connection systems |
US10111705B2 (en) | 2008-10-10 | 2018-10-30 | Intuitive Surgical Operations, Inc. | Integral electrode placement and connection systems |
US8894643B2 (en) | 2008-10-10 | 2014-11-25 | Intuitive Surgical Operations, Inc. | Integral electrode placement and connection systems |
US8333012B2 (en) | 2008-10-10 | 2012-12-18 | Voyage Medical, Inc. | Method of forming electrode placement and connection systems |
US9468364B2 (en) | 2008-11-14 | 2016-10-18 | Intuitive Surgical Operations, Inc. | Intravascular catheter with hood and image processing systems |
US11622689B2 (en) | 2008-11-14 | 2023-04-11 | Intuitive Surgical Operations, Inc. | Mapping and real-time imaging a plurality of ablation lesions with registered ablation parameters received from treatment device |
US20110172558A1 (en) * | 2009-12-09 | 2011-07-14 | Osprey Medical, Inc. | Catheter with distal and proximal ports |
US9295816B2 (en) | 2009-12-09 | 2016-03-29 | Osprey Medical, Inc. | Catheter with distal and proximal ports |
US20110144576A1 (en) * | 2009-12-14 | 2011-06-16 | Voyage Medical, Inc. | Catheter orientation control system mechanisms |
US8694071B2 (en) | 2010-02-12 | 2014-04-08 | Intuitive Surgical Operations, Inc. | Image stabilization techniques and methods |
US9814522B2 (en) | 2010-04-06 | 2017-11-14 | Intuitive Surgical Operations, Inc. | Apparatus and methods for ablation efficacy |
US9211372B2 (en) | 2011-08-11 | 2015-12-15 | Osprey Medical, Inc. | Systems and methods for limb treatment |
US9555183B2 (en) | 2011-08-11 | 2017-01-31 | Osprey Medical, Inc. | Systems and methods for limb treatment |
US10219855B2 (en) * | 2012-04-24 | 2019-03-05 | Cibiem, Inc. | Endovascular catheters and methods for carotid body ablation |
US9393070B2 (en) * | 2012-04-24 | 2016-07-19 | Cibiem, Inc. | Endovascular catheters and methods for carotid body ablation |
US9757180B2 (en) | 2012-04-24 | 2017-09-12 | Cibiem, Inc. | Endovascular catheters and methods for carotid body ablation |
US20130310823A1 (en) * | 2012-04-24 | 2013-11-21 | Mark Gelfand | Endovascular Catheters and Methods for Carotid Body Ablation |
US20170367749A1 (en) * | 2012-04-24 | 2017-12-28 | Mark Gelfand | Endovascular catheters and methods for carotid body ablation |
US9398930B2 (en) | 2012-06-01 | 2016-07-26 | Cibiem, Inc. | Percutaneous methods and devices for carotid body ablation |
US9808303B2 (en) | 2012-06-01 | 2017-11-07 | Cibiem, Inc. | Methods and devices for cryogenic carotid body ablation |
US9402677B2 (en) | 2012-06-01 | 2016-08-02 | Cibiem, Inc. | Methods and devices for cryogenic carotid body ablation |
US9283033B2 (en) | 2012-06-30 | 2016-03-15 | Cibiem, Inc. | Carotid body ablation via directed energy |
US9955946B2 (en) | 2014-03-12 | 2018-05-01 | Cibiem, Inc. | Carotid body ablation with a transvenous ultrasound imaging and ablation catheter |
Also Published As
Publication number | Publication date |
---|---|
US6830577B2 (en) | 2004-12-14 |
US20020198550A1 (en) | 2002-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6830577B2 (en) | System and method of use for treating occluded vessels and diseased tissue | |
US7534249B2 (en) | System and method of use for agent delivery and revascularizing of grafts and vessels | |
US6080170A (en) | System and method of use for revascularizing stenotic bypass grafts and other occluded blood vessels | |
US6652546B1 (en) | System and method of use for revascularizing stenotic bypass grafts and other occluded blood vessels | |
US6569147B1 (en) | Systems and methods of use for delivering beneficial agents for revascularizing stenotic bypass grafts and other occluded blood vessels and for other purposes | |
EP0925035B1 (en) | System for revascularizing stenotic bypass grafts and others blood vessels | |
US6579298B1 (en) | Method and apparatus for treating vein graft lesions | |
JP5429714B2 (en) | Device for thrombectomy and removal of soft debris | |
US8523801B2 (en) | Catheter with associated extension lumen | |
US8439878B2 (en) | Rheolytic thrombectomy catheter with self-inflating proximal balloon with drug infusion capabilities | |
EP0681458A1 (en) | Cutter for atherectomy catheter | |
JP2007534450A (en) | Device for thrombectomy and removal of soft debris | |
WO1993013716A1 (en) | Surgical cutting tool |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: KENSEY NASH CORPORATION, PENNSYLVANIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NASH, JOHN E;HOGANSON, DAVID M;EVANS, DOUGLAS G;REEL/FRAME:014930/0494;SIGNING DATES FROM 20020516 TO 20020520 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |